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The aim of this research was to develop and fully investigate a novel method of antibiotic 
drug delivery to the lung that will address problems with current therapeutic regimens for 
treatment of airway infections. To demonstrate the performance of prepared formulations, 
the design of suitable characterization methods were also aimed. A novel dissolution 
method for evaluating the in vitro dissolution behavior of inhalation formulations was 
developed. The membrane holder was designed to enclose previously air-classified 
formulations so that they could be uniformly tested in the dissolution apparatus. 
Dissolution procedures, the apparatus, the dose collection, the medium, and test 
conditions were developed and the dissolution behaviors of test compounds were 
evaluated by experimental and mathematical analysis. It was proved that the aerodynamic 
separation of formulation prior to dissolution assessment have a significant influence on 
the dissolution profiles. The optimized test method using the membrane holder was 
applied to evaluate in vitro dissolution profiles of the manufactured formulations of 
viii 
 
rifampicin (RF). The carrier/excipient-free RF dry powder formulation was investigated. 
The rifampicin dihydrate (RFDH) powders having MMAD of 2.2 m were prepared 
using a simple recrystallization process. The RFDH powders have a thin flaky structure, 
and this unique morphology provides improved aerosolization properties at maximal API 
loading. The manufactured RFDH formulation showed 80 % drug release within 2 hours. 
To retard the release rate of RF, the prepared RFDH crystals were coated with 
hydrophobic polymer, PLA or PLGA, using spray-dryer equipped with multi-channel 
spray nozzles. The multi-channel spray nozzle used in this study has two separate nozzles 
for aqueous solution and one for gas fluid. The RFDH crystals and the coating solutions 
were sprayed through the two separate liquid nozzles at the same time. The coated RFDH 
formulations were prepared using multi-channel spray nozzles. The coated formulations 
contained at least 50 % w/w of RF with no change of their flaky morphology. The initial 
RF release was lowered by coating; the lowest initial RF release was observed from the 
coated powders with PLA polymer as 32 % among the coated formulations. Overall, the 
80 % of RF was released within 8 hours. The RFDH and coated RFDH formulations 
delivered via the pulmonary route would be anticipated to provide higher local (lung) 
drug concentrations than that of orally delivered powders. Particularly, the coated RFDH 
powders deposited in the alveolar region may prolong the drug residence time in the site 
of infections. Additionally, it was proved that the RFDH and coated RFDH formulations 
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Chapter 1: Introduction1 
 
1.1. DRY POWDER INHALERS 
 
  Drug delivery to the lung has changed dramatically in recent years. 
Commercialization of the pressurized metered dose inhaler (pMDI), containing a 
chlorofluorocarbon (CFC) propellant, began as a convenient system for asthma 
management in the 1950s. The pMDI has become the most popular device for out-patient 
inhalation therapy, with its worldwide production exceeding 300 million per year [1, 2]. 
However, concerns have often been highlighted over potential drawbacks of pMDIs: an 
altogether environmentally incompatible propellant, harmful effects of Freon to patients  
and perhaps of most concern is the extensive oropharyngeal deposition of the active 
pharmaceutical ingredients (APIs) included in the device [3-5]. Because the contribution 
to ozone depletion of CFC was initially hypothesized by Molena and Rowland (1974), 
pharmaceutical companies were forced to find alternative propellants [6, 7]. As a result, 
hydrofluoroalkane (HFA)-based and propellant-free pMDIs were developed as a way to 
replace CFCs [8-11]. However, this replacement strategy has not been altogether 
successful because of several setbacks, including potency, manufacturing cost increase, 
and reformulation difficulty amongst others [12, 13]. 
 
1
Parts of this chapter were taken from : 
1) Yoen-Ju Son, Jason T. McConville, ―Advancements in dry powder delivery to the lung‖, Drug 
Development and Industrial Pharmacy, 2008, 34, P: 948–959. 
2) Yoen-Ju Son, Jolyon P. Mitchell, and Jason T. McConville, ―In vitro performance testing for pulmonary 
drug delivery‖, in ―Controlled Release Science and Technology: Pulmonary Delivery‖, Controlled 
Release Society (CRC) Book Series (In Press). 
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Problems with the pMDI performance and operational restrictions have spurred the 
exploration of dry powder systems. As a consequence, many dry powder inhalers (DPIs) 
have emerged, and a number of them have been introduced onto the market. Since the 
first single-dose DPI product, the Spinhaler®  (Sanofi-Aventis, Holmes Chapel, UK) 
(formerly Fisons, Loughborough, UK), appeared on the market, new DPIs have made 
remarkable progress in various aspects such as dose-metering, dose-dispensing, and 
aerosolization systems for dry powder particles [14-17]. Additionally, attempts have been 
made to deliver a variety of active pharmaceutical ingredients (APIs) via pulmonary route 
using novel inhalation devices such as Exubra®  (Nektar therapeutics, San Carlos, CA, 
USA), Spiro® (Dura Pharmaceuticals, San Diego, CA, USA), and AIR™ (Alkermes 
Cambridge, MA, USA).  
 
1.1.1. Advantages of dry powder inhalers  
The pulmonary route of administration has many potential advantages for the 
delivery of APIs over other administration routes. Advantages include: a large surface 
area for drug absorption, high permeability through a thin alveolar membrane [18, 19], 
few proteases for degradation of APIs [18], no first-pass hepatic clearance/metabolism 
[18, 19], and the reported excellent bioavailability for some molecules [20, 21]. 
Specifically, DPIs have become widely known as a very attractive platform for drug 
delivery by virtue of its propellant-free nature, high patient compliance, improved 
formulation stability and patient protection from harmful Freon [14, 22, 23]. Moreover, it 
has been known that the DPIs offer better drug deposition in central and peripheral 
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regions of the lung, with minimal oropharyngeal deposition, than the pMDI [24]. This is 
due to the differences in the aerosol generation mechanism between delivery devices. 
DPIs are generally activated by the patient‘s inspiratory airflow, which require little or  no 
coordination of actuation and inhalation. Whereas pMDIs are activated by pressurized 
propellant at high velocity, which can result in premature drug deposition in the 
oropharynx [25, 26]. Consequently, many patients have traditionally used DPIs to treat 
asthma and chronic obstructive pulmonary disease (COPD) [15, 27-29]. Recently, the 
development of new DPIs for delivering therapeutic proteins and antibiotics has also been 
accelerated by patient demands, and innovative research [30-32]. The current market for 
DPIs has over 20 devices presently in use and many devices under development for 
delivering a variety of therapeutic agents, for a variety of therapeutic needs. 
 
1.1.2. Particle deagglomeration mechanism  
Deaggregation and deagglomeration are the processes by which particle 
aggregates are dispersed into primary particles of suitable size for deep lung deposition 
by interaction with airflow. In pulmonary drug delivery, particles within the aerodynamic 
size range of 1-5 µm are effectively delivered to alveoli region by sedimentation [18]. 
However, due to their small particle size, powders used in DPIs are extremely adhesive 
and cohesive. To minimize the inter-particulate forces caused between those fine 
particles, most dry powder formulations contain coarse carrier materials, such as lactose 
[16]. However, these carriers can markedly affect the aerosolization properties of the 
powder [16, 33, 34], since the aerosolization performances of DPIs are predominantly 
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governed by the deagglomeration of fine particles from the surface of larger carrier 
particles; the incomplete detachment of fine API particles from the carrier particles leads 
to the poor aerosolization of APIs [35, 36]. To successfully overcome adhesive forces 
between the fine particles and the carriers, most DPI devices have been designed to 
incorporate their own particle separation mechanisms.  
The DPI devices can be divided into two categories according to energy sources 
to deagglomerate the fine particles: (1) passive devices and (2) active devices, as shown 
in Figure 1.1. The energy source for most passive DPIs is a patient‘s inspiratory flow rate 
and volume, and in this case a patient‘s inspiratory air flow pulls particles though a 
specific deagglomeration zone in a given device, where fine drug particles are separated. 
At present, the principal mechanism leading to powder deagglomeration in passive 
inhalers are frictional forces, drag and lift forces provided by air turbulence, and internal 
forces [37-40]. However, it‘s often reported that the passive devices may not provide 
therapeutically effective amounts of drug aerosol particles to the patient with asthma, 
chronic obstructive pulmonary disease (COPD), or in elderly patients and young children 
since their inspiratory airflow is not sufficient to achieve optimal aerosol generation [41, 
42]. Therefore, active devices, which have power-assisted powder dispersion systems, 
have been proposed to make up for potential variability displayed by passive devices as 
described above. Mechanical energy in the form of springs which can generate the 
compressed air or electrical energy, battery storage systems, and battery-driven impeller 
have all been used to generate the necessary separating forces for the particles in these 
systems [39]. A possible advantage of this type of device is that achieving uniformity of 
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dosage is less dependent on the patient‘s inspiration capability. Different types of powder 
dispersion mechanisms are displayed in Table 1.1. 
 
1.2. DRY POWDER FORMULATIONS 
 
1.2.1. Excipients to improve aerosolization properties 
1.2.1.1. Carrier particle 
The most common excipient in carrier-based DPI system is a lactose monohydrate 
due to its favorable toxicological profile, physicochemical stability, availability and 
compatibility with the majority of low molecular weight drugs [16]. Currently, a variety 
of lactose particle size grades are available from various suppliers. There are considerable 
number of studies have been explored to compare the capabilities for improving the 
aerosolization performances between different lactose grades since the physico-chemical 
characteristics of the lactose carrier, such as crystallinity, surface roughness, moisture 
sorption, shape factors, surface area and particle size, have a significant influence on the 
aerosolisation performance of the APIs [16, 43, 44].  
However, lactose may not be a choice of carrier for some APIs, such as 
formoterol, or protein/peptide drugs, due to its reducing sugar function that may interact 
with the functional groups of these APIs [45]. It is therefore reasonable to look for 
alternative carriers that still possess the positive aspects but overcome the above 
mentioned drawbacks of lactose monohydrate. The potential alternatives to lactose that 
have been investigated include carbohydrates, such as fructose, sucrose, trehalose; 
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alditols (such as mannitol and xylitol),  maltodextrin, dextrans, and cyclodectrins [16, 
45].  
 
1.2.1.2. Ternary components 
The idea of adding ternary components to the binary drug-carrier mixture to 
modify strong inter-particulate forces that often lead to low level of fine particle 
detachment from the carrier has been widely accepted. Although the mechanism of action 
of ternary components has not been clearly defined, it is generally believed that the 
additional ternary particles adhere preferentially to the high energy sites of carrier particle 
surface, thus forcing drug particles to adhere to less active sites of carrier surface [46, 
47]. During aerosolisation of the formulation, drug particles are therefore more easily 
liberated from the carrier, increasing the amount of drug available for inhalation. 
Materials that have been widely examined as ternary components are as follows: L-
leucine, magnesium stearate, lactose fines, polyethylene glycol 6000, and lecithin [16]. 
 
1.2.2. Particle engineering technologies 
1.2.2.1. Milling 
The majority of currently marketed DPI products consist of micronized APIs in 
either agglomerated or blended form. The most well-developed and convenient technique 
for size reduction of highly crystalline APIs is milling. There are many different milling 
methods, but only a few are able to mill powder to the respirable particle size range of 1 
to 5 µm. Vibration milling, ball milling and, in particular, jet-milling (fluid energy) are 
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well-established techniques used to manufacture dry powders for inhalation [40, 44]. 
Generally, the characteristic particle shape of milled crystalline API is either tabular or 
round showing high surface roughness, as shown in Figure 1.2 (A).  
The milling processes can adversely alter the surface and solid-state properties of 
APIs due to the harsh processing conditions, and are always accompanied with a heat 
generation and triboelectric charge generation [44]. It is often reported that the milling 
process generates amorphous domains on the particle surface that may possibly be 
subject to chemical degradation or recrystallization leading to crystal growth on the 
milled particle surface. Moreover, the cohesive and adhesive nature of milled crystals is 
known to be the primary hurdle in aerosol generation from the dry powder aggregates. 
Overall, the milling method, although it is a well-established technique, can only 
provide limited opportunity to manipulate and control the particle characteristics. It is 
generally not suitable for fragile molecules and more complex engineered structures, such 
as porous/hollow particles, non-spherical particles, composites, nano-aggregates as well 
as surface-modified, coated or encapsulated materials [44]. 
 
1.2.2.2. Spray drying 
Spray drying technology has been widely applied to various pharmaceutical 
processes due to its simplicity, availability of large-scale equipment and ability to 
produce composite materials. However, the production of resipirable particles using a 
spray drying method is a relatively new area; there is no marketed product available, with 
several products under development stage. One major reason for this is the limitations in 
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the size reduction capability of this method; generally an intense process optimization 
and large amount of excipients are required to achieve the desired powder properties. 
Additionally, there is common concern regarding a thermal degradation of sprayed 
products and the physical instability of amorphous-structured products. Nevertheless, the 
spray drying method is rapidly expanding as the technology becomes more optimized. 
Several new formulation approaches utilizing the spray drying technique have been 
introduced [44, 48].   
The concept of low density or hollow particles as a respirable dry powder 
formulation has been introduced [44, 48, 49]. Several studies have indicated that large 
porous particles (> 5 µm) which have low density are adventurous for pulmonary drug 
delivery since they improve dispersibility and delivery efficiency by lowering the 
aerodynamic diameter of the particles [44, 48, 49]. In terms of powder deagglomeration, 
these large particles do not require much energy input for generation an aerosol, because 
the large porous particles aggregate less and deaggregate more easily under less shear 
force than smaller and non-porous particles. The carrier particles that usually added to the 
micronized API formulations are not required for this type of formulation, indicating that 
the inhalation device having simpler and more compact features than other devices used 
for traditional carrier-based formulations can be applied for aerosol generation [39]. 
PulmoSpheres™ (Nektar Therapeutic, San Carlos, CA, USA) formulations have 
been engineered to show improved powder flow and dispersibility relative to traditional 
micronized dry powder formulations. These microparticles are manufactured by a spray 
drying of an emulsion, in which the dispersed phase typically has a submicron droplet 
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size and consists of a liquid that evaporates slower than the dispersed phase [50, 51]. 
Manufactured particles have a sponge-like appearance (Figure 1.2 (C)), unlike typical 
spray-dried particles that have a smooth and spherical morphology (Figure 1.2 (D)). 
Highly corrugated particles as shown in Figure 1.2 (B) can be created by using 
shell forming agents or materials with a high Péclet (Pe) number, such as leucine, 
trileucine, dipalmitoylphosphatidylcholine (DPPC), and materials with high molecular 
weight as polymers [48]. These materials cause early separation of a soft surface layer 
during the spray drying process since the diffusion of molecules from the atomized 
droplet surface to the inner core is slow, thus, the surface becomes enriched with shell 
former or molecules associated with the high Pe number, which finally folds to form a 
wrinkled morphology [44, 48]. Particles having a more corrugated morphology have 
shown better dispersion under shear force, than smoother particles due to less surface 
contact area, which will results in reduced van der Waals force of attraction [49, 50, 52-
55].  
Encapsulated drug particles by dispersibility enhancers, such as leucine and 
trileucine, have been engineered by spray drying. This type of formulation can be 
manufactured by modifying the diffusion coefficient of components using co-solvent 
systems. For instance, the dispersibility enhancers dissolved with APIs in 
aqueous/organic solvent mixture are rapidly supersaturated on the atomized droplet 
surface in the drying process due to their low aqueous solubility, implying that the 
surface of dried particles mainly consists of the molecules of dispersibility enhancers 
[48].   
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1.2.2.3. Polymorphic transformation 
Polymorphic transformation of drugs can be considered as a powerful particle 
engineering technique in the manufacture of respirable dry powders, although this 
method hasn‘t been widely applied for pulmonary drug delivery systems. Most drugs 
exhibit structural polymorphism and it is preferable to develop the most 
thermodynamically stable and physico-chemically favorable polymorph of the drug to 
achieve desired powder properties and the reproducible bioavailability of the product. At 
the molecular level, different particle shapes of crystalline materials may have different 
chemical functional groups on specific faces of the particles, leading to a variation in the 
surface energy, hygroscopicity, and electrostatic interactions. These differences will be 
manifested in the interparticulate forces at the particulate level. It has been proved that 
improved aerosolization properties can be achieved under such transformations, since the 
morphology of a particle can play the most important role in powder aerodynamic 
performance [54-58]. Several APIs have been successfully engineered as crystals with 
elongated (Figure 1.2 (E)) [56, 58], and flaky structures (Figure 1.2 (F)) [59]. These 
structural changes show significantly improved inhalation properties following 
polymorphic transformation [57-59]. Particularly, the elongated particles show very 
unique aerodynamic behaviors; the aerodynamic diameter of an elongated fiber is 
determined mainly by the width rather than by the length of the particle. Gonda and 
Khalik showed that the ratio of the aerodynamic diameter (Da) to the physical diameter 
(width, Df ) of an elongated particle increases with the aspect ratio (length/width) of the 
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particle and levels off at a value of about 2-2.5 when the aspect ratio is bigger than 15-20 
(Figure 1.3) [60]. 
 
1.2.3. Pulmonary sustained release formulations 
Recently, there has been an increased interest in research in focusing on DPI 
formulations to prolong drug residence time in the lung [61-65] since the sustained 
release (SR) system has certain advantages, including reduced dosing frequency by 
extending the duration of drug action, improved management of therapy,  improved 
patient compliance, and reduction in side effects [64, 66]. However, there are many 
limitations reported in manufacturing inhaled-SR formulations which produce a desired 
drug loading, release and aerosolization properties. The challenges are mostly related to 
the production of micron sized particles, since with a reduction in size there is a 
significant increase in surface area to mass ratio. Subsequently, with an increase in 
surface area, it becomes more difficult to produce a controlled release profile and 
incorporate effective release agents. Finding suitable non-toxic excipients is also known 
to be very challenging since excipients that have been used for pulmonary drug delivery, 
to date, is very limited.  
 
1.2.3.1. Microencapsulation 
Polymer-based matrix systems have been applied for modifying release systems 
of inhaled pharmaceuticals. Many synthetic and natural materials have been used to 
prepare controlled release microparticle systems. These microparticle systems include 
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biocompatible synthetic polymers such as poly lactic-co-glycolic acid (PLGA), polylactic 
acid (PLA), PEG, polyvinyl alcohol (PVA), and natural polymers or proteins such as 
chitosan or albumin [62, 64, 65, 67].   
PLGA and PLA have been the most commonly reported polymers utilized for 
potential respiratory sustained release systems [65, 68, 69]. These polymer matrices are 
typically prepared by spray drying co-dissolved API and polymer in vehicle solvent, or 
by using a multi-emulsion method (or solvent-evaporation method). However, common 
multi-emulsion techniques produce microspheres that have very low encapsulation 
efficiencies (1-10%), which is not ideal for pulmonary delivery due to the limitation in 
using potentially toxic polymers [65, 70]. A non emulsion spray drying process provides 
more flexible drug loading to the final formulation compared to the multi-emulsion 
method, but drug molecules are randomly positioned in the polymer matrix, but are 
mainly deposited on the spray-dried particle surface due to the diffusion rate difference 
between small drug molecules and large polymer molecules. Thus, traditionally spray-
dried microspheres show faster and more uncontrolled release rates than those prepared 
using a multi-emulsion method [62, 65, 71]. 
 
1.2.3.2. Aggregates of nanoparticles and micriparticle encapsulated nanoparticles 
Microparticles whose outer layer consists of polymeric nanoparticles 
encapsulating APIs have been investigated [63]. The preparation of this type of 
polymeric nanoparticle is achieved by the spray drying nanoparticles suspended in a 
continuous phase (vehicle solvent) that contains a shell former. Generally, spray-dried 
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nanoparticle aggregates show improved aerodynamic properties due to their hollow or 
porous structure, however, the porous structure may accelerate the release rate of 
encapsulated APIs [72]. For instance, PLGA nanoparticle aggregates encapsulating 
rifampicin show almost 90% drug release from the polymer matrix within 15 minutes 
[63]. Additionally, a large amount of drug loading into the nanoparticles is hard to 
achieve, as was previously discussed with the multi-emulsion method due to the 
similarity in drug encapsulation mechanism into the microparticles or nanoparticles.  
Lipid microspheres entrapping nanoparticles of hydrophilic drug can be prepared 
using a spray-drying approach [61]. Up to 33% of drug loading was achieved with 
retarded drug release profiles. However, the two phase systems required complicate 
manufacturing process. 
 
1.2.3.3. Hydrophobic coating 
Generally, hydrophobic coatings constitute approximately 10% to 50% of the 
final particle mass, which is substantially higher drug loading compared to the 
microencapsulated formulations. In US patent 6,984,404 [73], a physical vapor 
deposition (PVD) method using pulsed laser ablation (PLD), this is applied to achieve 
PLGA deposition onto the target particle surface, which offers nanometer thickness of 
coating layer with more than 90% drug loading. However, the use of a PLD method may 
possibly cause decomposition or degradation of APIs or polymers, due to severe 
processing conditions, which include exposure to UV radiation, high pressure, and heat. 
Moreover, the coating of each separate particle is difficult to achieve since there is no 
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suitable method to fluidize or agitate ultra-fine particles (1-5 µm) that exhibit strong 
cohesion properties during the coating process. A coating onto aggregated particles may 
lead to poor aerosolization performances, as the particle size of formulated particles will 
increase. 
A spray dry method to obtain coated particles has also been widely evaluated [74, 
75]. This technique is a relatively simple one-step process over other coating techniques. 
However, the application of this method is limited as micronized core forming particles 
have to be dispersed in the coating solution without dissolving the core-forming particle.  
Consequently, although several conventional methods have been attempted to 
coat particles classified into a Geldart Group C group or smaller particles [76, 77], those 
techniques have not been successfully applied for inhalation formulations. 
 
1.3. IN VITRO PERFORMANCE TESTING 
 
1.3.1. Aerodynamic particle size analysis 
Multi-stage cascade impactors (CIs) are defined in the US and European 
pharmacopeias (Table 1.2) for the measurement of inhaler aerosol aerodynamic particle 
size distribution (APSD). CIs are used both in the development and subsequent quality 
control (QC) of marketed inhaler products and the qualification of the clinical batches 
[78]. 
In its simplest form, a single stage impactor comprises a nozzle plate containing 
one or more circular or slot-shaped jets (nozzles) of diameter (W) located a fixed distance 
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(S) from a flat collection surface (Figure 1.4). Incoming particles are size classified on 
the basis of their differing inertia, which reflects the resistance to a change in direction of 
the flow. Liquid impingers are a variant in which the particles are captured in a liquid 
medium rather than on a solid substrate, an advantage is that particle bounce and re-
entrainment is avoided. Additionally, the liquid in the impinger can be the eluent medium 
for recovery and assay of active pharmaceutical ingredient(s). The multistage CI is 
constructed by coupling several stages (typically 7 or more) together with progressively 
finer and/or reduced number of jets such that particle velocity and hence inertia is 
progressively increased.  In this way the device fractionates the incoming aerosol into 
particles covering discrete and well-defined size ranges [79].  
The ACI (Figure 1.5 (A)) is currently still the most widely used multistage 
impactor for inhaler aerosol testing, although the NGI (Figure 1.5 (B)) is becoming more 
widely used as familiarity with its capability grows. Both CIs can operate in the flow rate 
range of interest for pMDI and DPI testing (30 to 100 L/min), but the ACI requires the 
removal of the lowermost stages (6 and/or 7) and insertion of new stages at the upper end 
(stages 1 and 2) for use at flow rates of 60 and 100 L/min [80]. On the other hand, the 
NGI does not require stage replacement [81] and can operate over the entire range with 
excellent size resolution [82]. It can even be used without its pre-separator and a back-up 
filter substituted for the multi-orifice collector [83]. Other CIs in use are the Marple-
Miller 5-stage design that uses collection cups, similar in concept to the NGI (Figure 1.5 
(C))) and which is available in a low flow version (4.9 and 12 L/min) for testing inhalers 
intended for pediatric use [84], as well as in the standard versions that operate at 30 and 
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60 L/min for routine testing of pMDIs and DPIs [85]. The 4-stage multi-stage liquid 
impinger (MSLI, Figure 1.5 (D)) is the last widely used CI for inhaler aerosol 
evaluations, being a popular choice where collection of the active substance in the eluent 
for subsequent assay is possible [86].   
Although the underlying principle for the CI method is simple to understand, its 
practical implementation is technically challenging because it is labor-intensive, requiring 
a high degree of manual skill. Thus, the following factors have to be taken into account in 
method development [87]: 
1) Collection solvent (impingers) or recovery solvent (dry impactor systems); 
2) Quantitation lower limit for the active pharmaceutical ingredient(s); 
3) Recovery techniques for the active pharmaceutical ingredient(s); 
4) Use of a pre-separator (important for many DPIs, in particular those based on the 
drug-carrier particle delivery principle); 
 
5) Environmental factors (barometric pressure, temperature, relative humidity). 
 
1.3.2. In vitro dissolution studies for evaluating inhalation products 
Dissolution testing allows one to examine the drug release behavior of 
pharmaceutical dosage forms in vitro in order to differentiate formulation types, and 
perhaps give an estimate of a dissolution behavior in vivo. Several USP general chapters 
(i.e. <711>, <724>, <1088>, and <1092>) play a key role in these evaluations as the gold 
standard tests. Those tests are routinely successfully applied to estimate in vitro 
dissolution behaviors of solid, or semi-solid dosage forms [88]. However, there is no such 
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universally accepted method to estimate the dissolution behavior of inhaled active 
ingredients, although many dissolution methods for testing aerosols have been 
investigated [89]. Designing a standardized method applicable to the lung is not an easy 
task, as the lung has several unique features which are difficult to replicate in vitro, such 
as the extremely small amount of aqueous fluid, and the presence of endogenous lung 
surfactants [19, 89]. 
For inhalation products, one of the most important steps with in vitro performance 
testing is characterization of the delivery of a given API from a specified delivery device 
using a pharmaceutical impactor/impinger to estimate actual dose delivered to the target 
site of the lung. Only a fraction of the API emitted from standard delivery devices is 
usually delivered to the target site of the deep lung since most inhaler products are 
mixture of fine API particles and course carrier particles or propellants [18]. Thus, an 
ideal dissolution test procedure for inhalation formulations would involve particle 
classification followed by an evaluation of the dissolution behavior for the classified drug 
particles that may deposit at various sites in the respiratory tract. Additionally, a stagnant 
dissolution system, rather than well stirred system would be required to estimate lung 
dissolution as the volume of lung fluid is approximately 10-20 mL/100 m
2
 [19]. 
Experimental difficulties exist in dose collection due to very fine powder and their 
electrostatic characteristics [89]. Therefore, to date most dissolution procedures on 
powders have been performed in the absence of aerodynamic classification, whereby 
formulations may have been directly dispersed into an apparatus 2 dissolution tester [90], 
or placed directly into a modified basket to prevent drug particles from escaping directly 
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into to the dissolution medium [62, 91]. However, these methods using existing 
configurations of dissolution apparatuses have following limitations: 
1) Formulations intended for pulmonary delivery are hard to disperse 
homogeneously into the vessel/basket; 
 
2) Dispersed particles stick on the vessel wall and/or paddle/basket during such 
dissolution tests; 
 
3) Floating powders may be inadvertently collected during the sampling procedure. 
4) Existing paddle/basket apparatus provide well-stirred environment; 
In an attempt to make up for some of the shortfalls of this type of testing using 
commercially available dissolution systems, several diffusion systems, a custom built 
diffusion cell [61], a twin-stage impinger (TSI) [92], and a dissolution cell [93, 94], have 
been investigated. However, no single in vitro test system has yet emerged as the ideal 
choice for performing dissolution measurements for inhalation formulations. 
 
1.3.3. Surface morphology 
The morphology (roughness or corrugation) of particles play a very important role 
in aerosolization performance of pharmaceutical powders. It has been shown that the 
broad adhesion force distributions between particles are attributed to the morphology of 
surface, in particular, the surface roughness [53, 95, 96]. A considerable number of 
studies have been explored to correlate the surface structure of particles with powder 
flow and aerosolization performance, and the interest keeps growing as various 
engineered particles having unique structural features have been introduced to the market. 
Commonly, scanning electron microscopy (SEM) is widely being applied to analyze the 
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surface morphology of particles, however, this method is only limited to visualize the 
particle structure, and cannot provide numerical values for the degree of difference since 
it is a qualitative analysis method [95]. The quantification of surface morphology can be 
achieved by various techniques, such as the atomic force microscopy (AFM) and the light 
scattering methods [52, 53, 97, 98].  
The AFM is the most common and most well-established method used to evaluate 
the surface roughness of a particle. The AFM consists of a cantilever with a fine tip at its 
end that is used to scan the specimen surface. When the tip is brought onto a sample‘s 
surface, the forces between the tip and the sample lead to a deflection of the cantilever, 
according to Hooke‘s law. In a study conducted by Islam et al., the surface roughness of 
various lactose carriers was quantified by AFM imaging, and the results showed 
significant roughness, even though the SEM images of those particles seemed to be 
smooth [96]. It has also been verified quantitatively by AFM imaging, that spray dried 
BSA particles having a high degree of surface corrugation have a better aerosolization 
efficiency than that of smooth particles [53]. 
 
1.4. PULMONARY TUBERCULOSIS 
 
Tuberculosis (TB) is a chronic infectious disease, which is considered the 
foremost cause of death due to a single microorganism [99]. According to the World 
Health Organization (WHO), approximately 9,270,000 people were newly diagnosed 
with the disease in 2007, about 1,300,000 people died, and about one third of the overall 
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population in the world was infected with the tubercles bacillus [100]. The occurrence of 
TB is most often due to Mycobacterium tuberculosis (MTB) infection and the lung is the 
primary site of infection; 80% of TB cases are of pulmonary TB alone [31]. 
MTB is an intracellular parasitic bacterium that mainly infects the respiratory 
tract and hides in alveolar macrophages (AMs). AMs are one type of immunecompetent 
cell present in the lungs. When foreign substances such as a disease organism are inhaled 
and reach an alveolus, they are endocytosed by AMs and eventually transported to 
phagosomes. The endocytosed foreign substance is then degraded by the digestive 
enzymes in the phagosome. However, when MTB is endocytosed, it inhibits formation of 
phagolysosomes and avoids degradation in the AM, resulting in a latent infection [101]. 
 
1.4.1. Treatment 
1.4.1.1. Antibiotics for treatment of pulmonary tuberculosis 
The most common treatment for TB involves oral administration of high systemic 
doses of single or combined antibiotics [102-104]. The chemotherapy regimens consist of 
four first line anti-TB drugs namely, rifampicin , isoniazid, pyrazinamide and ethambutol, 
used in an initial intensive treatment phase of two months and a continuation phase 
usually lasting 4-6 months [103, 104]. The recommended daily doses of four anti-TB 
drugs are 5, 10, 25 and 15 mg/body weight (kg) for rifampicin, isoniazid, pyrazinamide 
and ethambutol, respectively [103]. However, it has been reported that inappropriate 
monotheraphy can cause the development of TB that resistance to the first-line drugs 
[102-104]. To avoid problems associated with monotherapy, such as, over-dose or under-
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dosing, the first-line drugs have been recommended to be taken in combination [103, 
104]. Several fixed-dose combination (FDC) products containing rifampicin, isoniazid, 
pyrazinamide, and ethambutol are in use today [102, 103, 105]. 
However, concern has been expressed on the poor bioavailability and the unstable 
chemical potency of rifampicin from FDC products containing isoniazid and/or 
pyrazinamide [106, 107]. The existence of rifampicin in different crystal forms and the 
change from one form to another during processing are repeatedly quoted as the reasons 
for the variable bioavailability of rifampicin from FDC products [108-111]. The 
rifampicin is an important component in anti-TB therapy, thus using FDC tablets with 
poor rifampicin bioavailability could lead directly to treatment failure and may encourage 
drug resistance. Furthermore, clinical and bacteriological investigations have revealed 
that the anti-bacterial activity of rifampicin is dose-dependent [112]. Therefore, a good 
quality FDC tablet with demonstrated bioavailability of rifampicin is an absolute 
requirement for successful TB treatment.  
 
1.4.1.2. Anti-tubercular inhaled therapy 
To date, no aerosol products containing anti-TB drugs have been developed yet. 
However, several current studies are under investigation for administration of anti-TB 
drugs to the primary infection site, the lung, with the idea of increasing the local 
therapeutic effect and reducing overall systemic exposure [63, 65, 68, 113-116]. 
Specifically, pulmonary delivery of rifampicin has been widely studied [63, 65, 68, 113, 
115, 117] as it is the first choice drug in the treatment of TB [99, 118]. Furthermore, 
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pulmonary delivery bypasses drawbacks seen in current oral delivery systems, 
specifically, delivery of rifampicin to the neutral milieu of the lung avoids severe 
chemical decomposition of rifampicin in the acidic conditions of the stomach when taken 
orally [28, 102, 119]. Several respirable forms of rifampicin, such as nano/microparticles 
[63, 65, 68], liposome [115], and liquid [116], have been introduced to localize the 
rifampicin in the lung.  
Recently, there has been an increased interest in research in focusing on DPI 
formulations to prolong drug residence time in the lung [61-65] since the SR system has 
several advantages [64, 66]. Specifically, in anti-TB inhaled therapy, it‘s well established 
that the SR formulation enhances the efficacy of anti-TB drugs, presumably by targeting 
AMs and building up high intracellular drug concentrations. Generally, the phagocytic 
uptake of inhaled particles by AMs has been known to be the primary hurdle in extending 
drug residence time in the lung [64, 66]. However, in pulmonary anti-TB therapy, the 
phagocytic activities play a useful role in terms of targeting anti-TB drugs at the main site 
of the MTB proliferation [120, 121]. Several SR formulations that encapsulate anti-TB 
drugs into the polymeric microspheres have been introduced to target the AMs [63, 65, 
122, 123]. Respirable PLGA/PLA microspheres showing up to 3 days of in vitro drug 
release capability were manufactured by means of a solvent evaporation and a spray 
drying method [65, 120, 121]. A formulation consisting of PLGA nanoparticle aggregates 
was also introduced by sung et al. [63]. However, there are still numerous limitations in 
manufacturing the dry powder forms of SR formulations to have good aerosolization 
properties with controlled drug release capabilities due to their fine particle size. 
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Additionally, the low payload of APIs has been shown to be one of the problems in 
inhaled TB treatment, since the bactericidal activity is directly proportional to the 
concentration at the target site [112, 116] . Consequently, ideal SR formulations used to 
effectively treat airway infections like TB require both high drug payload and prolonged 
drug release from the delivery platform.  
Another issue in delivering the dry powder form of anti-TB antibiotics to the lung 
is that there are no DPI devices specifically designed to carry a large amount of antibiotic 
formulation. Currently available devices are all designed for delivering small amounts 
(microgram dose) of bronchodilators or steroids [39]. Only single-dose capsule devices 
have a capability to hold the substantial amount of (milligram dose) formulations among 
the current devices. However, those devices are relatively old type and show poor 
aerosolization properties compared to novel active devices. Thus, the development of 
formulations that show a low device dependency and good aerosolization performances is 










Table 1.1  Particle dispersion mechanisms used in selected devices 
 Device Developer Mechanism Type 
Passive 
Clickhaler®  ML Laboratories Impaction body Multi dose (Reservoir) 
Easyhaler®  Orion Pharma Narrow passage Multi dose (Reservoir) 
Novolizer®  Viatris Air classifier Multi dose (Reservoir) 
Airmax Yamanouchi Cyclone separator Multi dose (Reservoir) 
Taifun®  Leiras OY Vortex chamber Multi dose (Reservoir) 
AIR®  Alkermes Narrow passage Single dose (Capsule) 
Active 
Exubera®  Nektar therapeutics Air pump Multi dose (Blister) 
Aspirair®  Vectura Air chamber Multi dose (Blister) 
Spiros®  Dura Pharmaceutical Battery powder Multi dose (Disk) 













Table 1.2  Identification of apparatuses for APSD measurement in the US and European 
Pharmacopeias 
Impactor US Pharmacopeia European Pharmacopeia* 
Glass Twin Impinger (TI) Not Used 
Apparatus A for pMDIs, DPIs and 
nebulizers 
Andersen 8-stage 
without pre-separator (ACI) 
Apparatus 1 for pMDIs Apparatus D for pMDIs 
Marple Miller 
Model 160 (MMI) 
Apparatus 2 for DPIs Not Used 
Andersen 8-stage 
with pre-separator (ACI) 
Apparatus 3 for DPIs Apparatus D for DPIs 
Multi-Stage Liquid Impinger 
(MSLI) 
Apparatus 4 for DPIs Apparatus C for pMDIs and DPIs 
Next Generation 
Pharmaceutical Impactor (NGI) 
Apparatus 5 for DPIs 
Apparatus 6 for pMDIs 
Apparatus E for pMDIs and DPIs 
 
* Apparatus B was the single-stage ‗Metal Impinger‘ that was withdrawn from the European 












Figure 1.1  Schematic diagram of the particle deagglomeration mechanisms in passive 

















Figure 1.2  Morphologies of engineered particles by various micronization techniques; 
(A) milled API crystals, (B) highly corrugated particles, (C) low-density porous powders 
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Chapter 2: Research Outline 
 
2.1. OVERALL OBJECTIVES 
 
The goal of this research was to develop and fully investigate a novel method of 
antibiotic drug delivery to the lung that will address problems with current therapeutic 
regimens for treatment of airway infections, specifically, pulmonary tuberculosis (TB). 
The development of respirable form of dry powder formulations that encapsulate 
maximum potency of anti-TB drugs and show controlled drug release manner was aimed 
to increase both the therapeutic effect of delivered drug at the site of infections and the 
patient compliance. To demonstrate the performance of prepared formulations, suitable 
characterization methods were also investigated, more specifically, in vitro dissolution 
test method, since there is no optimized in vitro model to predict the rate and extent of 
drug dissolution in the lung following inhalation. 
 
2.2. SPECIFIC OBJECTIVES 
 
2.2.1. Development of novel in vitro dissolution method for inhaled pharmaceutical 
formulations 
There are several in vitro methods that exist for the prediction of respirable 
fraction and site of deposition in the lung following pulmonary administration (e.g. 
Andersen Cascade Impactor, Next Generation Impactor, Twin Stage Impinger). 
However, there is no optimized in vitro model to predict the rate and extent of drug 
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dissolution in the lung following inhalation. Currently available methods for evaluating 
the dissolution behavior of inhalation products rarely consider the impact of particle 
classification on the dissolution behavior. With pulmonary drug delivery systems, unlike 
other pharmaceutical dosage forms, only a fraction of the API emitted from standard 
delivery devices is delivered to the target site of the lung, and the deposited particles in 
the lung are in a deagglomerated state. Thus, an ideal dissolution test procedure for 
inhalation formulations would involve a particle classification step followed by an 
evaluation of the dissolution behavior of those discreet drug particles that could be 
deposited at various sites in the respiratory tract. The objective of this study was to 
develop a potential test method to characterize the dissolution properties of 
aerodynamically classified inhalation formulations. This study was focused the impact of 
the aerodynamic classification of aggregated powders on dissolution behaviors. 
 
2.2.2. Study factors affecting the dissolution behaviors of aerosol products using 
experimental and mathematical analysis 
A prototype membrane holder that was designed to be used to evaluate the 
dissolution behaviors of aerodynamically separated particles. Practically this membrane 
holder method demonstrated that the aerodynamic separation prior to dissolution 
assessment, has significant influence on the dissolution profile. However, in the 
dissolution setup using prototype membrane holder, the modification of NGI was 
required to collect aerodynamically classified drug particles on the membrane, and the 
whole dose collected on the membrane could not be used for dissolution testing due to a 
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substantial limitation imparted by the prototype holder frame size. The objective of this 
study was to develop a new membrane holder which can be directly incorporated with a 
pharmaceutical impactor, specifically, a Next Generation Impactor (NGI), and to 
investigate a standardized dissolution method using the newly manufactured NGI 
membrane holder. Several factors affecting the dissolution behaviors of aerodynamically 
separate aerosol particles in the NGI membrane holder were determined by both 
experimental and mathematical analysis. 
 
2.2.3. A new respirable form of rifampicin 
Several current studies have been proposed for the administration of anti-
tubercular drugs to the primary infection site, the lung, with the idea of increasing the 
local therapeutic effect and reduce the overall systemic exposure. Specifically, pulmonary 
delivery of rifampicin (RF) has been widely studied since it is the first choice drug in the 
treatment of TB. However, the aerosolization properties of developed formulations 
haven’t been adequately addressed to date, and represent the most important factors in 
determining the drug dose to the target site. The objective of this study was to develop a 
novel carrier/excipient-free dry powder inhalation (DPI) formulation of RF that has 
improved aerodynamic properties as well as a good stability profile. This study focused 
how the dihydrated form of RF (RFDH) was prepared from the pure RF form I, and how 
the crystalline structure and the physicochemical properties of RFDH were characterized 
by various analyses. The aerodynamic behavior of prepared RFDH was described with 
two DPIs; the Aerolizer®  and Handihaler® . 
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2.2.4. Preparation of sustained release rifampicin microparticles for inhalation 
Recently, there has been an increased interest in research focusing on DPI 
formulations to prolong drug residence time in the lung. A sustained release (SR) system 
has several advantages, including: reduced dosing frequency, improved patient 
compliance, and reduction in side effects. Specifically, in anti-TB inhaled therapy, it is 
well established that a SR formulation can enhance the efficacy of anti-TB drugs, 
presumably by targeting AMs and building up high intracellular drug concentrations [1-
3] . However, there are still numerous limitations in manufacturing SR formulations that 
have good aerosolization properties, high drug payload with controlled drug release 
capabilities due to their fine particle size. The objective of this study was to develop a 
novel carrier-free DPI formulation of RF that has a high drug payload, improved 
aerodynamic properties, and a sustained release capability. A spray-drying method was 
used to impart a hydrophobic coating of the dihydrate form of RF. The impacts of spray 
nozzles used for coating process on the coating properties were studied. The aerodynamic 
behaviors of prepared formulations were studied with a DPI device, the Aerolizer® . The 
dissolution behaviors of coated and uncoated formulations were evaluated using a newly 
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The aim of this research was to investigate a potential standardized test method to 
characterize the dissolution properties of formulations intended for pulmonary delivery. 
A USP type 2 dissolution tester was adapted to be used as a testing apparatus by 
incorporation of a membrane containing holder. The membrane holder was designed to 
enclose previously size-classified formulations, so that they could be uniformly tested in 
the dissolution apparatus. The influence of particle size, amount of drug loading, and the 
composition of a simulated lung fluid (SLF) dissolution media on the dissolution rate 
were studied. Dissolution rate was significantly affected by the uniformity of drug 
loading, and particle size. Diffusion coefficients, estimated using the Higuchi model, 








/hr as the particle size 
decreased. Addition of DPPC (0.02% w/v) to the SLF dissolution media also resulted in 
an increase in the diffusion coefficient value. This study demonstrated that developed 
method was reproducible and may be used to evaluate the dissolution properties of 
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Dissolution testing is an extremely well established and standardized test in all the 
Pharmacopoeias for evaluating solid and semi-solid dosage forms. Dissolution testing 
allows one to examine the dissolution behavior of pharmaceutical dosage forms in vitro 
in order to differentiate formulation types and perhaps give an estimate of a dissolution 
behavior in vivo. Dissolution testing is routinely used in quality control (QC) studies such 
as batch to batch consistency, stability, and detection of manufacturing deviations. While 
there are many standardized dissolution test methods for solid dosage forms such as 
tablets and capsules, there is no applicable method to estimate the dissolution behavior of 
inhaled active ingredients, although many dissolution methods for testing aerosols have 
been attempted [1]. Designing a standardized method applicable to the lung is not an easy 
task, as the lung has very unique features which are difficult to replicate in vitro, such as 
the extremely small amount of aqueous fluid and lung surfactant [1, 2]. Additionally, it 
would require that the collection of the specific API size fraction from the entire 
formulation before dissolution testing, as many inhalation products contain large carrier 
materials. Additionally, several experimental difficulties exist on dose collecting due to 
very fine and electrostatic powder characteristics [1].  
Commercial dissolution systems have been widely used to study the dissolution of 
aerosols. Dry powders have been directly dispersed into an apparatus 2 dissolution tester  
[3], or placed directly into a modified basket to prevent drug particles from escaping 
directly into to the dissolution media [4, 5]. However, dry powders intended for 
 50 
pulmonary delivery are hard to disperse homogeneously into the vessel/basket, and 
dispersed particles stick on the vessel wall and/or paddle/basket during such dissolution 
tests. In addition, floating powders may be inadvertently collected during the sampling 
procedure. In an attempt to make up for some of the shortfalls of this type of testing using 
standardized pharmacoepial dissolution systems, several custom built dissolution 
apparatuses have been investigated. Davies and Feddah modified a flow-through cell by 
direct incorporation of HPLC pump [6]. In this method the aerosol particles, obtained 
using impaction, were collected onto a glass pre-filter for dissolution studies. In another 
study using a horizontal diffusion cell, manufactured powders were dispersed onto the 
hydrated membrane and the dissolution rate was estimated by observing their diffusion 
rate [7]. In addition to these methods, twin-stage impinger (TSI) [8], dissolution cell [9, 
10], transwell [11] and shaking incubator [12, 13] apparatuses were also modified to 
conduct in vitro dissolution studies of dry powders. Although, these approaches do in 
some way make up for the drawbacks indicated above for standardized dissolution 
apparatuses, problems are still evident such as the impact of the amount of drug loading, 
adequate particle dispersion, and the uniformity of particle size distribution. Therefore, 
no single in vitro test system has yet emerged as the ideal choice for performing 
dissolution measurements for inhalation formulations. 
The aim of this paper is to describe a potential standardized test method to 
characterize the dissolution properties of the multitude of formulation types available for 
pulmonary delivery. Micronized hydrocortisone (HC) was selected as a model drug to 
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conduct in vitro dissolution on dry powders that were aerodynamically classified using 
the Next Generation Impactor (NGI).  
 
3.2. MATERIALS AND METHODS 
  
3.2.1. Materials 
Micronized hydrocortisone (HC) (USP grade) and size 3 empty gelatin capsules 
were purchased from the Spectrum Chemical Co. (Gardena, CA). Dipalmitoyl 
phosphatidylcholine (DPPC) was purchased from Avanti Polar Lipid, Inc. (Alabaster, 
AL). InhaLac
®
70 was donated by Meggle (Wasserburg, Germany). Polycarbonate (PC) 
membranes of 0.05 m and 1 m were purchased from Whatman (Florham Park, NJ). 
Cellulose acetate (CA) dialysis membranes with molecular weight cut-off (MWCO) sizes 
of 3500 and 12000 were purchased from Spectrum
®
Laboratories INC. (Rancho 
Dominguez, CA). An Aerolizer

 was donated by Schering-Plough (Kenilworth, NJ). 
Histology cassettes were purchased from VWR International, LLC (Suwanee, GA). 
Methanol (HPLC grade) and all other reagents were purchased from the Sigma Chemical 
Co. (St. Louis, MO). 
 
3.2.2. Solubility studies 
The solubility of HC was determined in simulated lung fluid (SLF), and modified 
simulated lung fluid (mSLF). The mSLF contained 0.02% w/v DPPC in addition to the 
standard ingredients contained in the SLF. Samples of HC (100 mg) were added to 20 mL 
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SLF, or 20 mL mSLF and shaken for 24 hours at 37°C. Samples (1 mL) were taken from 
each vial at 1, 2, 4, 8, 12, and 24 hour intervals and filtered using 0.45m syringe filters. 
All the samples were analyzed using a Agilent 8453 UV/VIS spectrophotometer (Santa 
Clara, CA) at 248 nm, the resultant equilibrium sample concentration was used to 
calculate the saturated solubility concentration. 
 
3.2.3. Dissolution apparatus 
A standard type 2 dissolution tester, Hanson SR8-plus dissolution test station 
(Hanson Co., Chatsworth, CA), was employed to conduct the dissolution study of 
micronized HC particles. A schematic diagram of modifications to the dissolution 
apparatus is shown in Figure 3.1. The two main components of the dissolution setup 
include: Component (A) the dissolution test station and component (B) a membrane 
holder. (A) the dissolution station consisted of i) mini-paddles (for 150 mL vessel), ii) 
dissolution vessels (150 mL glass vessel round-bottom), iii) a water bath, and iv) a 
sampling probe with 10 µm filter tip. The membrane holder (B) was customized and 
consisted of a histology cassette frame, with two pieces of selected membrane 
sandwiched inside the frame (acting a powder holding device). 
 
3.2.4. Dose collection 
3.2.4.1. Aerodynamic particle separation 
Particle separation of both bulk HC, or HC mixed with carrier lactose was 
conducted using a modified Next Generation Impactor (NGI) (MSP Co. Shoreview, MN). 
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Figure 3.3 (A) shows assembled NGI collecting plates. The NGI was fitted with a PC 
membrane at the base of each dose-collection plate. This membrane was placed beneath 
wax paper (which had been pre-trimmed to match the plate shape). A rectangular 
uniformly sized hole was pre-cut (22.5 cm) in the center of the trimmed wax paper that 
exposed the PC membrane situated beneath it. Micronized HC (2 g) was mixed with 30 g 
InhaLac®  70, and 150 mg of the powder mixture was filled into #3 empty gelatin 
capsules. Bulk HC (50 mg), without carrier, was also filled into #3 empty gelatin 
capsules. Capsules were placed into the Aerolizer®  (Schering-Plough, Kenilworth, NJ) 
and the device was primed according to the manufacturer‘s guidelines. Each of the HC 
containing capsules were dispersed into the NGI through the USP induction port at the 
flow rate 60 L/min, for 15 seconds per each actuation. The flow rate was measured by a 
Model DMF 2000 flow meter (MSP Co. Shoreview, MN). 
 
3.2.4.2. Scanning electron microscopy (SEM) 
Micronized bulk HC, and HC following particle separation by impingement were 
observed using a LEO 1530 SEM (Zeiss/LEO, Oberkochen, Germany). In this procedure 
each PC membrane containing separated HC particles was removed from the appropriate 
dose-collection plate of NGI and cut into a small segment (suitable for mounting on a pin 
plate SEM stub). The cut membrane segments from each dose-collection plate were 
mounted separately onto the stubs using double-sided copper tape, before sputter coating 
with Ag for 40 seconds under vacuum at 30 mTorr. Additionally, bulk HC powder was 
 54 
mounted and coated as described above. The SEM was operated at high vacuum with 
accelerating voltage 5kV and specimen working distance of 4 mm. 
 
3.2.5. Dissolution testing 
3.2.5.1. Dissolution media 
Simulated lung fluid (SLF), and modified SLF (mSLF) containing 0.02% (w/v) of 
dipalmitoylphosphatidylcholine (DPPC) were used for dissolution study. The SLF was 
first developed by Moss [14], and was described as being close to that of actual lung fluid 
in ionic composition and pH. The mSLF differs from the SLF by adding 200 g/mL 
DPPC to 100 mL of SLF solution. Both SLF and mSLF have been used in previous 
published in vitro dissolution studies due to their similarity in composition to actual lung 
fluid [6, 9, 10]. 
To prepare the mSLF, DPPC (200 mg) was weighed into a 500 mL round bottom 
flask and dissolved into a 40 mL chloroform/methanol (1:1) mixture. The solvent was 
evaporated by rotary evaporation (Buchi Corporation, New Castle, DE). The dry thin film 
was rehydrated with 200 mL distilled water at 55°C and rotated for 2 hrs. The warm 
suspension was placed into a Branson 5500 sonic bath (Branson ultrasonics, Denbury, 
CT) and sonicated at 55°C for 1 hour. The concentrated DPPC solution (0.2% w/v) was 




3.2.5.2. Dissolution testing of bulk HC particles   
Using the apparatus setup described above the dissolution medium was 
equilibrated at 37°C and the paddle speed was set to 50 rpm. Both bulk micronized HC 
and dispersed HC onto a membrane was tested. Firstly, bulk micronized HC (3 mg) was 
carefully weighed, and dispersed into each of 3 dissolution vessels containing 100 mL of 
SLF. Secondly, 3 mg HC was weighed separately onto a membrane (either PC or CA 
dialysis membranes). A second pre-soaked membrane with SLF of the same type was 
placed on top of the first membrane containing the powder; this was then sandwiched 
together and fitted into the membrane holder. Each holder was placed into a small 
volume dissolution vessel containing 100 mL of SLF (sink conditions were given all the 
test samples). Samples were manually withdrawn from the dissolution vessel at 0.5, 1, 
1.5, 2, 3, 4, and 6 hours to be analyzed by HPLC. The cumulative amount of dissolved 
HC was determined from the sum total of HC released. 
 
3.2.5.3. Dissolution testing of aerodynamically separated HC particles 
To aerodynamically classify carrier-free HC and carrier-mediated HC, capsules 
containing each formulation were fired separately into the NGI at the flow rate 60 L/min 
as previously described. The NGI dose-collection plates were assembled as above (with 
PC membranes and wax paper impaction templates). Following actuation for a given 
formulation the wax paper impaction template was removed from each dose-collection 
plate, and a PC membrane (pre-soaked with the appropriate dissolution media) was 
placed onto the top of each plate membrane (that now contained impinged HC particles). 
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The sandwiched membrane enclosed into the membrane holder as above, was then placed 
into a dissolution vessel (100 mL, 37°C, and 50 rpm, sink conditions were maintained for 
all of the test samples). The release rate of HC in either SLF and mSLF media were 
evaluated. Samples were withdrawn manually at the following time points: 10, 20, 40, 60, 
90, 120 minutes (SLF), and 5, 15, 30, 60, 90 minutes (mSLF). All samples were analyzed 
by HPLC. The residual amount of HC on the membranes was determined after the test by 
washing with 5 mL mobile phase prior to analysing using a validated HPLC method. The 
total amount of HC initially loaded between two membranes was back calculated using 
the sum of cumulated amount of HC, plus the remaining quantity of HC on each of the 
membrane holder. 
 
3.2.6. Analysis of HC dissolution with SLF or mSLF 
Collected samples from the dissolution studies that used SLF or mSLF were 
analysed by using a HPLC system (Waters Co., Milford, MA) with UV detection. The 
system consisted of a 717 plus autosampler, 2487 dual wavelength detector, 1525 binary 
pump, and 1500 column heater. Dissolution samples of HC in SLF or mSLF were filtered 
using 0.45 m PTFE syringe filter before injection. Chromatography was performed 
using a Capcell Pak C18 5 μm 4.6×250 mm column (The Shiseido Fine Chemicals, 
Tokyo, Japan) and a SecurityGuard™ guard column (Phenomenex®, Torrance, CA). The 
mobile phase which consisted of methanol, water, and phosphate buffer solution pH 7.4 
in a ratio of 10:10:0.4 respectively, was eluted at a flow rate of 1.0 mL/min and the UV 
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detector was set to a wavelength 220 nm [15]. The column temperature was maintained at 
40°C and the volume of each sample injected was 20 μL [15]. 
 
3.2.7. Mathematical modeling 
A diffusion coefficient for each dissolution study was determined using computer 
fitted data. The least square method was performed using MatLab (The Mathworks Inc., 
Natick, MA). The multidimensional unconstrained nonlinear minimization (Nelder-
Mead) method was used as an algorithm. 
 
3.2.8. Statistical analysis 
Data were expressed as the mean plus/minus standard deviation (SD). The 
statistical differences of release rates were studied by analysis of variance (ANOVA) 
using Jump 7.0 software (SAS Institute Inc., Cary, NC). Dissolution rate differences 
between, each NGI dose-collection plate containing different median particle sizes, were 
compared at several time points using a 1-way ANOVA. To identify the statistically 
significant differences between groups, Tukey-Kramer test was used.  value of 0.05 was 
applied to denote statistical significance. SD values were compared to assess consistency 








The saturated solubilities of HC in mSLF and SLF were 461 μg/mL and 345 
μg/mL, respectively. As indicated in the results, the addition of DPPC to SLF increased 
the solubility of HC. These results are in good agreement with the solubilising effect of 
lung surfactant, previously reported in the literature by several groups [16, 17].  
 
3.3.2. Membrane holder optimization 
A membrane holder was newly designed for conducting the dissolution studies of 
dispersed particles (Figure 3.1). To select a suitable membrane as the diffusion layer of 
dissolved drug, dissolution studies of model drug, HC, with three different membranes 
were conducted. In a comparison study between PC and CA dialysis membranes, the PC 
membrane demonstrated faster release of HC than that of other membranes as shown in 
Figure 3.2. An additional advantage was that the sandwiched PC membranes did not 
facilitate the formation of entrapped air between membranes, and visually demonstrated a 
tight seal due to their thin and rigid structure within the membrane holder. In contrast, 
entrapped air was readily seen between sandwiched CA dialysis membranes during 
dissolution.    
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3.3.3. Aerodynamic particle separation of HC particles 
HC aerosol particles were collected using the NGI (impaction plates before and 
after device actuation impingements are shown in Figure 3.3). In the figure, the wax 
paper impaction template can be clearly seen. Separated particles accumulated on the 
wax paper templates and exposed area of the PC membranes (under the template) on each 
dose-collection plate. The dispersion state of particles collected on each dose-collection 
plate was observed by SEM and is shown Figure 3.4. The SEM images show that bulk 
HC particles consist of irregularly shaped crystals ranging <1 to 5 μm. On the other hand, 
aerodynamically separated particles on each dose-collection plate displayed a very 
homogenous dispersion. The sizes of collected particles on dose-collection plates 3, 5, 
and 6 could be separated into ranges of approximately 3, 1, <1 μm, respectively. Dose-
collection plate cut-off particle sizes calibrated from the NGI are reported to be 4.46, 
2.82, 1.66, 0.94, 0.55, 0.34 μm at an inlet flow rate 60 L/min for dose-collection plates 2-
7, respectively [18, 19]. 
 
3.3.4. Dissolution 
3.3.4.1. Dissolution testing of bulk HC particles 
The dissolution behavior of micronized bulk HC was compared using two 
different dissolution methods, dissolution setup with a membrane holder and without a 
membrane holder. In this study, the impact of powder loading into the dissolution vessels 
on the test reproducibility and the dissolution of HC powders were investigated. As 
shown in Figure 3.5, the dissolution profiles of dispersed HC powders without membrane 
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holder into the dissolution vessel was much more variable than that of the same powder 
enclosed inside the membrane holder. However, there were no significant differences in 
the total dissolved amount of HC between the two methods. This result suggests that the 
membrane holder used in this study had no significant influence on the diffusion of 
dissolved drug, or diffusion of dissolution media into the holder. 
 
3.3.4.2. Dissolution testing of aerodynamically separated HC particles 
 
Influence of membrane pore size 
The influence of membrane pore size on the drug release profile was studied. PC 
membranes having different pore sizes (0.05 m and 1m) were tested. Figure 3.6 shows 
the release profiles of HC enclosed in two different membrane holders. It appears that the 
release profiles of HC particles accumulated in dose-collection plate 2 are not 
significantly different between the membranes. The PC membrane having pore size of 1 
m hindered initial drug release of HC particles accumulated in dose-collection plate 6 
which have a median particle size of 0.55 m. There is greater than a 20% difference in 
drug release rate in the first 40 minutes. 
 
Influence of particle size and drug loading 
The influence of powder presentation inside the membrane holder on the 
dissolution was studied. The total amount of loaded HC, by mass, following aerodynamic 
separation for dissolution studies is summarized in Table 3.1. Figure 3.7 shows release 
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profiles of HC for each NGI dose-collection plate. When the formulation contains a 
lactose carrier, the accumulated amount of HC on each dose-collection plate appeared to 
increase, as the NGI dose-collection plate number decreases (demonstrating the apparent 
efficiency of the carrier at preventing particle aggregation prior to deposition). The 
results demonstrate that the release rate of HC increases with decreasing particle size and 
amount of loading in accordance with the Noyes-Whitney equation for dissolution (as the 
exposed surface area is increased per unit mass of drug deposited). The degree of 
significance of these two factors on the release rate was further confirmed by the 
following studies. Multiple actuations were conducted to obtain different drug loadings, 
followed by dissolution testing. For each actuation, an average dose of 300 g was 
collected on dose-collection plate 2, and 70 g of HC powders were accumulated on the 
dose-collection plate 6. As shown in Figure 3.8, the dissolution rates of smaller particles 
are less affected by amount of loading drug compared to that of bigger particles. 
As expected for the carrier-free HC, amount of loading is much more variable 
between actuations of the Aerolizer
®
 compared to the carrier-mediated HC powders as 
shown in Table 3.1. The release profiles shown in Figure 3.9 reflect this non-uniform 
drug loading very well. A large degree of variability due to the irregular powder 
deposition is observed.  
 
Influence of dissolution media 
Figure 3.10 shows the release profiles of HC for dose-collection plates 2 and 6 in 
SLF or mSLF. The release rates of HC increased with the addition of 0.02% DPPC, 
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which was expected given the results from the solubility study that demonstrated 
increased saturation solubility in the media containing DPPC. The media containing 
DPPC may increase the wettability of hydrophobic drugs, and prevent aggregation to 
allow an enhanced dissolution rate [16, 17].  
 
3.3.5. Diffusivity from the membrane holder 
To verify the agreement between experimentally obtained results and a present 
mathematical diffusion model, the release profiles of HC particles were fitted to the 
Higuchi model (Equation 1), using the least square method, as shown in Figure 3.11. 
According to the Higuchi model [20], the cumulative amount of drug released from the 
holder per unit area, Q (g/cm
2




































                 (Equation 1) 
Where, h = thickness of PC membrane, C0 = initial loading concentration of drug, D = 
diffusion coefficient of drug, t = time after application and m = integer (from 0 to ∞). 
 
Using this fit from Equation 1, C0 and D could be calculated from the data (Table 
3.2). An important parameter, the volume of media (V) inside the holder could be 
calculated from obtained the C0 and from the experimental data. As shown in Table 3.2, 
overall volume of media between two membranes was constant, approximately 6 L, 
suggesting that the test condition inside the holder are very reproducible. C0 increased 
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with increasing HC mass (M) in the membrane holder. The diffusion constant (D) also 
increased with decreasing particle size, decreasing C0, or the addition of 0.02% DPPC. 
The D values, therefore, suggest that DPPC helps the migration of HC molecule from 
inside the holder into the dissolution vessel.  
 
3.3.6. Statistical analysis 
The HC mixed with carrier lactose shows more consistent release rates compared 
to that of carrier-free HC. Overall the relative standard deviation (% RSD) values were 
<10 in the case of carrier-mediated HC and > 30 for carrier-free HC. The release rate 
differences between the NGI dose-collection plates were much clearer with the carrier-
mediated HC particles (p < 0.05) than that of carrier-free HC particles (p > 0.05). For the 
carrier-mediated HC, the dissolution rate of the particles accumulated on dose-collection 
plate 6 was significantly different from that of all other groups for initial 40 minutes by 
Tukey-Kramer test. The differences between groups became less defined as dissolution 
reached 100% release. The influence of DPPC (0.02% w/v) on the release rate was not 
statistically significant, although DPPC helps with the solubilization of the drug as 








3.4.1. Dissolution apparatus 
A novel dissolution method for inhaled pharmaceutical formulations was 
developed, which comprised a commercial dissolution system, and a membrane holder as 
a formulation holding device. The mechanism of this dissolution method can be 
explained by dissolution-diffusion controlled drug release from the membrane holder. 
During the dissolution process using the membrane holder, the dispersed drug 
sandwiched between two membranes undergoes dissolution as dissolution media 
migrates through the pores on the membrane surface and the dissolved drug then releases 
out to the reservoir by diffusion.  
A PC membrane was selected as a diffusion layer of the holder. As shown in 
Figure 3.2, the PC membrane demonstrated almost a two-fold increase in drug release 
rate than CA dialysis membranes over the test period. This difference can be explained 
by the differences in physical structure of the two membranes. PC membranes are thin 
(approximately 6 µm) but still relatively robust for their handling requirements. 
Additionally, they do not swell and have a well-defined uniform pore size [21, 22], 
consisting homogeneous 0.05 µm cylindrical pores on the surface, to allow free diffusion 
of dissolved drug and dissolution media. These uniform characteristics are important for 
the purposes of this dissolution study because they can affect diffusion properties of 
dissolved drug. In contrast to PC membranes, although CA membranes have been 
successfully applied in various dialysis studies [23], many drawbacks have been reported 
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such as reduction of permeability induced by protein adsorption on the membrane 
surface, thick membrane structure, and swelling [24, 25].  
The PC membrane surface of the holder constitutes a perfect sink for the released 
drug. Dissolution media is able to rapidly diffuse into the holder and reach the drug inside 
through the numerous pores, subsequently allowing dissolved (released) drug to be 
immediately removed from the exposed membrane face under suitable hydrodynamic 
conditions. In comparison study between two different dissolution setups (with or without 
a membrane holder), no significant difference was found in the total dissolved amount of 
HC between the two methods, but the reproducibility was greatly affected (Figure 3.5). 
The differences in test reproducibility may suggest that dissolution properties of the 
dispersed particles varies considerably depending on their degree of aggregation, and 
may have a more profound meaning when one considers the electrostatic properties of 
inhalable formulations. As previously mentioned, fine dry powders are hard to disperse 
homogeneously, they may stick on the dissolution vessel wall or paddle, and they may 
also agglomerate. Conversely, powders enclosed within the membrane holder 
demonstrated a very consistent dissolution rates. This is due mainly to the uniform 
diffusion area of membrane holder (10 cm
2
), presented to the dissolution media, and the 
uniformity of the membrane barrier preventing premature particle escape (and a 
subsequent change in the surface area of drug presented to the media). 
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3.4.2. Dissolution studies 
It was confirmed that the PC membrane having a pore size of 0.05 m provided a 
perfect sink condition to the aerodynamically separated HC particles inside the holder. As 
shown in Figure 3.6, the obtained release profiles from two membrane holders are almost 
same for the big particles (dose-collection plate 2 of the NGI). However, PC membranes 
with larger pores often act as a diffusion barrier for small particles with similar particle 
size distribution to the membrane pore size. The enclosed particles are homogeneously 
separated thus, are easily released into the reservoir in the undissolved form and may clog 
the membrane pores in the process of escaping. 
The dissolution profiles of inhalation formulations were influenced by powder 
presentation inside the holder. As shown in Figure 3.3 (B), the dispersed powders form a 
powder bed on each dose-collection plate and the thickness of the powder bed is 
dependent on the amount drug loaded on each membrane. A larger amount of drug 
loaded on each dose-collection plate corresponds to a thicker powder bed deposited on 
the membrane (which would possibly lead to particle bounce with older types of vertical 
cascade impaction designs). Given that a thicker powder layer is deposited on the PC 
membrane then it follows that there will be more dissolution/diffusion activity required to 
release all of the drug from the inner space of the membrane holder. The size 
distributions of drug particles which constitute a powder bed also have effect on the 
dissolution rate. Bigger particles loaded inside the holder require more energy input to be 
completely dissolved and released out because the portion of the drug that remains 
undissolved inside the membrane holder acts as reservoir, allowing drug to dissolve in 
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accordance with the Noyes-Whitney equation [26]. Thus, the release rate of drug could 
be attributed to both particle size and amount of loading. The extent of significance of 
these two factors on the release rate can be explained from the data presented in Figure 
3.8. The results demonstrated that the release rates of the powder bed consisting of 
smaller particles were less influenced by the amount of loaded drug on the membrane due 
to their ability to wet and dissolve quickly (as the exposed surface area is increased per 
unit mass of drug ). It indicates that the amount of loading may determine the extent of 
powders wetting, and particle size could determine dissolution rate of the wetted particles 
inside the holder.  
This dissolution test setup may be directly applicable to the quality control studies 
for inhalation products, where the performance of carrier based delivery and the effect of 
electrostatic interaction of powders is critical for lung deposition and disease 
management. As shown in Figure 3.9, the dissolution profiles of aerodynamically 
dispersed particles reflect a powder dispersion status. For the carrier-free HC powder, a 
large degree of variability in test reproducibility was found due to the non-uniform drug 
loading, which can be directly attributed to the propensity of powder wetting within the 
membrane holder. Additionally, this method can be used to examine the dissolution 
behaviors of inhalation dosage forms with similar particle distribution by selecting drug 
particles accumulated in same dose-collection plate. It can be expected that dissolution of 
particles having similar size distribution may provide more discriminative capability to 
the result in formulation variables.  
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The dissolution media containing DPPC (mSLF) can be used to predict the 
solubility and solubilization process of inhalation formulations which have very low 
aqueous solubility. DPPC increases the wettability of hydrophobic drugs, and prevents 
aggregation to allow for an enhanced dissolution rate [16, 17] as shown in Figure 3.10. 
These results are in good agreement with the solubilising effect of lung surfactant, 
previously reported in the literature by several groups [16, 17]. 
 
3.4.3. Mathematical modeling 
Higuchi model was applied to calculate several unknown factors, such as D, Co 
and V. The Higuchi model is known to be a very simplified mathematical model to 
evaluate the release behaviours of matrix systems [26]. In particular, the Higuchi 
equation well describes the release kinetics of models based on a moving dissolution 
front that proceeds inwards with time separating a region of coexisting solid and 
dissolved drug from a region of completely dissolved drug. From the Higuchi equation 
(Eq. 1), D values for all the experimental release data were calculated (Table 3.2). The 
calculated D values are in good agreement with experimentally obtained release data. D 
values increased with decreasing particle size, decreasing C0, or the addition of 0.02% 
DPPC. The D values, therefore, suggest that DPPC helps the migration of dissolved HC 
molecules from inside the membrane holder into the dissolution vessel. Additionally, it 
indicates that non-uniform drug loading, and non-uniform size distributions (which are 
directly related to the device or aerosol performance) could contribute to diffusion rate of 
drug from the membrane holder. Generally, beyond saturated solubility, the amount of 
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initially loaded drug inside holder doesn‘t affect its release, if drug particles are evenly 
dispersed in the whole holder [27]. However, in the holder, sandwiched powders between 
two membranes form a layer so that the dissolution of drug gradually progresses inward 
layer by layer, until all solid drug particles have been wetted and dissolved. 
Consequently, the diffusion rate of molecules is governed by the thickness of the drug 




A new dissolution testing prototype apparatus for evaluating the in vitro 
dissolution behavior of inhalation formulations was designed. The dissolution rate of 
drug can be successfully estimated by analyzing the amount of drug released from the 
prototype membrane holder. This dissolution method may be used to quality control 
study for various dry powder inhalers (DPIs); in particular, the in vitro dissolution 
profiles of drug may provide an estimate of its dispersion characteristics which directly 









Table 3.1  Loaded amount of HC into the membrane holder for each stage. HC powders 
were loaded by aerodynamic separation of carrier-free HC and carrier-mediated HC. 
NGI Colle
ction-Plate 
Carrier-Free HC (mg) Carrier-Mediated HC (mg) 
Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 
Stage 2 2.97 0 3.02 0.76 0.60 0.80 
Stage 3 4.33 5.14 6.12 0.37 0.46 0.59 
Stage 5 2.31 6.10 1.57 0.32 0.36 0.29 
















Table 3.2  Estimated parameters calculated by data from release experiments. Standard 
deviation was calculated on three different tests. 
Test Sample M (mg ± SD) C0 (g/mL) V (L) D (cm
2
/hr) 
Stage 2-SLF 0.72 ± 0.11 10.9  10
4
 6.62 2.28  10
-7
 
Stage 3-SLF 0.47 ± 0.11 7.90  10
4
 5.96 2.70  10
-7
 
Stage 5-SLF 0.32 ± 0.04 5.22  10
4
 6.15 3.15  10
-7
 
Stage 6-SLF 0.06 ± 0.01 0.86  10
4
 6.41 9.60  10
-7
 
Stage 2-mSLF 0.62 ± 0.05 9.54  10
4
 6.55 4.86  10
-7
 
Stage 6-mSLF 0.06 ± 0.02 1.46  10
4
































Figure 3.1  Schematic diagram of the dissolution apparatus. Component A: dissolution 
station i) mini-paddles (for 150 mL vessel), ii) dissolution vessels (150 mL glass vessel 
round-bottom), iii) water bath, and iv) sampling probe with 10 µm filter tip. Component 















Figure 3.2  Release profiles of HC powders placed into the three different types of 
membrane holders (CA membrane: MWCO 3,500 and 12,000, PC membrane: 0.05 m 






















Figure 3.3 Modified next generation impactor (NGI). (A) NGI setup before impingement, 





























Figure 3.4  Scanning electron microscope (SEM) images of non-separated bulk HC 
powders (A), of aerodynamically separated HC into the dose-collection plate 3 (B), 5 (C), 





















Figure 3.5  Dissolved amount of HC dispersed into the dissolution vessel and placed 






















Figure 3.6  Release profiles of HC from two membrane holders having different pore 
size on the surface in mSLF for dose-collection plate 2, and 6. HC separated from the 






















Figure 3.7  Release profiles of HC separated from the lactose carrier in SLF for dose-






















Figure 3.8  Release profiles of HC from the membrane holder having different drug-
loading in SLF for dose-collection plate 2 (A) and 6 (B). HC separated from the lactose 


























Figure 3.9  Release profiles of HC separated from the carrier-free HC in SLF for dose-
























Figure 3.10  Release profiles of HC separated from the lactose carrier in SLF and mSLF 

























Figure 3.11  Release profiles of HC (open circle) from the membrane holder. Line 
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Chapter 4: Study Factors Affecting the Dissolution Behaviors of 






The aim of this study was to investigate an optimized test method to characterize 
the dissolution properties of numerous formulation types available for pulmonary 
delivery. A USP type 2 dissolution apparatus was adapted for this purpose by the 
incorporation of a specially designed NGI membrane holder. The NGI membrane holder 
was designed to be directly incorporated with a Next Generation Impactor (NGI) to 
seamlessly transfer and enclose air-classified formulations. Dissolution procedures, the 
apparatus, the dose collection, the medium, and test conditions were developed with 
reference to the USP General Chapter <1092>. Aerodynamically classified drug particles 
were collected on the NGI membrane holder followed by dissolution study. Two 
commercially available products, Ventolin®  HFA (albuterol sulfate) and 
PulmicortFlexhaler™ (budesonide) were tested. The dissolution profiles of budesonide 
(BD) and albuterol sulfate (AS) were successfully estimated by analyzing the amount of 
drug released from the NGI membrane holder. Additionally, several factors that influence 
dissolution behavior were also evaluated applying a mathematical model. This 
dissolution method has the potential to be widely used as an important quality control test 
procedure for inhalation products. 
 
4
Significat portions of this chapter were taken from : Yoen-Ju Son, Michelle Horng, Mark Copley, and 
Jason T. McConville
,
 ―Optimization of an in vitro dissolution test method for inhalation formulations”, 




For inhalation products, the most important step with in vitro performance testing 
is the delivery of a given API from a specified delivery device, and evaluation of its 
deposition using a pharmaceutical impactor/impinger. The impaction method is used to 
estimate actual dose delivered to the target site of the lung. In pulmonary drug delivery, it 
is well accepted that particles within the size range of 1 to 5 m can be successfully 
delivered to the targeted deep lung. However, only a fraction of the API emitted from 
standard delivery devices is usually delivered to this target site, due to the fine particle 
size distribution for most inhaler products [1]. Thus, an ideal dissolution test procedure 
for inhalation formulations would involve particle classification followed by an 
evaluation of the dissolution behavior of those sorted drug particles that may deposit at 
various sites in the respiratory tract. 
Experimental difficulties exist in dose collection due to very fine and electrostatic 
powder characteristics [2]. Therefore, most existing dissolution procedures on powders 
have been performed with no aerodynamic classification [3-8], although the particle 
separation has been shown to have a significant influence on dissolution profiles [9]. In 
an attempt to make up for the problems associated with aerodynamic particle separation, 
several custom built dissolution apparatuses have been investigated. Davies and Feddah  
reported a modified flow-through cell system [10]. In this method, the aerosol particles 
were separated and collected on the membrane placed at the base of a standard USP 
induction port of the Anderson Cascade Impactor (ACI), followed by flow through 
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dissolution testing. Another study using a Transwell®  permeable support system has 
been introduced by Arora et al.[11]. This permeability study also adopted the use of an 
ACI to separated aerosol particles on a membrane. Although, these approaches do, in 
some way, consider the particle separation prior to dissolution assessment, problems are 
still evident such as the amount drug loading, adequate dose collection on the impactor 
and hydrodynamic conditions employed. Moreover, there has been no reported study in 
focusing on mathematical modeling of the kinetics of dissolution, and permeation in the 
aforementioned dissolution apparatus.  
Numerous mathematical approaches have been proposed to estimate the 
dissolution behaviors of pharmaceutical dosage forms, such as Higuchi model [12], and 
the Noyes-Whitney equation [13]. However, most of efforts have been devoted to 
describe the release/diffusion kinetics of dissolved drug from drug delivery platforms that 
are predominantly matrix systems, intended for oral or transdermal drug delivery [13-15]. 
The main reason for this may be because of the diversity of formulation design; there are 
a wide variety of products showing different dissolution/release mechanisms targeted to 
the oral/transdermal route of administration. Conversely, formulation diversity for 
inhaled products is very limited, and is generally limited to physical mixtures of carrier 
particles with micronized APIs. Recently, there has been an increased interest in research 
focusing on novel inhalation formulations having different characteristic features, such as 
porous structures and prolonged release profiles [3, 4, 16-20]. Thus the usefulness of 
developing a new dissolution apparatus/method along with an appropriate mathematical 
interpretation of the results is set to increase.  
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This article describes the features of a newly developed membrane holder which 
was designed specifically to be incorporated into the NGI for better dose collection 
performance, than the prototype membrane holder device reported in Chapter 3. 
Additionally, several factors affecting the dissolution behaviors of aerodynamically 
separated aerosol particles in the NGI membrane holder were determined by both 
experimental and mathematical analysis. In the previous Chapter, a prototype membrane 
holder was used to assess the dissolution profiles of aerodynamically separated drug 
particles [9]. It was clearly shown that there was significant difference in dissolution 
performance between the bulk hydrocortisone (HC) formulation and an aerodynamically 
classified HC particles in the dissolution profile; the air-classified HC particles 
demonstrated at least three-folded increase in dissolution rate than that of non-separate 
bulk HC particles over the test period [9]. However, in the previous dissolution setup, 
modification of NGI dose-collection plates with polycarbonate (PC) membranes and wax 
paper impaction templates was required to collect dispersed particles on the membrane, 
and the whole dose collected on the membrane couldn’t be used for dissolution testing 
due to a substantial limitation imparted by the prototype holder frame size. The aim of 
this paper was to investigate a standardized dissolution procedure using the newly 
manufactured NGI membrane holder, and to develop an adequate mathematical model to 




4.2. MATERIALS AND METHODS 
 
4.2.1. Materials 
Ventolin®  HFA was purchased from GSK (Research Triangle Park, NC) and a 
PulmicortFlexhaler™ was purchased from AstraZeneca LP (Wilmington, De). 
Budesonide (99%) was purchased from the Sigma Chemical Co. (St. Louis, MO). 
Albuterol sulfate, USP was purchased from the Spectrum Chemical Co. (Gardena, CA). 
Dipalmitoyl phosphatidylcholine (DPPC) was purchased from Avanti Polar Lipid, Inc. 
(Alabaster, AL). Polycarbonate (PC) membranes of 0.05 m (76 mm) were purchased 
from Whatman (Florham Park, NJ). Methanol (HPLC grade) and all other reagents were 
purchased from the Sigma Chemical Co. (St. Louis, MO). 
 
4.2.2. Experimental analysis  
4.2.2.1. Dissolution apparatus 
A United States Pharmacopeia (USP) apparatus 2, Hanson SR8-plus dissolution 
test station (Hanson Co., Chatsworth, CA) was used to conduct the dissolution study. A 
NGI membrane holder (Copley Scientific Limited, Nottingham, UK) in position in the 
vessel of a standard USP apparatus 2 is shown in Figure 4.1 (A). The NGI membrane 
holder assembly (Figure 4.1 (B)) was customized and consists of a NGI dissolution cup 
(a), a removable impaction inset (b), a sealing ring (c), two sealing 0-rings, and a 
polycarbonate (PC) membrane to function as a highly porous diffusional powder 
retaining layer.  
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4.2.2.2. Dose collection 
To select a suitable particle size cut-off ranges for the subsequent dissolution 
study, aerodynamic particle separation was achieved using the NGI. Either the Ventolin
 
HFA device or the PulmicortFlexhaler device was actuated 5 times to obtain a 
quantifiable amount of drug. The NGI was operated at a flow rate of 30 L/min or 60 
L/min, for the Ventolin
 
HFA or the PulmicortFlexhaler, respectively. Air classified 
particles from each dose-collection plate of the NGI, which were not used in the 
dissolution studies, were reconstituted with mobile phase and analyzed using a validated 
HPLC method [21, 22]. 
For the dissolution studies, the dissolution cup assembled with the impaction 
insert was placed in the NGI as shown in Figure 4.2 (A). Either the Ventolin

 HFA or the 
PulmicortFlexhaler device was fired into the NGI at the same flow fate as above. 
Following actuation, the impaction insert was removed from the NGI dissolution cup for 
dissolution test.  
 
4.2.2.3. Scanning electron microscopy (SEM) 
BD particles following particle separation by impingement were observed using a 
LEO 1530 SEM (Zeiss/LEO, Oberkochen, Germany). In this procedure each PC 
membrane containing separated BD particles were removed from the dose-collection 
plate of NGI and cut into a small segment (suitable for mounting on a pin plate SEM 
stub). The cut membrane segments from each dose-collection plate were mounted 
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separately onto the stubs using double-sided copper tape, before sputter coating with Ag 
for 40 seconds under vacuum at 30 mTorr.  
 
4.2.2.4. Dissolution media 
Simulated lung fluid (SLF), and 0.2M phosphate buffer (pH 7.4), phosphate 
buffered saline (PBS), modified PBS (mPBS) containing dipalmitoylphosphatidylcholine 
(DPPC), and PBS containing polysorbate 80 (tPBS) were used in the dissolution studies.  
To prepare the mPBS, DPPC (500 mg) was weighed into a 500 mL round bottom flask 
and dissolved in a 100 mL of chloroform/methanol (1:1) mixture. The solvent was 
evaporated by rotary evaporation (Buchi Corporation, New Castle, DE). The dry thin film 
was rehydrated with 250 mL of PBS at 55°C and rotated for 2 hrs. The warm suspension 
was placed into a Branson 5500 sonic bath (Branson ultrasonics, Danbury, CT) and 
sonicated at 55°C for 1 hour. The concentrated DPPC solution (0.2%) was stored at 4°C. 
The prepared stock DPPC solution (0.2%) was diluted 10 fold with PBS before use. 
 
4.2.2.5. Solubility study 
The solubility of BD was determined in SLF solution. Samples of BD (10 mg) 
were added to 100 mL of SLF solution and shaken for 24 hours at 37°C. Samples (1 mL) 
were taken from each vial at 0.5, 1, 2, 4, 6, and 8 hour intervals and filtered with 0.45m 
syringe filter. All the samples were analyzed using a validated HPLC method [21] . 
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4.2.2.6. Dissolution study 
To aerodynamically classify budesonide (BD) and albuterol sulphate (AS) from 
the PulmicortFlexhaler device, or the Ventolin

 HFA device, each formulation was 
fired into the NGI as previously described. The NGI dose-collection plates were 
assembled as above (with the dissolution cup assembled with the impaction insert). 
Following actuation for a given formulation, the impaction insert was removed from the 
dissolution cup, and a PC membrane (pre-soaked with dissolution medium) was placed 
onto the top and sealed in place with the sealing ring of the NGI membrane holder. The 
sealed NGI membrane holder was then placed into each dissolution vessel containing 300 
mL of dissolution media (Figure 4.1 (A)). Dissolution testing was conducted at 50, 75, or 
100 rpm, to evaluate the effect of hydrodynamic conditions. Dissolution media (3 mL) 
was withdrawn manually using a glass syringe at timed intervals of 5, 15, 30, 60, 90, and 
120 minutes for the BD samples and at 5, 15, 30, 45, and 60 minutes for the AS samples. 
Collected dissolution samples of BD (2 mL) were diluted by adding 1 mL of mobile 
phase and filtered using 0.45 m PTFE syringe filters before analyzing. Alternatively, 
collected dissolution samples of AS were filtered using 0.45 m PTFE syringe filters. 
Fresh dissolution media (3 mL) was replaced into each vessel after sampling. All the 
samples were analyzed using a validated HPLC method [21, 22]. Adsorption of the drugs 
onto the syringe and filter was evaluated prior to the dissolution studies. 
The residual amount of BD and AS on the NGI membrane holder was determined 
after dissolution test by washing a membrane and the impaction insert with mobile phase 
(5 mL) prior to analyzing. The total amount of BD and AS initially loaded on the NGI 
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membrane holder was back calculated using the sum of cumulated release amount of 
each API, plus the remaining quantity of each API on the membrane holder. The percent 
drug release of AS and BD were calculated by dividing the amount of APIs released by 
the drug initially impacted and collected on to the membrane holder.  
 
4.2.2.7. Validated HPLC Analysis of BD and AS in the dissolution media 
Samples were analyzed by using a Waters HPLC system (Waters Co., Milford, 
MA) with UV detection. The system consisted of a 717 plus autosampler, 2487 dual 
wavelength detector, 1525 binary pump, and 1500 column heater. Chromatography was 
performed using a Capcell Pak C18 5μm 4.6×250 mm column (Shiseido Fine Chemicals, 
Tokyo, Japan) for BD and a Alltima C18 5μm 4.6×150 mm column (Grace, Deerfield, 
IL) for AS. The mobile phase for BD which consisted of methanol, acetonitrile, water, 
and acetic acid in a ratio of 50:10:28.3:1.7 respectively, which was eluted at a flow rate 
of 1.7 mL/min and the UV detector was set to a wavelength of 242 nm [21]. The mobile 
phase for AS which consisted of methanol and 0.1% ammonium acetate acetonitrile (pH 
4.5) in a ratio of 45:55 respectively, this was eluted at a flow rate of 0.8 mL/min and the 
UV detector was set to a wavelength 276 nm [22]. The column temperature for both APIs 
was maintained at 25°C and the volume of each sample injected was 100 μL for BD 
samples and 20 μL for AS samples. 
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4.2.2.8. Statistical analysis 
Data were expressed as the mean plus/minus standard deviation (SD). The 
statistical differences of release rates were studied by calculating a similarity factor (f2) 
[23]. For curves to be considered similar, f2 values should be close to 100. Generally, f2 
values greater than 50 (50-100) ensure sameness or equivalence of the two curves [23]. 
 
4.2.3. Mathematical analysis 
4.2.3.1. Theory 
The mathematical model has been derived for controlled release systems that 
show the sustained release of pharmaceutical compounds from a planer matrix system 
with simultaneous dissolution of crystal [13, 14]. This mathematical model was modified 
to evaluate the dissolution mechanism in the NGI membrane holder. As shown in Figure 
4.3 (A), a matrix containing solid drug particles assembled on the cross-sectional area of 
the matrix at x=x1, which is assumed to be achieved by one time actuation of aerosol 
generation device. In this system, as the solid drug dissolves and diffuses out, the size of 
the particles reduces with a dynamic that is governed by a finite dissolution rate. After the 
solid drug particles are fully dissolved in the media, the release process is governed by 
diffusion only. This primary model is extended to describe matrix systems containing 
solid drug particles assembled on N cross-sectional areas arbitrarily located at x1, x2,… xn 
(Figure 4.3 (B)) since the loaded drug particles into the membrane holder by aerodynamic 
separation do not always create a single layer. After a certain time, the exhaustion of the 
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particles begins and progresses inwards the matrix until all the solid drug particles are 
dissolved into the dissolution media. 
 
4.2.3.2. Model assumptions 
The underlying assumptions of the model to be mathematically formulated are: i) 
the mass transport of drug is one-dimensional; it takes place in the x-direction only (x0= 
no mass flux), (ii) the drug diffusion process is described according to Fick‘s second law, 
(iii) the drug dissolution kinetics are explained by Noyes-Whitney equation, (iv) particles 
distributed in the membrane holder are the same size, v) every device actuation creates a 
single particle layer, vi) solid drug particles dissolve keeping constant the original shape, 
which is assumed to be spherical, vii) the diffusion of dissolved drug through the 
membrane is not hindered, and viii) the membrane on the surface of holder is non-
erodible and non-swellable. Accordingly, the release process for the particles arbitrarily 
loaded in the membrane holder is described by following equations (the details of 




                                                                                                        
          
  
  
                                                                                          




                                                                                          
(Permeation of dissolved drug molecule through the PC membrane) 
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The equation (1), (2), and (3) can be described by a single equation as follows: 
 
  
        
  
   
                        
 
 
                                    
(in 0 < x < L, t > 0, n =1, 2,.., N, and N → ∞) 
 
to solve the time-dependent surface area (    function at  x1, x2,… xn, following 
equation can be used: 
 
  
       
       
   
   
 
                                                                 
For n = 1, 2,…, N, t > 0 with    
    
       
   as initial conditions 
Variables and parameters used in this modeling are displayed in Table 4.1. 
 
4.2.3.3. Numerical solution 
To simulate the changes in concentration gradient and surface area of loaded drug 
particles in the progress of drug dissolution within the membrane holder, equation (1) and 





      







      
 
   
                          
 
       
   
   
                     
         
Which are subjected to the following boundary conditions; 
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To calculate the drug concentration (C (x,t)) and the surface area of loaded drug 
(a) at any position in the membrane holder, equation (3) was solved by the PDEPE solver 
function in MATLAB®  (The Mathworks Inc., Natick, MA).  
 
4.3. RESULTS AND DISCUSSION 
 
4.3.1. Dissolution apparatus 
NGI membrane holders were placed at the bottom of dissolution vessels, with 
their release surface side up, and with the distance between the bottom edge of the paddle 
and the surface of the membrane holder maintained at 20  2 mm (Figure 4.1 (A)). The 
distance between the paddle and the surface of the NGI membrane holder can be adjusted 
within the range that allows for the paddle to effectively remove released drug from the 
exposed membrane surface and provide continuous circulation to the media in the vessel.  
The mechanism of this dissolution method can be explained by dissolution-
diffusion controlled drug release from the NGI membrane holder. During the dissolution 
process the dispersed drug within the membrane holder undergoes dissolution as 
dissolution media migrates through the pores on the membrane surface and the dissolved 
drug then releases out to the reservoir by diffusion [9]. Therefore, membrane properties, 
such as: pore size, pore tortuosity, and membrane thickness will have a profound effect 
on the release behavior of each drug. A PC membrane was selected as the diffusion 
barrier [9]. In the previous study reported by this group, the PC membrane demonstrated 
almost a twofold increase in drug release rate when compared to cellulose acetate (CA) 
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dialysis membranes [9]. This difference is attributed to the differences in the physical 
structure of the two membranes. PC membranes are thin (approximately 6 m) but still 
relatively robust for their handling requirements. Additionally, they do not swell, do not 
create air bubbles, have a well-defined uniform pore size [24, 25], and consist of 
homogeneous 0.05 m non-tortuous cylindrical pores on the surface that allow free 
diffusion of dissolved drug and dissolution media.  
 
4.3.2. The dissolution procedure 
4.3.2.1. Dose collection 
Aerodynamic particle classification was achieved with the NGI for both 
Ventolin
 
HFA and PulmicortFlexhaler to select a suitable particle size cut-off and the 
amount of drug loading for the following dissolution study. Unlike usual dissolution 
methods, drug loading into the NGI membrane holder is achieved by the particle 
impingement activity, thus, the particle deposition profile on each dose-collection plate is 
essential in determining the amount of initial drug loading and the particle size cut-off. 
Dose-collection plate 4 for PulmicortFlexhaler and plate 5 for Ventolin
 
HFA were 
selected for dissolution method validation study as these consistently displayed the 
maximum deposition for each product, as shown in Figure 4.4. Additionally, the median 
aerodynamic particle size values (D50) for dose-plate 4 and plate 5 of the NGI fall into the 
respirable particle size range (1-5 m) as 1.66 and 1.36 m at a flow rates of 60 L/min 
and 30 L/min, respectively [26].  
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To enable the dissolution studies, the impaction insert of the NGI membrane 
holder was inserted into the pre-selected NGI dissolution cup of the NGI (impaction 
plates before, and after device actuation impingements are shown in Figure 4.2). The 
amount of BD or AS that was collected on the impaction insert of the NGI membrane 
holder is presented in Table 4.2. The NGI membrane holder assembly used in this study 
was designed to facilitate maximum particle collection over a uniform collection area (18 
cm
2
). Particles having different particle size distributions can be easily collected by 
replacing a standard dose-collection plate with a dissolution cup, equipped with the 
impaction insert of the NGI membrane holder. Additionally, this method can be used to 
examine the dissolution behaviors of inhalation dosage forms with similar aerodynamic 
particle distributions by selecting drug particles accumulated in same dose-collection 
plate. It would be anticipated that dissolution of particles having a similar aerodynamic 
size distribution would provide more inter formulation discrimination. 
Dissolution profiles of BD particles having different particle size cut-off were 
conducted to evaluate particle size dependency in dissolution process. For the dissolution 
study, an average 25 g of BD powder were collected on the impaction insert placed in 
dose-collection plates 2-5. Figure 4.5 shows that the release profiles of BD particles 
accumulated on NGI dose-collection plates 2, 3, and 4 reached 80% after 15 minutes, 
with a significant difference in initial release rates. The similarity factors (f2) are 52.5 for 
dose-collection plate 2 and 59.7 for dose-collection plate 3 when individually compared 
to the dissolution profile of reference test, dose-collection plate 4 (Table 4.3). With 
particles accumulated on dose-collection plate 5, the overall dissolution profile is not 
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equivalent to the reference test (dose-collection plate 4), as f2 is 40.6. This may be 
attributed to the fact that smaller particles have better wettability and dissolve more 
quickly due to their larger surface area, as explained in the previous study [9]. Dose-
collection plate cut-off particle sizes calibrated from the NGI are reported to be 4.46, 
2.82, 1.66, 0.94, 0.55, 0.34 μm at an inlet flow rate 60 L/min for dose-collection plates 2 
through 7, respectively [26].  
 
4.3.2.2. Hydrodynamic conditions 
Dissolution tests of BD were conducted at 50, 75, and 100 rpm paddle speeds. 
Dissolution profiles obtained at a rate of 75 rpm were shown to be the most consistent, as 
shown Figure 4.6. For the paddle apparatus, 50 rpm is most commonly used, however, a 
higher paddle speed was required due to the ―dead‖ volume between the NGI membrane 
holder and the bottom of the vessel. The dissolution media circulates through the gap 
between the holder and the vessel wall around the holder. However, due to the narrow 
gap, the circulation of media is somewhat hindered and a higher agitating speed is 
required to provide better circulation to the media under the holder. The release profile of 
BD at an agitating speed of 100 rpm was not plotted as an eddy was observed at that 
agitating speed (this was a consequence of using a relatively low volume of dissolution 
media was used in these studies). 
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4.3.2.3. Dissolution media 
The dissolution profiles of BD (PulmicortFlexhaler) in simulated lung fluid 
(SLF), 0.2 M phosphate buffer, and phosphate buffered saline (PBS) were investigated. 
The dissolution profiles from three media were similar as shown in Figure 4.7 (A). Table 
4.3 shows the similarity factors (f2) between PBS and phosphate buffer as 63.4 and 51.6 
when compared to the SLF, respectively. Therefore, either phosphate buffer, or PBS 
could be used as an alternative dissolution media. The SLF used was first developed by 
Moss [27], and was described as being close to that of actual lung fluid in ionic 
composition and pH. SLF has been used in previous published in vitro dissolution studies 
due to their similarity in composition to actual lung fluid [5, 10, 27]. However, SLF 
media may not be preferable for the routine quality control (QC) study for inhalation 
products due to its low buffering effect. In particular, the use of SLF media would not be 
recommended for evaluating inhalation dosage forms that show pH-dependency or 
sustained-release manner in their dissolution profile. As shown in Figure 4.7 (B), the pH 
of SLF increases from 7.4 to 8.8 over 24 hours without continuous CO2 bubbling. It has 
been reported that the pH of SLF media is significantly increased without CO2 bubbling 
[27].  
A volume of 300 mL media was used for the dissolution studies. This was 
determined to be a minimum volume needed to occupy the 20  2 mm distance between 
the membrane holder surface and the bottom edge of paddle, as shown in Figure 4.1 (A). 
The volume of media may be raised up to 900 mL, and is dependent on the concentration 
and sink condition of the drugs to be evaluated. The dissolution of drug from the NGI 
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membrane holder occurs by diffusion of dissolution media through the pores on the 
membrane surface. The amount of dissolution media diffused through the pore was 
mainly determined by the paddle speed and pore size on the membrane surface, and not 
the amount of media in the vessels. Normally, for the paddle and basket apparatus, the 
volume of media is 500 mL to 1L, where 900 mL is most common volume. However, the 
dissolution system may optimally be less than sink conditions in order for test 
compounds to approximate dissolution behaviors of formulations in the lung, since the 
volume of lung fluid is extremely small, approximately 10-20 mL/100 m
2 
of surface [1, 
2]. The NGI membrane holder, used in this study, was designed to maintain a very thin 
liquid layer between the membrane and test powders. Dissolution media is continuously 
exchanged from the vessel reservoir to the drug particles enclosed inside the holder by 
agitation, and a very thin liquid layer is maintained to dissolve drug particles [9]. In other 
words, a dynamic equilibrium is rapidly established for solute exchange, following the 
commencement of a given dissolution test with the membrane holder. 
 
4.3.2.4. Amount of drug loading 
The amount of drug loading on the NGI membrane holder showed significant 
influence on the drug release rate, especially for the PulmicortFlexhaler which contains 
the hydrophobic steroid BD. The amount of drug loaded on the membrane holder is 
summarized in Table 4.2. It can be shown in Figure 4.8 (A) that 80% dissolution was 
achieved in 30 minutes when 29.4 g of drug is loaded by 1 time device actuation (1T). 
As the loading amount increased from 29.4 g (1T) to 224 g (10T), the dissolution rate 
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significantly slowed. Conversely, the dissolution rates of Ventolin

 HFA, that contains 
the hydrophilic AS, did not display the same degree of dose dependency as 90% 
dissolution was achieved in 5 minutes for all the test samples, as shown in Figure 4.9. 
This indicates that the loading amount may determine powder wetting inside the holder, 
and the significance of this was shown to be dependent on the hydrophobicity of the API 
used. When the device is actuated, dispersed powders form a powder bed on each dose-
collection plate and the thickness of the powder bed is dependent on the amount of drug 
loaded on each dose-collection plate. A larger amount of drug loaded on the plate 
corresponds to a thicker powder bed, as shown in Figure 4.10. Given a thicker load of 
powder bed on the NGI membrane holder, there will be more dissolution/diffusion 
activity required to release all of the drug from the inner space of the NGI membrane 
holder as the dissolution of loaded drug gradually progresses inward layer by layer until 
all solid drug particles have been wetted and dissolved. Consequently, the release rate of 
molecules is governed by the thickness of the drug layer and by the solubilization rate of 
that drug layer. Ideally, the device needs to be actuated one time to obtain well dispersed 
particles in an approximately single layer. However, the thickness of the powder bed can 
also be varied according to the drug dose. For instance, a 1 time actuation of a high dose 
formulation can create a thicker powder bed than a 1 time actuation of a low dose 
formulation. Additionally, in some cases, multiple actuations may be necessary to obtain 
quantifiable drug concentration in the media since at least 300 mL of dissolution media is 
required to conduct dissolution study. Care must be taken when the loading dose is high 
or is obtained by multiple device actuations, especially for poorly water soluble drugs.   
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For very poorly soluble compounds, dissolution media may contain a percentage 
of surfactant to enhance drug solubility for testing very poorly soluble compounds [28]. 
To improve the wettability of BD particles and to help their solubilization, two different 
surfactants, polysorbate 80 and dipalmitoyl phosphatidylcholine (DPPC) were added to 
PBS media. Polysorbate 80 provided a better solubilization effect to the BD powder than 
that of DPPC, as shown in Figure 4.8 (B). DPPC may help powder wetting, however, the 
effect was not significant. Initial drug release rate of BD in the mPBS during first 45 
minutes were similar to that of SLF media.  
DPPC is a main component of lung surfactant and the effect of lowering surface 
tension at the air/water interface is essentially performed by a DPPC monolayer [29]. Due 
to their similarity in composition to actual lung fluid, the dissolution media containing 
0.02% of DPPC has been used to predict the solubility and solubilization process of 
inhalation formulations that have very low aqueous solubility [10, 30]. However, in this 
study using the NGI membrane holder, DPPC in the media may not be able to freely 
diffuse and reach the drug particles inside the membrane holder as DPPC forms 
liposomal aggregates in aqueous media [31]. These liposomal aggregates have a bigger 
particle size distribution (50 -150 nm) than the membrane pore size on the surface. Thus, 
although wettablity of BD powders was somewhat increased by adding DPPC, significant 
wetting, or solubilizing of BD was not found over the test period. As shown in 4.8 (B) 
and Table 4.3. PBS containing 0.2% w/v polysorbate 80 was found to be an ideal 
dissolution media to evaluate 5 times actuated BD, as f2 was 64.7 when it is compared 
with the dissolution curve of 1 time actuated BD which is assumed to be an ideal dose for 
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dissolution. The concentration of surfactant needs to be justified by showing profiles at 
several different concentrations for variety of different dose loadings, and dissolution 
profiles need to be compared with that of standard sample to determine a suitable 
concentration of surfactant.  
 
4.3.3. Mathematical analysis 
4.3.3.1. Mathematical model 
There has been several mathematical models to analyze drug release from systems 
containing both diffusion of dissolved compound and dissolution of dispersed compound 
in the matrix system [13, 14]. These mathematical models consist of a dissolution 
reaction term described as the Noyes-Whitney equation with a diffusion term described 
as Fick‘s law. In these models, unlike general diffusion models that show only the mass 
flux of dissolved drug in pharmaceutical matrix systems, the effects of the relative rate of 
drug dissolution to drug diffusion and of non-uniform drug loadings on the drug release 
pattern for planar matrix systems were taken into account. Due to the similarities in the 
dissolution/release mechanism of loaded drug particles from, which can be explained by 
the dissolution-diffusion controlled drug release from the planar matrix systems, the 
developed mathematical model was applied to analyze the factors affecting the 
dissolution of loaded drugs in the membrane holder. In the mathematical analysis, the 
sealed NGI membrane holder with a PC membrane is considered as a planar matrix 
system consisting of a thin liquid layer and loaded drug particles in the form of either a 
single or multi-layer. The existing mathematical model was simplified with parameters 
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and variables having unit instead of dimensionless parameters used in the existing 
models. For numeric calculation, Eq.(4) in the form of Dirac delta function may be 
converted to the continuous function of x as Eq.(6). The numerical calculations were 
performed by the PDEPE solver function in MATLAB®  (The Mathworks Inc., Natick, 
MA). Full description of the derivation procedures is given in Appendix A. 
 
4.3.3.2. Single layer system 
The dissolution kinetics of drug particles loaded in the NGI membrane holder was 
analyzed by mathematical simulations. Specifically, the mathematical analysis focused 
on the impacts of the amount of hydrophobic drug (BD) in the membrane holder, which 
was shown to be the most critical factor in dissolution study, on the dissolution profiles. 
The results of mathematical calculation for the 1 time actuated sample (1T), which was 
assumed to be the ideal condition for dissolution study, is shown in Figure 4.11. There 
was no concentration gradient observed at any positions within the membrane holder 
(from x=0 to x=L, x=0 represents the very bottom layer of the powder bed, and x=L 
represents the very front layer of the powder bed facing the PC membrane); the levels of 
BD concentration were equal throughout the membrane holder. This data implies that the 
diffusion of dissolved drug toward the PC membrane layer is not retarded by dissolution 
media or undissolved particles in the holder, unlike usual matrix systems having release 
retarding layer, such as polymers and gels. It has been known that the concentration 
gradient in the matrix system is usually created by the slowed diffusion of drug molecule 
in the release retarding layer of matrix, leading to sustained drug dissolution/release [13, 
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14, 32]. As shown in Figure 4.11, the concentration of BD in the NGI membrane holder 
increased as time passed, whereas the surface area of drug particles gradually decreased 
as a function of time, indicating that the dissolution media in the NGI membrane holder is 
immediately replaced with the dissolution media containing dissolved BD in the reservoir 
(dissolution vessel), with continuous dissolving of BD particles loaded in the holder. 
 
4.3.3.3. Multi-layer system 
For the 10 times actuated sample (10T), contrary to the result of 1T sample, the 
difference in BD concentrations at different positions of the membrane holder was 
observed; overall, BD concentrations at x=0 were slightly higher than the concentrations 
at x=L over the period of dissolution time, as shown in Figure 4.12 (B). The difference in 
the concentration gradient between 1T and 10T samples can be explained by the relative 
rate of BD dissolution to the diffusion of dissolution BD molecule through the powder 
bed having different thickness (L). In the mathematical calculation, it was assumed that 
the BD particles loaded x=xn position dissolve at the same dissolution rate (KD) and the 
diffusivities (D) of dissolved BD molecules in the NGI membrane holder are same for 1T 
and 10T samples. From the calculation results applying the conditions above, it was 
found that the dissolution of BD particles within the powder bed was relatively faster 
than the diffusion of dissolved molecule through the powder bed. This indicates that the 
dissolved BD molecules close to x=0 position require more time to reach x=L layer than 
the molecules close to x=L position to be released out to the reservoir. Consequently, 
more dissolved BD molecule is accumulated in the powder bed as the thickness of 
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powder bed (L) increases. From the series of results, it may be estimated that the 
concentration gradient within the NGI membrane holder (consisting of a powder bed) 
become more significant if the diffusion of dissolved molecule is slowed by the powder 
bed consisting of undissolved drug particles. 
To simulate the impact of diffusivity (D) of drug molecule in the powder matrix 







/s were applied to the mathematical calculation. The value of 
6.3×10
-6 
was the free diffusion coefficient of BD in the dissolution media calculated by 
applying the Stoke-Einstein equation [33] and other values were assumed. The decrease 
in the diffusion coefficient as drug particle size and the amount of powder loading 
increased was confirmed by our previous study [9]. The simulation results were shown in 
Figure 4.13. The images show the BD concentration at x=xn positions as a function of 
time for the D values of 6.3×10-6, 6.3×10-7, and 6.3×10-8 cm2/s. The degree of 
concentration gradient created within the NGI membrane holder (consisting of a powder 
bed) increased as D values decreased, indicating that a powder bed consisting of more 
packed and denser particle aggregates may act as a release retarding layer, resulting in a 
sustained drug release from the powder matrix (powder bed). It was clearly seen from 
Figure 4.13 (B) that the lowest D values, 6.3×10-8, demonstrated a marked difference in 
the BD concentrations within the NGI membrane holder (from x = 0 to L) compared to 
higher D values. Moreover, the BD concentrations in the NGI membrane holder were 
much more concentrated than that of reservoir until the BD concentrations between the 
holder and the reservoir reached a hydrodynamic equilibrium state at 120 minutes. This 
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result is opposite of what was obtained with higher D values (3×10-6 and 6.3×10-7 cm2/s), 
indicating the dissolved BD molecule is trapped within the packed powder bed. The 
plateaus at the BD release profiles obtained from 5T and 10T samples shown in Figure 
4.8 (A) can be explained by the series of data above; the dissolution of BD particle in the 
powder bed may be slowed by limited amount of dissolution media, and the diffusion of 
dissolved BD molecules may be hindered and finally stopped by saturated BD 
concentration in the powder bed. It can be more clearly seen from Figure 4.14 that the 







/s as a function of time, implying that more BD molecules 
stacked up in the powder bed instead of releasing out to the reservoir due to the slow 
diffusion of BD molecule in the powder bed. It was clearly shown that the thickness and 
density of powder bed (amount of drug particles) had significant influence on the release 
profiles of drug molecules. As mentioned above, a monolayer created by 1 time device 
actuation is ideal condition to conduct this type of dissolution study, however, this 
condition cannot be applied for all dissolution studies of inhalation products since high 
dose formulations can create a thicker powder bed by 1 time actuation than low dose 
formulations. Besides, the thick powder bed does not always retard drug release. Even 
though, the powder bed is thick, the release rate may not be delayed by the thick powder 
bed if the drug particles rapidly create void spaces in the powder bed by dissolving as the 
case of AS. Therefore, the amount of drug loading may be varied with the 





A new easy to use NGI membrane holder for evaluating the in vitro dissolution 
behavior of inhalation formulations was designed. The dissolution rates of commercially 
available drug formulations were successfully estimated by analyzing the amount of drug 
released from this attachment for the NGI. Factors having impact on the dissolution 
profiles were evaluated by mathematical model. This dissolution method may be used for 
a quality control studies for various dry powder inhalers, in particular, the in vitro 















Table 4.1  Parameters and variables used for modeling  
Factors Abbreviation Unit Value 
Diffusion coefficient  
(when particles are aligned in 
monolayer, Figure 4.1(A)) 
D cm2/s 6.3e-6  
Thickness of membrane hM cm 6e
-4 
 
Partition coefficient  
(matrix/membrane) 
K - 1  
Permeability coefficient P cm/s 1.01e-2  




 16.2  




 Experiment data  
Surface area of single drug 
particle at x = xn 
(as an initial condition) 
  
  cm2/s 
Varies with the particle size 
deposited on each NGI 
dose-collection plate  
Number of particles associated 
to the drug dissolution source 
at x = xn 
Sn - 
Varies with the amount of 
drug loaded on the NGI 
membrane holder 
Dissolution rate constant KD cm/s 6e
-4
 
Thickness of matrix L cm 
Varies with both the 
number of device actuation 
and the particle size  
 







Table 4.2  Amount of drug loaded on the dose-collection plate 4 (BD) and plate 5 (AS) 
for dissolution studies. (The amount of loading was calculated by adding a remaining 
quantity of APIs on the NGI membrane holder to the total quantity of APIs released from 












1 29.4  5.1 15 259.5  42.4 
2 55.2  3.8 20 320.7  17.7 
5 151  12.7  















Table 4.3  Similarity factors (f2) between two dissolution curves of BD collected from 
PulmicortFlexhaler device (Rt: reference performance, Tt: test performance, T: number 
of actuation) 
Rt Tt f2 Rt Tt f2 Rt Tt f2 
SLF -
1T 













































Figure 4.1  Schematic diagram of the dissolution apparatus. NGI membrane holder in 
position in the vessel of a standard USP 2 test apparatus (A), and NGI membrane holder 

















Figure 4.2  Modified next generation impactor (NGI). (A) NGI setup before 

























Figure 4.3  Schematic illustration of different architectures of membrane holder 
containing aerodynamically classified drug particles to be mathematically described 



























HFA, and PulmicortFlexhaler™ were actuated 5 
times at 30 L/min and 60 L/min, respectively. The error bars indicate the standard 




















Figure 4.5  Release profiles of BD for dose-collection plate 2-5 (T: Number of actuation, 





















Figure 4.6  Release profiles of BD at rotating speed of 50 rpm, and of 75 rpm.(T: 





















Figure 4.7  Release profiles of BD in three different dissolution media, PBS, 0.2 M 
phosphate buffer and SLF (A), and pH of PBS, 0.2 M phosphate buffer and SLF media 
measured for 24 hours without continuous CO2 bubbling (B) (T: Number of actuation, the 






















Figure 4.8  Release profiles of BD from the NGI membrane holder having different 
drug-loadings in SLF media for dose-collection plate 4 (A) and release profiles of BD in 
PBS media containing 0.02% DPPC, 0.02% polysorbate 80, and 0.2% polysorbate 80 (B). 























Figure 4.9  Release profiles of AS in SLF medium (T: Number of actuation, the error 




















Figure 4.10  Scanning electron microscope (SEM) images of aerodynamically separated 
BD particles on the NGI dose-collection plate stage 4: (A) 1 time device actuation (1T), 

















Figure 4.11  Profiles of (A) surface area of single BD particle and (B) BD concentration 
as function of axial coordination, at every 24 minutes intervals, for BD particles collected 
on the NGI dose-collection plate 4 by 1T device actuation. The calculation performed 
using parameters listed in Table 4.1. Solid line in blue, red and black represent 
mathematically calculated values at 0, 24,48 minutes, respectively, and broken line in 





















Figure 4.12  Profiles of (A) surface area of single BD particle and (B) BD concentration 
as function of axial coordination, at every 24 minutes intervals, for BD particles collected 
on the NGI dose-plate 4 by 10T device actuations. The calculation performed using 
parameters listed in Table 4.1. Solid line in blue, red and black represent mathematically 
calculated values at 0, 24,48 minutes, respectively, and broken line in blue red and black 













Figure 4.13  Profiles of BD concentration in the NGI membrane holder as a function of 
time for BD particles collected on the NGI dose-collection plate 4 by 10T device 





, and (c) 6.3e
-8
. Other parameters are listed in Table 4.1 Solid line in blue, 
red and black represent mathematically calculated values at 0, 24,48 minutes, 
respectively, and broken line in blue red and black represent mathematically calculated 
values at 72, 96, and 120 minutes, respectively.
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Figure 4.14  Profiles of BD concentration at x=0 and x=1 planar as a function of time for 
BD particles collected on the NGI dose-collection plate 4 by 10T device actuations: D 




, and (C) 6.3e
-8
. Other parameters are 
listed in Table 4.1. Solid line in blue and red represent mathematically calculated 
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Chapter 5: A New Respirable Form of Rifampicin5 
 
Abstract 
The aim of this research was to investigate a novel dry powder formulation of 
Rifampicin (RF) that presents an improved lung deposition profile by means of a 
polymorphic transformation into a flake-like crystal hydrate. Rifampicin dihydrate 
(RFDH) was prepared by recrystallization of RF in anhydrous ethanol and amorphous RF 
(SP-RF) was prepared by spray-drying. The physicochemical properties of the RFDH and 
the SP-RF were characterized. Aerosol performances of RFDH and SP-RF were studied 
using a Next Generation Impactor (NGI). The RFDH powder, successfully prepared 
using a simple recrystallization process, had a MMAD of 2.2 m. The RFDH powders 
were characterized as having a very thin flaky structure; this morphology provided 
improved aerosolization properties. The maximum fine particle fraction (FPFTD) of 68% 
for the RFDH was achieved with the Aerolizer®  device. Significant chemical 
degradation was not observed from the RFDH, while the SP-RF showed significant 
chemical degradation over a 9 month period. The flaky morphology of RFDH resulted in 
a reduced agglomeration tendency, relative to spherical SP-RF particles. The excipient 
free formulation of the RFDH would offer the benefit of delivering a maximum potency 
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Tuberculosis (TB) is a chronic infectious disease, which is considered the 
foremost cause of death due to a single microorganism [1]. The occurrence of TB is most 
often due to Mycobacterium tuberculosis (MTB) infection and the lung is the primary site 
of infection. The most common treatment for TB involves oral administration of high 
systemic doses of single or combined antibiotics, which causes unwanted side-effects by 
high systemic exposure of said antibiotics [2]. Several current studies have been proposed 
for the administration of anti-tubercular (TB) drugs to the primary infection site, the lung, 
with the idea of increasing the local therapeutic effect and reduce the overall systemic 
exposure [3-9]. Pulmonary delivery of rifampicin (RF) has been widely studied [3-6, 8, 
10] since it is the first choice drug in the treatment of TB [1, 11]. Several respirable forms 
of RF, such as nano/microparticle [3-5], liposome [8], and liquid [9], have been 
introduced to localize the RF in the lung. However, the aerosolization properties of these 
types of formulation have not been adequately addressed to date, and represent the most 
important factors in determining the drug dose to the target site. The aerosolization 
properties are especially important in dry powder inhalation (DPI) formulations, as the 
dispersion and subsequent deposition profiles of powders are predominantly governed by 
the physicochemical properties of the drug and the excipient used for manufacturing [12-
15].  
The polymorphic transformation of drugs may be considered to be a powerful 
particle engineering technique in the manufacture of respirable dry powders. Improved 
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aerosolization properties may be achieved under such transformations, since the 
morphology of a particle can play the most important role in powder aerodynamic 
performance. It has been shown that adhesion force distributions between particles can be 
attributed to their morphology, for instance, the surface roughness [16-18], and the 
crystal shape [19-21]. Several active pharmaceutical ingredients (APIs) have been 
successfully engineered as crystals with elongated [19, 21], and flaky structures [20]. 
These structural changes may show significantly improved inhalation properties 
following polymorphic transformation [19, 20, 22]. Current research strategies for 
respirable dry powder RF formulations are predominantly focused on the amorphous 
form, having a spherical shape [3, 4, 6]. This is due to the fact that they are prepared by a 
microencapsulation followed by either a spray-drying or solvent evaporation process [3, 
4, 6]. These spherical particles may be either blended with carrier materials [6, 23], or 
manufactured as a carrier-free low density powders containing relatively large amounts 
of excipient [4], in an effort to minimize adhesion forces between particles. However, 
low density particles have limitations in the drug payload due to this significant quantity 
of incorporated excipient. And in the case of RF a substantial amount (milligram dose) 
needs to be delivered to the lung to be efficacious [4, 5]. Additionally, the amorphous 
form of several investigated RF formulations may not provide long term stability, since 
amorphous materials often undergo chemical degradation or a recrystallization processes.  
The aim of this study is to develop a novel carrier-free dry powder inhalation 
(DPI) formulation of RF that has improved aerodynamic properties as well as a good 
stability profile. It is the goal of this research to demonstrate that the use of a 
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polymorphic transformation directly from RF crystals can offset some of the 
aforementioned limitations with other investigated formulation types. This study 
describes how the dihydrated form of RF (RFDH) was prepared from the pure RF form I, 
and how the crystalline structure and the physicochemical properties of RFDH were 
characterized by various analyses. The aerodynamic behaviors of prepared RFDH are 
also described with two dry powder inhalers (DPIs), the Aerolizer®  and Handihaler® .  
 
5.2. MATERIALS AND METHODS 
 
5.2.1. Materials 
Rifampicin (RF) was purchased from the Sigma Chemical Co. (St. Louis, MO). 
Size 3 hydroxypropylmethyl cellulose (HPMC) capsules were donated from Capsugel 
(Peapack, NJ). Polycarbonate membranes of 0.05 m, were purchased from Whatman 
(Florham Park, NJ). An Aerolizer

 dry powder inhaler device was donated by Schering-
Plough (Kenilworth, NJ). A Handihaler

 device was donated from Boehringer Ingelheim 
GmbH (Rhein, Germany). A NGI membrane holder was provided by Copley Scientific 
(Nottingham, UK). All other reagents were purchased from the Sigma Chemical Co. (St. 
Louis, MO).  
 
5.2.2. Preparation of rifampicin hydrate and amorphous rifampicin  
Rifampicin dihydrate (RFDH) was prepared by heating the anhydrous ethanol 
suspension of the form I rifampicin (RF) to 60C. RF powder (900 mg) was added to the 
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hot anhydrous ethanol solution (30 mL) and stirred until a saturated solution was 
obtained, after the solution had been allowed to cool to room temperature. The 
suspension was homogenized with a Ultra-Turrax®  high-shear homogenizer (IKA
®
 
Works Inc., Wilmington, NC) at 10,000 rpm for 2 minutes to homogeneously disperse 
the particles. The resultant suspension was then spray dried with constant stirring using a 
Büchi Minispray dryer B-290 (Büchi Laboratory-Techniques, Flawil, Switzerland). The 
following conditions were used during spray drying: drying airflow, 40 m
3
/h; spraying 
airflow, 500 L/h; suspension feed rate, 5 mL/min; nozzle size, 0.5 mm; the inlet 
temperature was established at 70ºC and the outlet temperature was between 40 and 50ºC. 
To measure the dissolved amount of RF in the suspension, the suspension containing 
recrystallized particles was prepared as above and centrifuged at 10,000 rpm for 5 
minutes and the RF content in the filtered solution was analyzed using a validated HPLC 
method [3].  
Amorphous RF (SP-RF) was prepared as a control formulation by spray drying. 
1g of RF was dissolved in 50 mL of dichloromethane and spray-dried under the same 
spray conditions as above. The resultant powders, RFDH and SP-RF were stored at 
ambient condition (25C/50% RH). 
The content uniformities of the RF, RFDH, and SP-RF powders were determined 
using HPLC. A stock solution of each sample was prepared; each powder (25 mg) was 
weighed separately and dissolved with 25 mL of methanol. 1 mL of each stock solution 
was diluted with 9 mL of mobile phase. For identification of RFDH and SP-RF, a 
concentration of 100 g/mL RF, SP-RF, and RFDH solution were each prepared from 
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their respective stock solutions. The prepared RF solution (10 mL) was then spiked with 
the RFDH and the SP-RF solutions (10 mL) and analyzed using HPLC [3].  
 
5.2.3. Characterization 
5.2.3.1. Fourier transform infrared spectroscopy (FTIR) 
Potassium bromide (KBr) pellets were prepared by compressing 1-2 mg of sample 
mixed with 300-400 mg of dried KBr. Spectra were recorded using a Nicolet 360 FTIR 
spectrophotometer (Thermo Fisher Scientific Inc, Waltham, MA), and the data was 
analyzed using Omnic ESP software (Thermo Fisher Scientific Inc, Waltham, MA). 
 
5.2.3.2. X-ray diffraction of powders 
The crystalline structures of prepared samples were examined using wide angle 
X-ray diffraction (XRD). A Philips 1710 X-ray diffractometer (Philips Electronic 
Instruments Inc., Mahwah, NJ) with a copper target (CuKα1,λ = 1.54056 Å ), and a nickel 
filter, at a voltage of 40 kV and a current at 40 mA, was used to obtain the XRD 
patterns. . Samples were analyzed in the 2-theta (2) range from 5 to 50° using a step size 
of 0.02 2 degree with a dwell time of 2 sec. 
 
5.2.3.3. Thermal analysis 
Thermograms were measured using a differential scanning calorimetry (DSC), 
Model 2920 (TA Instruments, New Castle, DE). Dry nitrogen gas was used as the purge 
gas through the DSC cell at a flow rate of 40 mL/min. Samples (5 mg) were weighed into 
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aluminum crimped pans. The mass of the empty sample pan was matched with that of the 
empty reference pan within ± 0.2 mg. Samples were heated at a ramp rate of 10°C/min 
from 30 to 350°C. Thermogravimetric anaysis (TGA) was conducted using a Perkin 
Elmer TGA 1 system (Perkin Elmer Inc., Waltham, MA). Mass loss from 5 mg samples 
at a heating rate of 10°C /min from 30 to 350°C under a nitrogen purge (40 mL/min) was 
recorded. 
 
5.2.3.4. Moisture sorption analysis 
Dynamic vapor sorption (DVS) was used to investigate the moisture sorption of 
RFDH RF, and SP-RF powders. Samples (10 mg) were pre-weighed and added to quartz 
sample pans which were placed in the sample chamber of a DVS-1 apparatus (Surface 
Measurement Systems Ltd., London, UK). During this measurement, all samples, RF, 
SP-RF, or RFDH, were separately exposed to a continuous flow of N2. Each sample was 
dried at 0% RH for two hours before being exposed to 10% RH increments for two 0 -
90% RH cycles at 25C. To prevent desolvation, another condition was applied for 
RFDH. The humidity increments started from 50% RH to 90% RH. Equilibrium moisture 
content at each increment was determined by a dm/dt of 0.002%/min.  
 
5.2.3.5. Particle size distribution, density and aerodynamic diameter  
Particle size distributions, based on volume fractions of prepared powders were 
measured using a Spraytec®  particle size analyzer equipped with an inhalation cell  
specifically modified to measure the particle size diameter (PSD) generated from aerosols 
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(Malvern Instruments, Ltd., Worcestershire, UK). It consisted of a Spraytec®  unit with a 
USP inhalation induction port held in place by the inhalation cell, and a connection for 
the selected aerosol generating device. The entire assembly operated in a closed system, 
and allowed for a controlled airflow rate (60 L/min) through the measurement zone. Size 
3 HPMC capsules were filled with 15 mg of powder, and loaded in to the Aerolizer®  
device. The Aerolizer®  device was then fired into the Spraytec®  particle size analyzer at 
flow rate of 60 L/min to allow the particle size distribution of DPIs to be measured under 
simulated actuation conditions.  
The bulk densities of the SP-RF and RFDH powders were determined by pouring 
a known mass of powder (approximately 0.1 g) under gravity into a calibrated measuring 
cylinder, then recording the volume occupied by the powder. The tapped density was 
measured by following a USP method [24]. Theoretical estimates of aerodynamic 
diameter (dae) were derived from the particle sizing (d0.5) and tapped density data (p), 
according to Eq. 1 [25]. 
                
1

 ddae  , Where 1 = 1 g cm
-3
                       (1)                       
 
5.2.3.6. Scanning electron microscopy (SEM) 
The morphology of prepared samples, RF, SP-RF and RFDH, was observed using 
a LEO 1530 SEM (Zeiss/LEO, Oberkochen, Germany). Each sample was mounted 
separately onto SEM stubs using double-sided copper tape before sputter coating with Ag 
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for 30 seconds under vacuum at 30 mTorr. The SEM was operated at high vacuum with 
accelerating voltage 5 kV and specimen working distance 4 mm. 
 
5.2.3.7. Hot stage microscopy 
Thermal events of each of the prepared samples: RFDH, SP-RF, and RF, were 
observed on a hot stage (Mettler FP 82 HT, Mettler Instrument Corp., Highstwon, NJ) 
under optical microscope equipped with polarizer (Olympus BX 60, Olympus America 
Inc., Center Valley, PA). The samples were mounted on a glass slide, without a cover 
slip, and heated from 25ºC to 200ºC at a rate of 10ºC/min. Images were transferred via a 
Spot Insight QE Color 4.2 (Diagnostic Instruments, Sterling Heights, MI) and analyzed 
using SPOT
™
 imaging software (version 3.5.5). 
 
5.2.3.8. Saturation solubility 
The solubility of each sample, RFDH, SP-RF, and RF, was determined in pH 7.4 
phosphate buffered saline (PBS) containing 0.02% (w/v) ascorbic acid as an antioxidant, 
to prevent the oxidative degradation of the dissolved samples [3]. Samples (50 mg) were 
added to 20 mL of the prepared PBS and shaken for 24 hours at 37°C. Samples (1 mL) 
were taken from each vial at 1, 2, 4, 6, 8 and 24 hour intervals and filtered with a 0.45 m 
polytetrafluoroethylene (PTFE) syringe filter. Ethanol (100 L) was added to the 900 L 
of collected samples and analyzed using a validated HPLC method [3]. The resultant 
equilibrium sample concentration was used to calculate the saturated solubility 
concentration. 
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5.2.3.9. High performance liquid chromatography (HPLC) 
Drug content, solubility and dissolution samples were analysed using a HPLC 
system (Waters Co., Milford, MA) with UV detection. The system consisted of a 717 
plus autosampler, 2487 dual wavelength detector, 1525 binary pump, and 1500 column 
heater. Chromatography was performed using a Bondapak C18 10 μm 3.9×300 mm 
column (Waters, Milford, MA) and a SecurityGuard™ guard column (Phenomenex®, 
Torrance, CA). The mobile phase, consisting of methanol, acetonitrile and phosphate 
buffer solution pH 5.2 in a ratio of 50:17:33 respectively, was eluted at a flow rate of 1.2 
mL/min and the UV detector was set to a wavelength 337 nm. The column temperature 
was maintained at 25°C and the volume of each sample injected was 50 μL [3]. 
 
5.2.4. Aerosol classification 
The aerosolization performaces of RFDH and SP-RF were studied using a Next 
Generation Impactor (NGI) (MSP Co., Shoreview, MN). The prepared RFDH powders 
(7, 15, or 30 mg) and 15 mg of SP-RF powders were filled into the size 3 HPMC capsules 
and placed into either an Aerolizer®  or Handihaler®  dry powder inhaler (DPI). Each 
capsule was pierced and actuated into an NGI though a stainless steel USP throat adapter 
(aerosol induction port) at a flow rate 30 L/min or 60 L/min for 8 and 4 seconds, 
respectively. The powder deposited in the throat, in each dose collection-plate of the 
NGI, and in the remaining capsule, were each reconstituted with 10 mL of acetone. The 
powders remaining in the device were washed with 10 mL of ethanol. Collected samples 
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were analyzed by an 8453 UV/VIS spectrophotometer (Agilent, Santa Clara, CA) at 474 
nm [26].  
The emitted dose (ED), defined as the percent of total loaded powder mass exiting 
the capsule, was determined by subtracting the amount remaining in the capsule from the 
initial mass loaded into the capsule. The fine particle fraction (FPFTD), defined as the 
total dose of particles with aerodynamic diameters smaller than 5 m, was calculated via 
interpolation from the cumulative mass against the cutoff diameter of the respective 
stages of the NGI. The FPFTD is expressed as a percentage of the total drug dose, and not 
of the emitted dose. Each measurement was repeated three times. The MMAD was 
determined by the % cumulative undersize on probability scale versus logarithmic 
aerodynamic diameter data. 
 
5.2.5. Dissolution studies 
Dissolution behaviors of air classified RFDH and SP-RF were studied using a 
membrane holder method previously developed by this group [27, 28]. To briefly 
summarize, the prepared powders (7 mg) were filled into size 3 HPMC capsules, placed 
into the Aerolizer®  device, and actuated into the NGI equipped with a dissolution cup 
(MSP Co. Shoreview, MN) equipped with a dissolution impaction insert (Copley 
Scientific, Nottingham,UK) at a flow rate of 60 L/min for 4 seconds. The impaction 
insert containing air classified particles was removed from the dissolution cup, and a pre-
soaked polycarbonate membrane was placed onto the top and sealed in place with a push 
fitted sealing ring. The sealed NGI membrane holders were placed into each dissolution 
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vessel containing 300 mL of PBS containing 0.02% ascorbic acid. Dissolution testing 
was conducted at 75 rpm. The dissolution media (2 mL) was withdrawn manually using a 
glass syringe and filtered using a 0.45 m PTFE syringe filter at timed intervals of 15, 30, 
60, 120, 180, 240, 360, and 480 minutes. Fresh dissolution media (3 mL) was replaced 
into each vessel after sampling to maintain a constant volume. Ethanol (100 L) was 
added to the 900 L of collected samples and analyzed using the validated HPLC 
method, described above [3]. 
 
5.2.6. Stability 
The prepared samples, SP-RF and RFDH, were stored at ambient conditions in 
amber vials (25C/50% RH). Drug contents and thermal behavior using differential 
scanning calorimetry (DSC), of stored samples were monitored every two months using 
the method described above. 
The desolvation behavior of RFDH was studied. The prepared powder stored in 
the uncapped amber vial was vacuum dried (25C/5% RH) in the desiccators for 1 week. 
The dried samples were analyzed using DSC to confirm the desolvation and the 
crystalline structure were examined using the XRD procedure described above.  
 
5.2.7. Statistical analysis 
Data were expressed as the mean plus/minus standard deviation (SD). Statistical 
differences were studied by analysis of variance (one-way ANOVA) using Jump 7.0 
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5.3.1. Physicochemical characteristics 
Bulky RFDH powders were prepared as shown in Figure 5.1. Flake-like RFDH 
crystals were the result of a polymorphic transformation of RF, as shown in SEM images 
(Figure 5.1). The original crystals of RF and SP-RF powders indicate a rod shape and a 
corrugated spherical shape, respectively (Figure 5.1). The spray-dried RFDH crystals 
contain approximately 3.5% (w/w) of the amorphous RF form, as the dissolved RF in the 
suspension was also sprayed with the solid crystal. 
The chemical identification for the RFDH and the SP-RF samples were conducted 
via the spiking test. The retention time (Rt) for both spiked samples with RF was found at 
5.9 minutes, and one completely overlapped peak was observed from the HPLC 
chromatogram. The RF contents of samples, RF, RFDH and SP-RF, were 99.4, 95.8 and 
102, respectively as shown in Table 5.1.  
The saturation solubilities of RF, SP-RF, and RFDH in PBS buffer (pH 7.4) 
containing 0.02% (w/v) ascorbic acid, were determined to be 0.59, 1.32 and 1.28, 
respectively (Table 5.1). The solubility study was continued for 24 hours and the 
saturated concentration was achieved at 8 hours for all samples as shown in Figure 5.2. 
 146 
It was found that the RFDH is a dihydrate, as indicated by thermal analysis, with 
the main thermal events summarized in Table 5.1. The DSC thermogram of RFDH shows 
two endothermic processes associated with weight loss as seen in Figure 5.3 (A). The 
first one corresponds to the evaporation of physically absorbed water and the second one 
at 90-150ºC is consistent with the release the water of crystallization. The dehydrated 
RFDH melts at 180ºC, followed by the decomposition of the product at 257ºC. The 
thermal events of RFDH crystal can also be clearly seen from Figure 5.4; the bright 
orange color of RFDH crystals mounted on the hot stage was gradually darken as 
temperature increased, and finally melt at 180ºC. From the TGA analysis (Figure 5.3 
(B)), the total weight loss of 5.2% (w/w) upon drying was determined, and the weight 
loss corresponding to the dehydration of the water of crystallization measured over a 
temperature range (65-110ºC), was 4.2% (w/w). The series of thermal events for RFDH 
was further confirmed by a hot stage microscope (HSM) study. The transparency and 
brightness of crystals gradually decreased until they were melted at 180ºC while 
maintaining their original shape (Figure 5.5), indicating that desolvation causes the 
crystalline lattice to collapse.  
The thermograms of SP-RF and RF were also studied (Figure 5.3). In DSC and 
TGA analysis, no thermal event or weight loss was observed for pure RF until it 
decomposed at 260ºC. For the SP-RF, the glass transition temperature (Tg) was observed 
at 165ºC, followed by thermal decomposition at 257ºC.  
The crystalline structure of prepared samples was analyzed using XRD. As shown 
in Figure 5.6, the characteristic peaks of the RF form I appeared at 13.65 and 14.3 2θ, 
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respectively. The SP-RF was judged to be an amorphous structure since no characteristic 
peaks for RF were observed, and a halo at the baseline appeared on the x-ray 
diffractogram. The RFDH crystal shows characteristic peaks, although the intensity of 
those peaks, and the subsequent degree of crystallinity, appears to be lower than that of 
the pure RF form. It was also found that the RFDH is a different polymorphic form than 
that of pure RF, as the XRD diffraction patterns were not identical. After desolvation of 
water from the RFDH crystal, the XRD pattern shifted, with a small halo at the baseline 
indicating that the crystal lattice collapses upon desolvation as confirmed by HSM study. 
Representative moisture sorption isotherms for the SP-RF, the RFDH spray dried  
and pure RF form I are shown in Figure 5.7 (A), (B) and (C), respectively. In general, the 
two samples, SP-RF and RFDH, had very different gravimetric responses to moisture 
sorption. The SP-RF shows 14% moisture uptake between 0-90% RH and a remarkable 
hysteresis is seen on Figure 5.7 (A) indicating extensive surface moisture binding 
capacity. Contrary to SR-RF, the RFDH showed an approximately 2.3% moisture uptake 
between 50-90% RH. No remarkable hysteresis was shown from the isotherm graph 
(Figure 5.7 (B)). The moisture sorption study for the RFDH was conducted under two 
separate conditions, 0-90% RF cycle and 50-90% RH cycle, however, the 50-90% RH 
condition was chosen, as the RFDH showed very fast desolvation at 0% RH. The RF 
showed a 1% moisture uptake between 0-90% RH without hysteresis (Figure 5.7 (C)). 
Difference in H-bonding of prepared samples were characterized by FTIR 
spectroscopy and interpreted based on the article by Pelizza et al. [29]. The SP-RF 
exhibited double peaks at 1714 cm
-1




the main peaks of interest to define 
 148 
the existence of an H-bond between acetyl C=O and C23-OH [29-32]. Contrary to the SP-
RF, a single peak was observed at 1727 cm
-1 
from the RFDH and the RF samples. The 
absorption band due to the ansa OH in the RF manifested as a sharp peak at 3490 cm
-1
, 
but was seen as a broad band 3250-3600 cm
-1
 in the SP-RF and the RFDH samples. The 
main observed absorption bands are listed in Table 5.2.  
The median particle sizes (d0.5) of SP, SP-RF, and RFDH were 116, 26.4, and 8.8 
m, respectively as listed in Table 5.3. The SP-RF and the RF powder samples showed 
much higher variability in particle size than that of the RFDH. It was clearly seen from 
Figure 5.8 that the SP-RF powder sample showed a bimodal distribution, indicating that 
particles were not completely deagglomerated at the airflow (60 mL/min), whereas 
RFDH powder samples demonstrated a unimodal distribution. The calculated dae value 
for the RFDH was 2.3 m and the dae value for SP-RF could not be obtained since the 
tapped density could not be measured properly due to the cohesive properties of powders. 
 
5.3.2. Aerodynamic properties 
The aerosolization properties of RFDH and SP-RF were compared using two DPI 
devices, the Aerolizer®  and the Handihaler® . The ED, FPFTD, and MMAD of SP-RF and 
RFDH powders are displayed in Table 5.4. The aerodynamic performances of the RFDH 
powders were improved by changing the crystalline structure to a flake-like dihydrate 
form, with at least 60% FPFTD for each DPI device. Although, the SP-RF was 
manufactured as a highly corrugated powder to improve the dispersibility, the FPFTD 
values obtained from Handihaler and Aerolizer were lower than those of RFDH, at 
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50.9% and 36.6% respectively. The mass of RFDH powders deposited on each dose 
collection-plate was not dependent on the capsule fill mass, as shown in Figure 5.9. The 
FPFTD values of RFDH obtained from different capsule fill masses (7, 15, and 30 mg) 
were 59.1, 63.8, and 60%, respectively, with more than 90% of the capsule contents 
being emitted during aerosolisation testing at an air flow of 60 L/min. The flow rate has 
an influence on the dispersion of RFDH powder as the FPFTD lowered to 47.8% at 30 
L/min. The significant difference in the mass deposition between two different devices 
was also found for the SP-RF and the RFDH powders, as shown in Figure 5.10. For 
RFDH, the Aerolizer shows better particle separation than that of the Handihaler. 
Conversely, for the SP-RF, the Handihaler shows better separation than the Aerolizer 
as the FPFTD values for RFDH and SP-RF were 63.8% and 50.9% with the Handihaler 
device, and 68.5% and 36.6% with the Aerolizer respectively. In particular, the ED of 
SP-RF showed a significant difference between the two devices.  
The MMAD of RFDH calculated from the Handihaler device was in the range 
of 3.1 to 3.7 m at an air flow of 60 L/min compared to 2.2 m in the Aerolizer at the 
same airflow. The theoretical estimate of dae for RFDH powders was more similar to the 
MMAD value obtained from the Aerolizer device, indicating that the Aerolizer 
device is more efficient in particle deagglomeration than Handihaler. For the SP-RF, 




The physicochemical stabilities of the SP-RF and RFDH were studied. The RF 
contents of stored formulations for 9 months are summarized in Table 5.5. No significant 
change in RF content was found from the RFDH samples over the 9 month study period. 
The DSC thermograms of RFDH samples at 4 and 6 months were identical to that of the 
initial sample, as shown in Figure 5.11. Contrary to the RFDH, the SP-RF showed a 
significant difference in drug content, which was lowered to 75.5% at 9 months. The 
DSC thermograms of 4 and 6 months samples show that the peaks corresponding to the 
Tg at 165C are gradually shifted to 180C, implying a change in the order of molecular 
arrangement (Figure 5.11). It also demonstrated by the DSC thermograms shown in 
Figure 5.11 that the peak corresponding to drug decomposition is broadened, and the 
onset of degradation is earlier than that of initial sample. Additionally, a color change 
was also observed for SP-RF powder (Figure 5.12 (A)). The recrystallization of SP-RF (4 
month sample) was further confirmed by the hot stage microscope study (Figure 5.12 
(B)). A bright interference color was observed with the 4 month samples of SP-RF 
powder over the temperature range of 30C to 200C. 
Desolvation of the water of crystallization was confirmed by the DSC study. 
Following the drying procedure prior to analysis, the peak at 110-150C had disappeared 
and the endothermic peak, corresponding to the physically absorbed water was increased, 
which was consistent with most of the particles losing their crystalline structure. Under 
vacuum, the desolvation was completed in 1 week. It was also found that this process was 
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accelerated by the N2 gas used in the DVS study (The properties of desolvated RFDH are 
described in Appendix B). 
 
5.3.4. Dissolution studies 
Dissolution studies were performed with the SP-RF and RFDH formulations. For 
dose collection, the particles were air-classified using NGI as explained above, the 
particles deposited on the collection-plate stage 3 were used for the dissolution study as 
the particle size on this plate showed similar MMAD values for both formulations. The 
MMAD values for the RFDH and the SP-RF were 2.2 and 2.8 m with Aerolizer®  
respectively and the particle size cut-off for dose collection-plate stage 3 was 2.82 m 
[33]. The amount of powder deposited on stage 3 for both formulations was 1 mg. Figure 
5.13 shows that 74% and 82% of the RF were released for the RFDH and the SP-RF 




5.4.1. Polymorphic transformation to the flake-like crystal of RF 
The flake-like RF dihydrate crystal was prepared by recrystallization in anhydrous 
ethanol followed by spray drying of the prepared suspension, as shown in Figure 5.1. 
Generally, the drying of recrystallized particles involves heat and low pressure conditions 
to remove solvents used in the recrystallization process. However, those conditions may 
not be suitable if the prepared crystal is in the hydrate or solvate form since desolvation 
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may occur during the drying process [34, 35]. Desolvation of the hydrate form of crystal 
usually results in the rearrangement of the crystal lattice, generally leading to loss of 
crystallinity or significant structural change [34, 35]. Figure 5.6 shows that the 
desolvation of RF causes the crystalline lattice to collapse whether it is dried via vacuum 
conditions or N2 gas purge. The properties of desolvated RFDH are described in 
Appendix B. The spray-drying process allows the RFDH crystals to dry without 
desolvation since it allows for very rapid drying. Thus, the crystals are not heated while 
they are drying [36]. Additionally, aggregation or caking of the RFDH particles was 
prevented as particles were further deaggregated by atomization involving the break-up 
of liquid feed into very fine droplets. The physicochemical properties of RFDH dried via 
filtering method were given in Appendix B.  
The dihydrate form of RF was confirmed by thermal analysis. The DSC 
thermogram of RFDH (Figure 5.3 (A)) showed an endothermic peak corresponding to the 
release of the water of crystallization at 90-150ºC, and the TGA weight loss for the 
desolvation was 4.2% which was equivalent to 2 moles of water per mole of RF (Figure 
5.3 (B)). Generally, a hydrate is formed from the aqueous media or the mixture of 
aqueous/organic solvent by the association of water molecules in the crystal lattice. 
However, in RF the formation of several hydrates, mono, di, and heptahydrate, from 
several organic solvents has been reported, which can be attributed to the traces of water 
in the solvents. Specifically, it was reported that the mono and heptahydrate forms of RF 
are a results of recrystallization from anhydrous ethanol (containing less than 1%  
water). These polymorphs are believed to be the product of the imbibitions of water [29, 
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31]. The extreme complexity in the chemical structure due to the various hydrogen 
bonding sites and ionization states that exist, may also contribute to the formation of 
various hydrate forms [29-31, 34, 35].    
The hydrate of RF is presumed to be a stoichiometic hydrate due to the fading of 
the bright interference color after dehydration on the HSM study (Figure 5.5), and to the 
peak shift with the halo at the baseline on the XRD diffractogram (Figure 5.6), indicating 
that the majority of crystalline lattice changed to an amorphous state. This was further 
confirmed by DSC analysis. As indicated in Figure 5.3 (A), the melting of dehydrated 
RFDH at 180ºC is not accompanied with an endothermic process since no heat is 
required for amorphous material to pass to the liquid phase [29]. It is known that the 
water molecule in the stoichiometic hydrate is an essential component in the maintenance 
of the molecular network. Thus, desolvation results in a disordered crystalline state [29, 
34, 35].  
The XRD results of RFDH and RF confirm the polymorphic transformation of the 
RF form I to the different crystal form. Figure 5.6 shows that two main characteristic 
peaks of the RF form I, at 13.65 and 14.3 2θ°, disappear following recrystallization, and 
several different characteristic peaks appear on the XRD diffractogram of RFDH 
although the peak intensities are relatively low. The RFDH shows less crystallinity than 
the RF form I, which may be attributed to the disturbed crystalline packing of the water 
molecule inside the crystal lattice [29, 31]. The saturation solubility of RFDH was similar 
to that of amorphous structured SP-RF, at 1.28 mg/mL and 1.32 mg/mL, respectively 
(Table 5.1). This is because, although the RFDH has a crystalline structure, the packing 
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density is low and the surface area of those two powders, SP-RF and RFDH, are very 
large due to the small particle size.  
The RFDH and the SP-RF are chemically identical to the RF form I. However, the 
arrangement of several hydrogen bonding sites, and the ionization state between samples 
are different. This results in different crystalline structures since the intra-molecular 
hydrogen bonding plays a critical role in RF crystalline packing. The main characteristic 
peak determining the packing density is the peak at 1727 cm
-1
, implying a non hydrogen 
bonded acetyl C=O which allows for maximum conformational stability [29-32]. The IR 
spectra of RF form I and RFDH show a single peak at 1727 cm
-1
, whereas the SP-RF 
spectrum shows double peaks at 1718 cm
-1
 and 1733 cm
-1
, indicating that the ordered 
crystalline packing of the SP-RF is prevented by the two different conformations of the 
acetyl group [29-32]. The IR results are in agreement with the XRD data (Figure 5.6).  
 
5.4.2. Dry powder formulation and the aerodynamic properties 
As seen in Figure 5.1, the RFDH shows a very thin, flake-like crystal. As listed in 
Table 5.3, the median particle size (d0.5) of the RFDH is about 8 m, whereas the 
estimated aerodynamic diameter (dae) of 2.3 m falls into the respirable particle size range 
(1-5 m), due to the low powder density. The low density RFDH crystals were 
manufactured by a very simple recrystallization process without adding any excipients, 
unlike other low density dry powder formulations that generally involve complicated 
manufacturing processes and large amounts of excipients. The excipient-free RFDH 
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formulation allows a high RF dose and may also prevent chemical degradation caused by 
drug-excipient interaction.  
As shown in Figure 5.10, the FPFTD values of RFDH powders were higher than 
the SP-RF for both the Handihaler and Aerolizer devices. This is attributed to the 
flaky morphology and the large particle size (d0.5: 8 µm) of the RFDH crystals that 
prevents the formation of strong aggregates with weak cohesion forces [20]. The 
morphology and geometric size distribution of particles has significant influence on the 
aerosol performance since the different particle size and shapes lead to a variation in 
surface energy and interparticulate forces [12, 14, 37, 38]. In general, more corrugated, 
larger, and lower density particles exhibit better aerosol dispersion than denser, smaller 
particles, due to weaker van der Waals forces, leading to easier deaggregation of particle 
aggregates within the air steam [12, 14, 16, 25, 39, 40]. It has been also reported that 
powders with elongated structures provide improved aerosolization performances since 
the contact state between fibrous particles is extremely unstable, leading to excellent 
fluidization and deaggregation [19, 21, 22]. The unique flaky shape of RFDH powders 
may also contribute to the formation of unstable aggregates by reducing the particle 
contact area as elongated particles. The powder dispersion behavior of prepared 
formulations at a given air flow (60 L/min) was further confirmed by the particle size 
distribution data generated using the Spraytec

 light diffraction apparatus (Figure 5.8 and 
Table 5.3). As expected, it appears that the SP-RF powders require more energy to be 
deaggregated than the RFDH, due to the strong interparticulate forces which parallels the 
NGI results shown in Figure 5.10. It can be clearly seen from Figure 5.8 that the particle 
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size distribution of the SP-RF is very broad, with a median particle size (d0.5) of 24.6, 
unlike the particle size shown in the SEM image (Figure 5.1) which indicates a range of 
about 2-3 m. This finding suggests that the SP-RF powders form much stronger and 
more stable powder aggregates than the RFDH powders due to their smaller particle size 
and spherical shape. The significantly low yield of the SP-RF powders can also be 
explained by the data discussed above (Table 5.1). Contrary to the RFDH powder, the 
sprayed SP-RF powders were very adhesive/cohesive. Thus, the majority of powders 
were lost during the spray dryer recovery process.   
Significant differences in the powder dispersion behaviors were observed between 
two different devices for both the RFDH and SP-RF formulations. The differences in 
FPFTD and ED between the two devices were more obvious for the SP-RF powders than 
the RFDH crystals. In particular, the emitted dose of SP-RF powders obtained from the 
Handihaler®  demonstrated almost a two-fold increase when compared to the Aerolizer®  
device. The different particle dispersion results between two devices can be explained by 
the difference in the device resistance. The Aerolizer is classified as a low resistance 
device with a specific resistance of 0.056 cm H2O
1/2
/L/min [41], whereas the 
Handihaler is classified as a high resistance device with a resistance of 0.18 cm 
H2O
1/2
/L/min [37, 42], implying the Handihaler requires more inspiratory effort to 
operate the device. However, at a given flow rate, 60 L/min, a greater pressure drop 
across the device is achieved by the high resistance device, the Handihaler, than the low 
resistance device, the Aerolizer, resulting in higher shear force for powder entrainment 
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and aerosolization. Accordingly, the higher FPFTD and ED for SP-RF powders are 
attributed to the high turbulence generated by Handihaler® , which is in general 
agreement with previous studies using DPI devices with different resistances; the higher 
the device resistance, the greater the powder deagglomeration is likely to be obtained [37, 
38, 42].  
Unexpectedly, the Aerolizer provided maximum particle separation for the 
RFDH powders as the FPFTD values for the Aerolizer®  and Handihaler®  were 68.5% 
and 63.8%, with more than 95% of capsule contents being emitted from both devices. 
The differences in the particle deposition on each NGI dose-plate between two different 
devices were also found. As shown in Figure 5.10, 5.8% and 30% of the RFDH powders 
were deposited at the earlier stages (stage 1 and 2) of NGI with maximum deposition at 
stage 4 and 3 for the Aerolizer and Handihaler devices, respectively. These results 
suggest that parts of the RFDH powders are emitted without being deagglomerated to 
fine particles by the dispersion force of the airstream in the Handihaler. This may be 
due to the differences in the powder emptying mechanism through the capsule apertures 
between two devices. The size of the apertures on the capsule end pierced by the 
Handihaler is bigger than those of the Aerolizer, resulting in faster powder emptying 
from the device. A large aperture on the capsule allows agglomerates to readily empty 
from the capsule, but at the same time causes impaction at the earlier impactor stages and 
thus, reduces the FPF [43]. Therefore, the lower FPFTD for the Handihaler is attributed 
to the shorter powder emptying time, which is not enough time for all particle aggregates 
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to be deagglomerated into separated single particles. The similar MMAD (2.2 m) and 
dae (2.3 m) of the RFDH further confirmed that the Aerolizer device was more 
efficient in particle deagglomeration for this sample than the Handihaler device. The 
emitted SP-RF powders from two different devices showed similar powder distribution 
behavior to that of the RFDH powders. As shown in Figure 5.10, emitted SP-RF powders 
show maximum deposition at stage 1 (22%) and stage 4 (14.8%) for the Handihaler and 
for the Aerolizer, although the ED and FPFTD values were higher for the Handihaler 
than for the Aerolizer. This data indicates that larger apertures may be better for 
withdrawal of highly aggregated SP-RF from the capsule. However, the emitted particle 
aggregates may not be completely deaggreagated due to the short powder emptying time. 
Overall, the differences in ED, powder distribution, and FPFTD between devices for the 
RFDH are less significant than for the SP-RF powder, since the RFDH powders do not 
require much energy to be aerosolized, implying that the device-dependent aerosol 
performances can be minimized by using an engineered RFDH formulation. 
The aerosol performances of RFDH were not dependent on the capsule fill mass 
since the powders were very bulky, thus the particles were not closely packed even at 
higher fill mass, as shown in Figure 5.9. The FPFTD of RFDH obtained at different 
capsule fill masses (7, 15, and 30 mg) was at least 59% with more than 90% of ED at an 
air flow of 60 L/min. The particle deposition profiles on each dose-plate of NGI for three 
different samples (powder fill mass) were shown to be very similar each other. The flow 
rate influenced the dispersion of RFDH powder as the FPFTD (particles on stage 3-5) was 
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lowered to 47.8% at 30 L/min (Table 5.4), although the amount of powder deposited on 
each dose-plate was shown to be similar to the data obtained at the higher air flow rate 
(60 L/min). Dose-plate cut-off particle sizes for NGI calibrated at 30 L/min were applied 
to calculate the FPFTD.  
 
5.4.3. Dissolution 
As shown in Figure 5.13, the release rate for the RFDH and the SP-RF at 1 hour 
were 74 and 82%, respectively. Overall, release patterns between the two samples in the 
PBS media (pH 7.4) were similar, although differences in crystalline structure exist due 
to the small particle size of powders loaded on the membrane holder. The dissolution 
profile of RFDH was relatively slower for the first 4 hours than that of the SP-RF, and 
became similar to that of the SP-RF at 8 hours. This result is in good agreement with the 
saturated solubility data in Figure 5.2; the saturation solubility between two formulations 
was similar, but the RFDH showed much slower powder wetting than the SP-RF. In 
general, amorphous structured material is believed to provide higher solubility and faster 
dissolution rates than crystalline materials. However, in RF, the amorphous form shows 
the slowest dissolution rate, although the intrinsic dissolution rate (IDR) and the 
saturation solubility are not significantly different from that of the crystalline RF [30, 32, 
44]. This behavior is attributed to the electrostatic properties of the very fine particles in 
the high energy amorphous powders, leading to poor powder wetting [30, 32, 44]. It has 
been reported that when the test compounds are added to the dissolution media, the 
amorphous RF aggregates to form a hydrophobic layer on the dissolution media surface 
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[32]. Therefore, to obtain accurate dissolution results, particle separation should be 
considered prior to dissolution assessment. Specifically, the test compound is very small 
and cohesive like the SP-RF and RFDH powders. In our previous study, we proved that 
the aerodynamic classification of aggregated powders in the powder introduction step 
into the dissolution apparatus, has a significant influence on the dissolution profiles [27, 
28]. Thus, a new membrane holder method, designed specifically to be incorporated into 
the Next Generation Impactor (NGI) for easy particle separation, was applied to properly 
compare the dissolution profiles of the manufactured formulations. From the dissolution 
study, similar dissolution profiles between two different RF polymorphs were obtained. 
These results parallel the saturation solubility results and may be attributed to the good 
separation of powders. 
RF has a pH-dependent dissolution profile [3, 30, 31]. The RF dissolves and 
degrades immediately in low pH media (pH 1.2), but dissolves and degrades slowly in 
neutral conditions, the dissolved RF decomposes rapidly by hydrolysis/oxidization [30, 
31]. This pH dependent dissolution may indicate that the release rate of inhaled RF is 
potentially retarded in the lung compared to when it is delivered to the GI tract. A 
comparison study by Jang et al. clearly shows that RF formulations delivered to the lung 
showed higher plasma concentrations and a longer plasma duration than that of orally 
delivered RF following an in vivo pharmacokinetic study, although the in vitro 
dissolution profiles of prepared formulations were similar at neutral conditions (pH 7.2) 
[4]. This could be attributed to the pH-dependent dissolution behavior of RF as it is a 
Biopharmaceutic Classification System (BCS) class II drug of the, where rate and extent 
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of dissolution is critical for optimum bioavailability [30]. Additionally, it is widely 
known that the high variability in RF bioavailability is caused by the different solubility 
profiles between commercial RF forms [30, 44].  
 
5.4.4. Stability studies 
While Table 5.5 shows that the chemical potency of RFDH decreases by only 3% 
after 9 months at ambient storage conditions, the SP-RF shows significant decrease in 
drug content (26%). These results can be explained through the moisture uptake behavior 
of two formulations studied using DVS analysis. As shown in Figure 5.7 (A), the SP-RF 
powders take up 14% moisture between 0-90% RH and 10.3% moisture between 50-90% 
RH. A large hysteresis on the isotherm graph between sorption and desorption was also 
shown, indicating that water absorbed from the atmosphere was strongly bound to the SP-
RF, and the chemical degradation or the crystalline structural rearrangement could be 
accelerated by this. It has been reported that the primary degradation product of RF in 
solid state is an 3-formylrifamycin, and the degradation is accelerated in the presence of 
moisture and/or light [45]. Contrary to the SP-RF, the RFDH showed a 2.3% moisture 
uptake between 50-90% RH and the hysteresis was not significant since the crystalline 
materials were less hygroscopic than the amorphous structure. Additionally, increased 
stability of RFDH is attributed to hydrogen bonding sites that may be stabilized by the 
water of recrystallization from hydrated structures. In contrast, the amorphous structure 
of SP-RF and subsequent lack of strong hydrogen bonding, may result in more rapid 
chemical degradation. The stabilities of the SP-RF and RFDH were further confirmed by 
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the DSC and the HSM study (Figure 5.11 and 5.12). The bright interference color was 
observed for amorphous SP-RF powder at 4 months and the bright color did not 
completely disappear upon heating to its Tg, indicating the presence of the crystalline 
forms of RF or an RF degradation product. 
Desolvation of the water of crystallization was studied, as the presence of the 
water of crystallization in the crystal lattice significantly influences the stability of the RF 
crystalline structure [34, 35]. As shown in the Figure 5.3 (A), the desolvation of the 
RFDH occurred at temperature ranges of 90-150C or at very low humidity (0% RH) (as 
confirmed by DVS study in Appendix B) [34, 35]. However, the RFDH is to date, very 




The rifampicin dihydrate (RFDH) powders having MMAD of 2.2 m were 
successfully prepared using a simple recrystallization process. The RFDH powders have 
a thin flaky structure, and this morphology provides improved aerosolization properties at 
maximal API loading. The maximum FPFTD of the RFDH achieved with Aerolizer®  
device, was 68%. These powders are predicted to deposit predominately in the central 
and peripheral regions of the lung following inhalation, with minimal oropharyngeal 
deposition. RFDH powders delivered via the pulmonary route would be anticipated to 
provide higher local (lung) drug concentrations than that of orally delivered powders. 
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Additionally, RFDH powders can be estimated to have much better stability than the 






















Table 5.1  Physical characterizations of prepared samples, RF, RFDH and SP-RF 
(values are means ± SD, n = 3). 
 RF RFDH SP-RF 
RF contents (%) 99.4 ± 0.47 95.8 ± 0.02 102  ± 1.06 
Yield (%)  - 91 ± 2.3 36 ± 6.3 
Water contents (%) 0.02 5.2 0.94  
Desolvation (ºC) - 90-150 - 
Melting (ºC) - 180  165 (Tg ) 
Decomposition (ºC) 260 257 257 
Solubility at 37ºC (mg/mL) 0.59 ± 0.05 1.28 ± 0.01 1.32 ± 0.02 
 
 Yield was calculated for 3 different batches 































Ansa OH Furanone C=O Acetyl C=O Amide C=O N-CH3 
RF 3490 1648 1727 1569 2806 
RFDH 3250-3565 1652 1727 1569 absent 


































Table 5.3  Particle size distribution measured by Spraytec®  at a flow rate of 60 L/min 
for RF form I, RFDH and SP-RF (values are means ± SD, n = 3).  
 
Samples d0.1 (m) d0.5 (m) d0.9 (m) dae (m) 
RF 42.6 ± 4 116 ± 6.9 368 ± 57 - 
RFDH 2.4 ± 0.02 8.8 ± 0.07 22.6 ± 0.71 2.3 ± 0.05 


































Table 5.4  Aerodynamic characteristics of the formulations (values are means ± SD, n = 
3). 
 RFDH  SP-RF 
DPIs Handihaler  Aerolizer  Handihaler Aerolizer 
Fill mass (mg) 
(flow rate L/min) 
7 (60) 15 (60) 30 (60) 15(30)  15 (60)  15 (60) 15 (60) 
ED (%) 91.4±1.5 97.6±0.3 95.2±1.9 96±0.6  98.3±0.2  94.1±1.7 56.1±0.2 
PFPTD (%) 59.1±1.2 63.8±1.5 60.2±3.7 47.8±1  68.5±2.4  50.9±2.2 36.6±0.4 






























Table 5.5  RF contents analysis for RFDH and SP-RF formulations stored under 
ambient condition (25ºC/50% RH) over 9 months (values are means ± SD, n = 3). 
Samples Initial 2 Months 4 Months 6 Months 9 months 
RFDH  
95.81 ± 0.57 
 
95.81 ± 0.02 
(100%)** 
95.84 ± 0.30 
(100%) 
93.76 ± 0.25 
(97.9%) 
92.96 ± 0.56 
(97%) 
SP-RF 
102 ± 1.06 
 
91.2 ± 0.71 
(89.4%) 
84.23 ± 1.06 
(82.6%) 
80.77 ± 0.46 
(79.2%) 
75.46 ± 0.81 
(74%) 
 
 The drug contents of RFDH indicates RF contents  







































Figure 5.2  Saturation solubility of RF form I, RFDH, and SP-RF in SLF medium at 37 





















Figure 5.3  DSC thermogrmas (A) of (a) desolvated RFDH, (b) RFDH, (c) SP-RF and (d) 









Figure 5.4  Photographic image of RFDH crystals on the hot stage at (A) 60C, (B) 120 















Figure 5.5  Hot stage microscopy images (HSM) of RFDH at (A) 30C, (B) 120C, (D) 













Figure 5.6  Powder X-ray diffractograms of (a) RF form I (characterization peaks of 












Figure 5.7  Dynamic vapor sorption (DVS) isotherm of (A) SP-RF, (B) RFDH, and (C) 



















Figure 5.8  Average particle size distribution measured by Spraytec®  at a flow rate of 




Figure 5.9  Powder deposition profiles for RFDH having different powder fill mass at a 
flow rate of 30 L/min or 60 L/min with Handihaler® , expressed as the percentage of total 
loaded dose (Values are means ± SD, n = 3).. 
 
 










Figure 5.10  Powder deposition profiles for the RFDH and the SP-RF actuated from two 
devices, Aerolizer®  and Handihaler®  at a flow rate of 60 L/min, expressed as the 
percentage of total loaded dose (Values are means ± SD, n = 3). 
 
 
 The statistical difference between devices for the RFDH powders 
+ The statistical difference between devices for the SP-RF powders 
# The statistical difference between formulations for the Handihaler®    





































Figure 5.12  Photographic image of SP-RF powder (A) at a) initial, b) 4 months and c) 6 
months, and Hot stage microscopy images (B) of the 4 months stability sample of SP-RF 

















Figure 5.13  Release profiles of RFDH and SP-RF in PBS containing 0.02% ascorbic 
acid (pH 7.4). Powders accumulated on the dose-collection plate 3 were selected for 
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The aim of this research was to investigate whether a novel carrier-free dry 
powder formulation of rifampicin (RF) for inhalation, could present a controlled release 
profile. The RF dihydrate (RFDH) crystals were coated with hydrophobic polymers, 
PLGA and PLA, using a spray-dryer equipped with two different types of three-fluid (3F) 
spray nozzles; modified 3F nozzle (3F-M) and standard 3F (3F-S). Suspensions of RFDH 
crystals (the core forming particles), and polymer solutions were prepared separately. 
Each of the prepared liquid solutions was then sprayed through the separate channels of 
the 3F nozzles. Matrix polymeric microspheres encapsulating RF (MRF microsphere) 
were prepared as control groups by the co-spray drying of a dissolved RF and polymer in 
dichloromethane (DCM) using a standard two-fluid (2F) nozzle. The coated RFDH 
powder, encapsulating at least 50% of RF, was successfully prepared by simple in-situ 
coating methods using two different types of 3F nozzles. The coated RFDH powders had 
MMAD values of 3.5 to 4.6 m. The thin flaky morphology of RFDH powders that 
provides improved aerosolization properties (Chapter 5) was maintained after coating. 
The coated RFDH formulations showed relatively low initial RF release, compared to the 
uncoated RFDH crystals followed by slow RF release (about 70%) over 8 hours in PBS 
media (pH 7.4). The coated RFDH powders also showed slower RF release in acidic 
dissolution media (pH 5.2) than it was in pH 7.4. Significant chemical degradations were 
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not observed from the crystalline-structured RFDH formulations, while the amorphous-
structured MRF powders showed chemical degradation in 6 months. These polymer 
coated RFDH formulations may be a valuable alternative in the treatment of tuberculosis 
since the carrier-free formulation offers the benefit of delivering a maximum potency 
formulation of the antibiotic directly to the site of infection, with longer drug residence 



















Tuberculosis (TB) is a chronic infectious disease, which is considered the 
foremost cause of death due to a single microorganism [1]. The occurrence of TB is most 
often due to Mycobacterium tuberculosis (MTB) infection by inhalation and the lung is 
the primary site of infection. Once in the lung, MTB is phagocytosed by alveolar 
macrophages (AMs), where it remains alive. The most common treatment for TB 
involves oral administration of high systemic doses of single or combined antibiotics, 
which causes unwanted side-effects by high systemic exposure [2]. Several current 
studies have been proposed for the administration of anti-tubercular drugs to the primary 
infection site, the lung, with the idea of increasing the local therapeutic effect and reduce 
the overall systemic exposure [3-9]. Specifically, pulmonary delivery of rifampicin (RF) 
has been widely studied [3-6, 8, 10] since it is the first choice drug in the treatment of TB 
[1, 11] and several drawbacks in current oral delivery systems, mainly attributed with the 
severe chemical decomposition of RF in the acidic conditions of the stomach [12-14], can 
be avoided by delivering RF to the lung that has a neutral milieu. Several respirable 
forms of RF, such as nano/microparticles [3-5], liposome [8], and liquid [9], have been 
introduced to localize the RF in the lung.  
Recently, there has been an increased interest in research in focusing on dry 
powder inhalation (DPI) formulations to prolong drug residence time in the lung [3, 4, 
15-17] since the sustained release (SR) system has certain advantages, including reduced 
dosing frequency, improved patient compliance, and reduction in overall systemic side 
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effects [17, 18]. Specifically, in anti-tubercular (TB) inhaled therapy, it‘s well established 
that the SR formulation enhances the efficacy of anti-TB drugs, presumably by targeting 
AMs and building up high intracellular drug concentrations. Generally, the phagocytic 
uptake of inhaled particles by AMs has been known to be the primary hurdle in extending 
drug residence time in the lung [17, 18]. However, in pulmonary anti-TB therapy, the 
phagocytic activities play a useful role in terms of targeting anti-TB drugs at the main site 
of the MTB proliferation [19, 20]. Several SR formulations encapsulating anti-TB drugs 
into the polymeric microspheres have been introduced to target the AMs [3, 4, 21, 22]. 
Respirable PLGA/PLA microspheres that show up to 3 days of in vitro drug release 
capability were manufactured by means of a solvent evaporation and a spray drying 
method [3, 19, 23]. A formulation consisting of PLGA nanoparticle aggregates was also 
introduced by Sung et al. [4]. However, there are still numerous limitations in 
manufacturing SR formulations that have good aerosolization properties, with controlled 
drug release capabilities due to their fine particle size. Additionally, the low payload of 
APIs, typically in the range of 1 to 20%, offered by conventional microencapsulation 
methods, is one of the problems in inhaled TB treatment since the bactericidal activity is 
directly proportional to the concentration at the target site [9, 24] . 
Hydrophobic coating methods have been applied under the modified release 
concept. Generally, these coatings constitutes approximately 10 to 50% of the final 
particle mass, which is substantially higher drug loading compared to the 
microencapsulated formulations. In US patent 6,984,404 [25], a physical vapor 
deposition (PVD) method using pulsed laser ablation (PLD) is applied to achieve the 
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PLGA deposition onto the target particle surface, which offers nanometer thickness of 
coating layer with more than 90% drug loading. However, the use of a PLD method may 
possibly cause decomposition or degradation of APIs or polymers during the process due 
to severe processing conditions, such as UV radiation, high pressure and heat. Moreover, 
the coating of each separate particle is difficult to achieve since there is no suitable 
method to fluidize or agitate ultra-fine particles (1-5 µm) that exhibit strong cohesion 
properties during the coating process. A spray dry method to obtain coated particles has 
also been widely evaluated [26, 27]. This technique is a relatively simple one-step 
process over other coating techniques. However, the application of this method is limited 
as micronized core forming particles have to be dispersed in the coating solution without 
dissolving the core-forming particle.  
The aim of this study is to develop a novel carrier-free dry powder inhaler (DPI) 
formulation of RF that has a high drug payload, improved aerodynamic properties, and a 
sustained release capability. It is the goal of this research to demonstrate that the use of 
multi-channel spray nozzles can offset some of the aforementioned limitations with other 
investigated formulation types. In the previous study, the flake-like rifampicin dihydrate 
(RFDH) crystal having improved aerosolization properties was successfully prepared by 
a simple recrystallization process [28] (see Chapter 5). However, the RFDH formulation 
shows high initial drug release. Thus, we aimed to minimize the amount of initial RF 
release by means of surface coating. This study describes how the coating of RFDH 
crystal was achieved by spray drying with multi-channel spray nozzles, and how the 
physicochemical properties of coated RFDH were characterized. The aerodynamic 
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behaviors of prepared formulations were described using an Aerolizer®  DPI device. And 
the dissolution behaviors of prepared formulations were evaluated using a newly 
developed membrane holder method [29, 30] (see Chapter 4). 
 
6.2. MATERIALS AND METHODS 
 
6.2.1. Materials 
Rifampicin (RF), poly (DL-lactide) (PLA, Mw= 75,000-12,000), poly (DL-
lactide-co-glycolide) (PLGA, lactic acid:glycolic acid ratio=75:25; molecular weight= 
66,000-107,000) and cholesterol were purchased from the Sigma Chemical Co. (St. 
Louis, MO). Size 3 hydroxypropylmethyl cellulose (HPMC) capsules were donated from 
Capsugel (Peapack, NJ). Polycarbonate (PC) membranes of 0.05 m, were purchased 
from Whatman (Florham Park, NJ). An Aerolizer

 dry powder inhaler device was 
donated by Schering-Plough (Kenilworth, NJ). A dissolution membrane holder was 
provided by Copley Scientific (Nottingham, UK). All other reagents were purchased 
from the Sigma Chemical Co. (St. Louis, MO).  
 
6.2.2. Formulation design 
6.2.2.1. Preparation of rifampicin dihydrate (RFDH) and matrix microparticles (MRF) 
using a spray dryer equipped with two-fluid (2F) spray nozzle 
Rifampicin dihydrate (RFDH) microcrystals were prepared by a polymorphic 
transformation of RF form I [28]. To briefly summarize, RF powder (900 mg) was added 
to 30 mL of hot anhydrous ethanol solution (60C) and stirred until a saturated solution 
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was obtained. The suspension was placed into a Branson 5500 sonic bath (Branson 
ultrasonics, Danbury, CT) and sonicated at 25°C for 2 minutes to homogeneously 
disperse the particles. The resultant suspension was then spray dried with constant 
stirring using a Büchi Minispray dryer B-290 (Büchi Laboratory-Techniques, Flawil, 
Switzerland). The following conditions were used during spray drying: drying airflow, 40 
m
3
/h; spraying airflow, 500 L/h; suspension feed rate, 5 mL/min; nozzle size, 0.5 mm; the 
inlet temperature was established at 70C and the outlet temperature was between 40 and 
50C.  
Amorphous MRF microspheres were prepared by spray drying. 0.5 g of RF 
dissolved together with 0.5 g of either PLGA or PLA in 100 mL dichloromethane and 
spray dried under the same spraying conditions as above [5].  
 
6.2.2.2. Preparation of coated RFDH using a spray dryer equipped with two different 
types of three-fluid (3F) spray nozzles 
Polymer coated RFDH formulations were prepared by in-situ spray drying of the 
RFDH suspension and a coating solution. The RFDH suspension, consisting of 4% w/v 
of RF, was prepared by recrystallization of RF in anhydrous ethanol solution as above. 
The coating solutions of polymers, PLGA and PLA, (0.3% and 0.5% w/v), were prepared 
by dissolving polymers in acetone. Two prepared spraying solutions were sprayed 
separately through two different liquid channels of the 3F spray nozzle (Büchi 
Laboratory-Techniques, Flawil, Switzerland) as shown in Figure 6.1. The RFDH 
suspension was introduced through the inner nozzle with constant stirring at the feed 
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speed of 1 mL/min (40 mg/min). The coating solutions (0.3 and 0.5% w/v) were supplied 
to the outer spray nozzle disposed concentrically about a core nozzle at the feed speed of 
8 mL/min, provided 62.5% and 50% RF loading, respectively. The 3F nozzles used in 
this study consisted of three separate nozzles: two for aqueous solution and one for a 
suitable gas fluid. The sizes of inner and outer aqueous nozzle are 0.7 and 2.0 mm, 
respectively. The distance between the bottom edge of the inner nozzle and the end of the 
outer nozzle is adjustable as 0 mm (standard 3F nozzle (3F-S)), and 1 mm (modified 3F 
nozzle (3F-M)), as shown in Figure 6.1. The spray drying was performed using a Büchi 
Minispray dryer B-290 (Büchi Laboratory-Techniques, Flawil, Switzerland) under 
following conditions for both nozzles: drying airflow, 40 m
3
/h; spraying airflow, 600 L/h; 
the inlet temperature was established at 70C and the outlet temperature was adjusted 
between 40 and 50C.  
 
6.2.3. Characterization 
6.2.3.1. Assay  
The RF contents of prepared formulations were determined using HPLC. A stock 
solution of each sample was prepared; each powder (25 mg) was weighed separately and 
dissolved with 25 mL of acetone. 1 mL of each stock solution was diluted with 9 mL of 
mobile phase and analyzed using validated HPLC method [3].  
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6.2.3.2. X-Ray diffraction of powders 
The crystalline structure of prepared samples was examined using wide angle X-
ray diffraction (XRD). A Philips 1710 X-ray diffractometer (Philips Electronic 
Instruments Inc., Mahwah, NJ) with a copper target (CuKα1,λ = 1.54056 Å ), and a nickel 
filter, at a voltage of 40 kV and a current at 40 mA, was used to obtain the XRD 
patterns. . Samples were analyzed in the 2-theta range from 5 to 50° using a step size of 
0.02 2 degree with a dwell time of 2 sec. 
 
6.2.3.3. Thermal analysis  
Thermograms were measured using a differenctial scanning calorimetry (DSC), 
Model 2920 (TA Instruments, New Castle, DE). Dry nitrogen gas was used as the purge 
gas through the DSC cell at a flow rate of 40 mL/min. Samples (5 mg) were weighed into 
aluminum crimped pans. The mass of the empty sample pan was matched with that of the 
empty reference pan within ± 0.2 mg. Samples were heated at a ramp rate of 10°C/min 
from 30 to 350°C.  
 
6.2.3.4. Moisture sorption analysis 
Dynamic vapor sorption (DVS) was used to investigate the moisture sorption of 
prepared formulations. Samples (10 mg) were pre-weighed and added to quartz sample 
pans which were placed in the sample chamber of a DVS-1 apparatus (Surface 
Measurement Systems Ltd., London, UK). During this measurement, all samples were 
separately exposed to a continuous flow of N2. Each sample was dried at 0% RH for two 
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hours before being exposed to 10% RH increments for two 0-90% RH cycles at 25C. To 
prevent desolvation, another condition was applied for the coated RFDH samples. The 
humidity increments started from 50% RH to 90% RH. Equilibrium moisture content at 
each increment was determined by a dm/dt of 0.002%/min.  
 
6.2.3.5. Particle size distribution, density and aerodynamic diameter  
Particle size distributions, based on volume fractions of prepared powders was 
measured using a Spraytec®  particle size analyzer equipped with an inhalation cell  
(Malvern Instruments, Ltd., Worcestershire, UK). It consists of a Spraytec®  unit with a 
throat held in place by the inhalation cell, and a connection for an aerosol generating 
device. The entire assembly operated in a closed system that allowed for a controlled 
airflow rate (60 L/min) through the measurement zone. Size 3 HPMC capsules were 
filled with 15 mg of powder, and loaded in to the Aerolizer®  device. The Aerolizer®  
device was then fired into the Spraytec®  particle size analyzer at a flow rate of 60 L/min 
to allow the particle size distribution of DPIs to be measured under simulated actuation 
conditions.  
The bulk densities of the prepared formulations were determined by pouring a 
known mass of powder (approximately 0.5 g) under gravity into a calibrated measuring 
cylinder, then recording the volume occupied by the powder. The tapped density was 
measured by following a USP method [31]. Theoretical estimates of aerodynamic 
diameter (dae) were derived from the particle sizing (d0.5) and tapped density data (p), 
according to Eq. 1 [32]. 
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6.2.3.6. Scanning electron microscopy 
The morphology of prepared samples was observed using a LEO 1530 SEM 
(Zeiss/LEO, Oberkochen, Germany). Each sample was mounted separately onto SEM 
stubs using double-sided copper tape before sputter coating with Ag for 30 seconds under 
vacuum at 30 mTorr. The SEM was operated at high vacuum with accelerating voltage 5 
kV and specimen working distance 4 mm. 
 
6.2.3.7. Confocal microscopy 
A laser scanning confocal microscope (Leica SP2 AOBS, Bannockburn, IL), 
equipped with an argon ion laser, was used to investigate the structure of the RFDH and 
the coated RFDH microparticles. For the imaging of coated particles, 40 mg of 
Fluorescein Isothiocyanate (FITC) was added to the prepared 0.5% w/v of PLA coating 
solution (80 mL) and sprayed with the 4% of RFDH suspension (10 mL) through the two 
separate liquid channels of the 3F-S nozzle as above. For RFDH imaging, no 
fluorescence dye was added since RFDH is an auto-fluorescing material. The prepared 
dry powders were dispersed onto the receiving glass slide without oil immersion (to 
prevent drug dissolution in oil). All samples were imaged with two excitation 
wavelengths of 488 nm and 594 nm for FITC and RFDH, respectively. 
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6.2.3.8. High performance liquid chromatography (HPLC) 
Drug content and dissolution samples were analysed using a HPLC system 
(Waters Co., Milford, MA) with UV detection. The system consisted of a 717 plus 
autosampler, 2487 dual wavelength detector, 1525 binary pump, and 1500 column heater. 
Chromatography was performed using a Bondapak C18 10 μm 3.9×300 mm column 
(Waters, Milford, MA) and a SecurityGuard™ guard column (Phenomenex®, Torrance, 
CA). The mobile phase, consisting of methanol, acetonitrile and phosphate buffer 
solution pH 5.2 in a ratio of 50:17:33 respectively, was eluted at a flow rate of 1.2 
mL/min and the UV detector was set to a wavelength 337 nm. The column temperature 
was maintained at 25°C and the volume of each sample injected was 50 μL [3]. 
 
6.2.4. Aerosol classification 
The aerosolization performances of prepared samples were studied using a Next 
Generation Impactor (NGI) (MSP Co., Shoreview, MN). 15 mg of each powder 
formulation were filled into size 3 HPMC capsules and placed into an Aerolizer®  dry 
powder inhaler (DPI). Each capsule was pierced and actuated into an NGI though a 
stainless steel USP throat adapter at a flow rate of 60 L/min for 4 seconds, respectively. 
The powder deposited in the throat, in each dose collection-plate of the NGI, and in the 
remaining capsule were each reconstituted with 10 mL of acetone. The powders 
remaining in the device were washed with 10 mL of ethanol. Collected samples were 
analyzed by an 8453 UV/VIS spectrophotometer (Agilent, Santa Clara, CA) at 474 nm 
[33].  
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The emitted dose (ED), defined as the percent of total powder mass exiting the 
capsule, was determined by subtracting the amount remaining in the capsule from the 
initial mass loaded into the capsule. The fine particle fraction (FPF), defined as the total 
dose of particles with aerodynamic diameters smaller than 5 m, was calculated via 
interpolation from the cumulative mass against the cutoff diameter of the respective 
stages of the NGI. The FPF is expressed as a percentage of the total drug dose (FPFTD), 
and not of the emitted dose. Each measurement was repeated three times. The MMAD 
was determined by the % cumulative undersize on probability scale versus logarithmic 
aerodynamic diameter data. 
 
6.2.5. In vitro dissolution testing using novel dissolution method  
Dissolution behaviors of air classified powders were studied by a membrane 
holder method previously developed by this group [29, 30] (see Chapter 4). To briefly 
summarize, powder formulations containing approximately 1 mg of RF were loaded onto 
the membrane holder inserted in the NGI dose-collection plate at stage 3, by aerodynamic 
separation using the NGI. Appendix C describes how the amount of RFDH loading is 
determined. To achieve equal powder loading into the holder, the amount of powder 
added into the size 3 HPMC capsule was varied from 7 mg to 20 mg with the powder 
deposition profiles in each dose-collection plate of the NGI. The capsule fill mass was 
calculated by dividing the target RF loading amount by the powder deposition ratio in the 
dose-collection plate stage 3 obtained from the aerosol classification study. The capsule 
filled with powders was placed into the Aerolizer®  device, and actuated into the NGI 
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equipped with a gravimetric sampling cup (MSP Co. Shoreview, MN) equipped with a 
dissolution impaction plate (Copley Scientific, Nottingham, UK) at a flow rate of 60 
mL/min for 4 seconds. The dissolution impaction plate containing air classified particles 
was removed from the gravimetric sampling cup placed in the dose-collection plate of 
stage 3, and a pre-soaked PC membrane was placed onto the top and sealed in place with 
a push fitted sealing ring. The membrane covered dissolution impaction plate was placed 
into each dissolution vessel containing either 300 mL of PBS (pH 7.4) or 0.2 M citrate 
buffer (pH 5.2) containing 0.02% of ascorbic acid. Dissolution testing was conducted at 
75 rpm. The dissolution media (2 mL) was withdrawn manually using a glass syringe and 
filtered using a 0.45 m PTFE syringe filter at timed intervals of 15, 30, 60, 120, 180, 
240, 360, and 480 minutes. 
The residual amount of RF on the membrane holder was determined after 
dissolution test by washing a membrane and the impaction insert with acetone (10 mL) 
prior to analyzing. The total amount of RF loaded on the membrane holder was back 
calculated using the sum of cumulated release amount of API, plus the remaining 
quantity of API on the membrane holder and compared with the theoretical amount of 
powder loading calculated from the aerosol classification study. Fresh dissolution media 
(3 mL) was replaced into each vessel after sampling to maintain a constant volume.  
Ethanol (100 L) was added to the 900 L of collected samples and analyzed using the 
validated HPLC method, described above [3], to prevent decomposition of dissolved RF  




The prepared formulations were stored at ambient conditions in amber vials 
(25C/50% RH). Drug contents and thermal behavior, using differential scanning 
calorimetry (DSC), of stored samples were monitored every three months using the 
method described above. 
 
6.2.7. Statistical analysis 
Data were expressed as the mean plus/minus standard deviation (SD). Statistical 
differences were studied by analysis of variance (one-way ANOVA) using Jump 7.0 
software (SAS Institute Inc., Cary, NC). P values of less than 0.05 were considered as 
statistically significant. To identify the statistically significant differences between 
groups, Tukey–Kramer test was used.  value of 0.05 was applied to denote statistical 
significance.  
 
6.3. RESULTS AND DISCUSSION 
 
6.3.1. Characteristics of sprayed formulations 
The SEM images of the prepared formulations are shown in Figure 6.2. The 
RFDH particles show a very thin flake-like structure (less than 200 nm in thickness) with 
a smooth surface, which was the result of a polymorphic transformation of RF (Figure 6.2 
(A)) [28]. The coated particles prepared by two different types of 3F nozzles also showed 
a flake-like structure with more corrugated surface structure than the core particle, 
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RFDH, due to the polymer layer on the surface (Figure 6.2 (C) and (D)). Generally, 
spray-dried large molecules as polymers have a very corrugated surface structures since 
the diffusion of molecule from the atomized droplet surface to the inner core is slow, 
thus, the surface becomes enriched with molecules associated with a high Peclet (Pe) 
number as polymers, resulting in a crumpled surface structure [34, 35]. It can also be 
shown from the Figure 6.2 (B) that MRF microspheres have a very corrugated spherical 
shape. The distribution of polymer on the coated particle surface was further confirmed 
by confocal laser scanning microscopy (Figure 6.3). The intensity profiles obtained from 
the cross-sectional confocal laser scanning images (CLSI) of coated and uncoated RFDH 
particles showed that the fluorescent intensity of FITC (λex= 488) increased after coating 
with FITC embedded PLA, whereas the RFDH intensity (λex= 594) decreased after 
coating. 
The RF loaded formulations prepared by the spray drying process using three 
different types of spray nozzles, 2F, 3F-S, and 3F-M, are listed in Table 6.1 with the 
characterization results. The core-forming particles, RFDH, showed 95.8% of RF 
contents since it hosts 2 moles of water per one mole of RF molecule [28]. All other 
formulations contain about 50 or 60% w/w of RF and the loading efficiencies were in the 
range between 93 to 103% (w/w). Overall, the encapsulation efficiency of the 
formulations was close to the estimated values of drug loading. However, significant 
difference in product yield was found between the coated RFDH and MRF formulations. 
The significantly low yield of the MRF microspheres prepared by the 2F nozzle explains 
the cohesive nature of polymeric microspheres (Table 6.1). It was seen that the majority 
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of dried microspheres stuck on the wall of the cyclone separator gradually melted on the 
wall due to the low Tg of PLA/PLGA polymer. In contrast, the yield of coated 
formulations was not as low as those of MRF microsphere formulations, although the 
surface of the manufactured particles was modified with polymer. There was a higher 
yield for the coated particle because the bulky flake-like structure of microparticles was 
quickly removed from the cyclone separator due to low density and low inter-particulate 
forces, as evidenced in our previous study with the RFDH crystals [28] (see Chapter 5).  
Representative x-ray diffractograms of the manufactured formulations, RFDH, 
coated RFDH, and MRF microsphere are shown in Figure 6.4. X-ray powder diffraction 
(XRD) patterns show that the coating process using a 3F nozzle did not affect the 
crystalline structure of RFDH, whereas the MRF microsphere shows no characteristic 
crystalline peaks with a halo at the baseline appearing on the x-ray diffractogram, 
indicating that the RFDH crystals sprayed through the inner nozzle were successfully 
coated without dissolving of the crystals in the stream of coating solution sprayed 
through the outer nozzle. The characteristic crystalline peaks representing the polymer-
coated samples correspond to those for the RFDH, although peak intensity decreased due 
to an amorphous PLGA or PLA content in the formulations. The core-forming crystal, 
RFDH, is freely soluble in most organic solvents except ethanol, thus conventional 
coating methods that require a dispersion of core particles in organic coating solution, 
like a spray coating process using a 2F nozzle, can‘t be applied. This is unfortunate as 
spray coating using a spray dryer with 2F nozzle is a common method used to over other 
coating process to obtain coated particles since it is a relatively simple one-step process 
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and has the capability to coat very small particles [26, 27, 36]. The issues associated with 
solvents to dissolve or disperse RFDH and PLA/PLGA can be solved by spraying two 
prepared liquid solutions separately through the two liquid passages of 3F nozzle.  
Laser diffraction data are presented in Table 6.1, with a representative size 
distribution displayed in Figure 6.5. The median (d50) particle size of each of the coated 
and uncoated RFDH powders was in the range of 8 to 12 µm with a unimodal size 
distribution profile. In contrast, the MRF microspheres showed broad particle size 
distribution with d50 values of 22-25 µm, unlike the particle size shown in the SEM 
image (Figure 6.2 (B)), which indicates a range of 2-5 m, suggesting that the MRF 
microspheres were not deagglomerated completely at the airflow (60 mL/min). The 
formation of strong aggregates is very undesirable for pulmonary administration, since it 
leads to a decrease in the fine particle dose (FPD) to the target site, the lung. The dae 
value for MRF formulations could not be obtained since the tapped density of those 
formulations wasn‘t measured properly due to the adhesive powder property. The 
calculated dae values for the RFDH and the coated RFDH formulations fell into the 
respirable particle size range (1-5 m), although the d50 values were larger than 8 µm, due 
to the low density. The dae values of the coated RFDH, prepared using the 3F-M nozzle 
were larger than that of the particles coated by the standard 3F nozzle (3F-S), whereas the 
geometric particle size (d50) were very similar to each other at about 10 µm (Table 6.1). 
This indicates the 3F-M nozzle produces a thicker coating layer on the RFDH surface 
than the 3F-S nozzle, resulting in an increase the settling velocity of airborne particles. 
From the study, we can estimate that the optimal aerodynamic properties of formulations 
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will be in the following rank order: RFDH > coated particles by 3F-S > coated particles 
by 3F-M.   
 
6.3.2. Aerodynamic properties  
In vitro aerosolization properties of manufactured formulations were compared 
using NGI with Aerolizer®  device. The ED, FPFTD, and MMAD of each formulation are 
displayed in Table 6.2. The aerodynamic performances of the RFDH powders were 
considerably improved by changing the crystalline structure to a flake-like dihydrate 
form, with 68% of FPFTD. It has been known that the flaky or elongated morphology of 
microparticles significantly improves particle deaggragation and dispersion properties 
since the different particle shapes lead to a variation in surface energy and inter-
particulate forces [37-40]. The FPFTD and the MMAD values of coated RFDH 
formulations are in good agreement with the estimated aerodynamic properties of 
formulations from the dae values. The coated RFDH formulation by the 3F-S nozzle 
showed smaller MMAD and higher FPFTD values of about 3.5 µm and 54% than those of 
powders coated using the 3F-M (bigger than 4 µm and about 40% FPFTD), implying that 
the settling velocity of the coated particles by the 3F-M nozzle is faster than the particles 
coated by the 3F-S nozzle in the airborne state due to the larger amount of polymer 
deposited on the particle surface. It was also shown in Figure 6.6 that the maximum 
particle depositions of the RFDH, the coated RFDH by 3F-S and 3F-M nozzle were 
achieved at the NGI dose-collection plate stage of 4, 3 and 2 among the 7 dose-collection 
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plates, respectively, with more than 95% of the capsule contents being emitted during 
aerosolization testing at an air flow of 60 L/min.  
The difference in coating thickness can be explained by the mechanisms of two 
coating methods using different 3F nozzles, 3F-S and 3F-M. As depicted in Figure 6.1, in 
the process using a 3F-S nozzle, two liquid phases are supplied to two separate spray 
channels and they are atomized by mixing of high-speed compressed air supplied through 
the separate gas channel at the end of nozzle tip (mixing zone), leading to a collision of 
atomized polymer mist with atomized solid RFDH crystals (core-forming particles) with 
a certain probability. As a result, the collided polymer mist is rapidly deposited on the 
core particle surface and forms a thin layer.  
Contrary to the 3F-S process, in the process using the 3F-M nozzle, the ethanol 
suspension containing core-forming particles is combined with the coating solution in the 
outer nozzle followed by continuous atomization (Figure 6.1). The mixing of the ethanol 
suspension and the acetone coating solution may occur immediately due to the rapid 
diffusion of ethanol into the acetone without anti-solvent precipitation of PLGA/PLA 
polymer [41, 42]. The continuous polymer solution surrounding the core-forming 
particles forms a thin layer upon atomization. In the 3F-M process, the RFDH crystals do 
not dissolve upon contact with the acetone/ethanol solvent mixture as evidenced by the 
XRD data. This solvent stability of the RFDH crystals is likely due to the fact that the 
atomization of solvent mixture is achieved at almost the same time as the solvent mixing. 
Consequently, the polymer mist generated by the 3F-S nozzle forms a thinner coating 
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layer than the continuous liquid phase surrounding the core-forming particle in the 3F-M 
nozzle.  
The ED values of the MRF microsphere formulations were significantly lower 
(about 70%) and more variable compared to the coated RFDH formulation, although the 
MRF formulations were manufactured as a highly corrugated powder to improve the 
dispersibility. This low ED is attributed to their small and spherical shape leading to a 
strong particle aggregation.  
 
6.3.3. In vitro dissolution studies  
Although several in vitro methods exist for the prediction of respirable fraction 
and site of deposition in the lung following pulmonary administration (e.g. Andersen 
Cascade Impactor, Next Generation Impactor, Twin Stage Impinger), there is no 
optimized in vitro model to predict the rate and extent of drug dissolution in the lung 
following inhalation. Currently available methods of evaluating the dissolution behavior 
of inhalation products rarely consider the impact of particle classification on the 
dissolution behavior [15, 16, 43, 44]. Unlike other pharmaceutical dosage forms, in 
pulmonary drug delivery systems, only a fraction of the API emitted from standard 
delivery devices is delivered to the target site, the lung, and the deposited particles in the 
lung are in a deagglomerated state. Thus, an ideal dissolution test method for inhalation 
formulations would involve a particle classification step prior to dissolution assessment. 
We have indicated that the aerodynamic classification of aggregated powders prior to the 
powder introduction step into the dissolution apparatus has a significant influence on the 
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dissolution profiles [29]. In this study, a new membrane holder method which was 
designed specifically to be incorporated into the Next Generation Impactor (NGI) for 
easy dose collection performance was applied to properly compare the dissolution 
profiles of the manufacture formulations [29, 30]. 
As expected, the uncoated RFDH powder underwent the most rapid dissolution 
among the formulations, with 63% of initial RF release in 15 minutes followed by a 
sustained RF release for 8 hours (Figure 6.7). The release rate at the first time points were 
mainly attributed to the pre-dissolved RFDH crystals in the membrane holder since the 
pre-soaked membrane replicating the thin lung lining fluid in the membrane holder setup 
may activate the drug dissolution by improving powder wetting before the sealed 
membrane holder is added to the dissolution media. Consequently, the actual drug 
dissolution rate between 0 and 15 minutes, although data are plotted as a straight line, 
may be slower than what is shown in the graph. Nevertheless, these studies do give 
comparative information about the rate of drug release from different formulations.  
The coated RFDH formulations exhibited delayed release characteristics with a 
lowered initial burst, implying that the polymer layer surrounding the RFDH particle 
prevents the RFDH from dissolving at the early phase by minimizing the chance for the 
core-forming particles to contact the dissolution medium, which is in general agreement 
with the results of coated formulations with hydrophobic polymers [25, 45]. The 
formulations prepared by the 3F-M nozzle were associated with a lower initial RF release 
than the formulations prepared by the 3F-S nozzle. In particular, the PLA coated 
formulation, C50L-M, showed the lowest initial RF release as 32% with a moderated 
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biphasic release profile in the coated formulations. However, overall, RF release from the 
formulations coated by the 3F-M nozzle after the initial burst (15 min) was not 
significantly retarded when it is compared with the formulations prepared by the 3F-S 
nozzle. This explains the thickness of the coating layer obtained from two different spray 
nozzles is not considerably different to modify the diffusion rate of dissolution media 
through the membrane barrier, but the completeness of coating layer may be influenced 
by the type of spray nozzle. The higher initial RF release from the formulations prepared 
by the 3F-S may be due to the larger amount of incompletely coated RFDH portion in the 
formulation compared to that of powders coated by the 3F-M nozzle. The RF release 
profile from the formulation encapsulating a 60% of RF (C60L-M) was shown to be 
faster than that of the formulation loaded 50% of RF (C50L-M) due to the lower amount 
of polymer deposited on the RFDH particle surface. From the release studies with coated 
formulations, we can conclude that the 3F-M nozzle is more effective in controlling the 
initial RF release with higher drug loading than the 3F-S nozzle. In inhaled anti-TB 
antibiotic treatment, the formulations exhibiting a large initial release with high loading 
efficiency (high doses of encapsulated drug) has been known to be more effective for 
effective treatment of pulmonary TB than the formulation with no initial drug release [5, 
6]. Accordingly, the well-controlled initial drug release from the coated formulations may 
be beneficial in achieving the therapeutic concentration immediately after dosing, 
followed by sustained release to maintain the achieved therapeutic dose in the lung until 
next the dose. Generally, sustained release formulations having no burst effect to 
maintain certain systemic drug concentration have been known to be ideal. However, that 
 211 
is not always ideal to treat diseases, in particular, the use of initial burst as a first does 
may be more effective for the treatment of local respiratory infections as many bacterial 
species inoculated in the lung show slow proliferation by immediately reaching their 
minimum inhibitory concentration (MIC) [5, 46]. For instance, a study conducted by 
Suarez et al. shows that the formulation exhibiting a large initial RF release followed by 
sustained release is more effective to inhibit a MTB bacterial growth in the lung [5] since 
the antibiotic effect of RF against MTB bacteria is dose-time dependent [9, 24].  
As shown in Figure 6.7, the largest burst effect was observed for the PLGA MRF 
microsphere formulations, M50LG, in the manufactured sustained release formulations, 
while the PLA MRF formulation, M50L, showed the lowest initial RF release (25%) with 
a plateau at 45%. The large initial RF release from the PLGA MRF formulation is 
attributed to the RF release from the superficial area of microparticles. It has been known 
that the most challenging part in microencapsulation is to effectively control drug loading 
to achieve both sufficient therapeutic doses and desired changes in the dissolution profile, 
since in most cases of sustained release systems, drug release rate is inversely 
proportionate to the amount of encapsulated drug. Polymers having higher molecular 
weight or having more hydrophobic moiety have been used to obtain formulations with 
more extended release profile, however, those polymers often lead to incomplete drug 
release from the microparticles due to the extremely slow erosion or diffusion 
characteristics of polymers [3] as the release profile of the PLA MRF microsphere shown 
in Figure 6.7. 
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The pH of the dissolution medium significantly affected RF release as well as the 
decomposition of dissolved RF. Dissolution data collected at 15 minutes and 8 hours 
were plotted (Figure 6.8). Dissolved RF in an acidic dissolution media (pH 5.2) 
decomposes rapidly by oxidization and hydrolysis [47, 48], thus dissolved RF contents in 
the dissolution media after 15 minutes couldn‘t be analyzed (Data collected at 8 hours 
was plotted against the RF amount subtracted from the initial loading from the remaining 
RF amount in the membrane holder). At pH 5.2, the initial drug release was decreased for 
both RFDH and the coated RFDH formulation compared to the values at neutral pH (pH 
7.4) due to the pH-dependency of RF in dissolution [3, 47, 48]; the RF shows the fastest 
dissolution at pH 1.2, the slowest dissolution at slightly acidic conditions (pH 4-5) and a 
moderate dissolution in neutral conditions. However, difference in the cumulative amount 
of released RF for 8 hours in two different pHs is more significant for the coated RFDH 
formulations than uncoated one; for uncoated RFDH crystals, almost the same amount of 
RF was dissolved in pH 5.2 media as it was in pH 7.4 media for 8 hours, whereas the 
coated RFDH formulations released a 32% lower amount of RF at pH 5.2 compared to 
that at pH 7.4. This result suggests that the pH-dependent dissolution of RF, coupled with 
the minimum exposure of core-forming particles to dissolution medium by the polymer 
barrier on the surface, results in a much slower RF release in low pH dissolution media. 
This pH-dependent dissolution may be beneficial to target AMs, which is a safe site for 
their prolonged survival, since polymeric microparticles in the size range between 1 to 10 
μm are very actively phagocytosed by AMs in 1 hour [19, 20]. From the in vitro 
dissolution study, it can be estimated that the deposited coated RFDH particles dissolves 
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quickly in the first hour to achieve therapeutic concentrations in the alveolar region (pH 
7.4) followed by slow RF release from the coated particles either phagocytosed by AMs 
in the phago-lysosome interior (pH 4-5) or from those that could remain in the alveoli.  
 
6.3.4. Correlation between stability and moisture uptake  
In our previous study, the significant decrease in drug content for the spray-dried 
amorphous RF was found, which was 26% degradation in 9 months at ambient storage 
condition, whereas the RFDH crystal did not show a significant difference [28] (see 
Chapter 5). Thus, the impacts of moisture sorption-desorption properties of the 
manufactured formulations on the physicochemical stabilities were studied by means of 
DVS method. As shown in Table 6.3, the decrease in chemical potency for the 
crystalline-structured formulations was less significant than that of the amorphous-
structured formulations. More hydrophobic polymer, PLA, was shown to be better 
excipient to protect RFDH from the chemical decomposition than PLGA. These results 
can be explained through the moisture uptake behavior of formulations studied using 
DVS analysis. It can be seen from Table 6.3 that the degree of chemical degradation is 
closely related to the hysteresis between the moisture sorption and desorption cycle; 
formulations showing larger hysteresis on the isotherm graph was associated with more 
chemical decomposition. As shown in Figure 6.9 (A), the MRF microspheres, M50LG, 
take up 3.5% moisture between 0-90% RH and 2.3% moisture between 50-90% RH. A 
large hysteresis between sorption and desorption isotherm profiles was also shown from 
amorphous formulations (Table 6.3), indicating that water absorbed from the atmosphere 
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is strongly bound to the amorphous RF when the powders are stored at ambient 
condition, and the chemical degradation or the crystalline structural rearrangement could 
be accelerated by this. Conversely, the coated RFDH formulations showed a range of 1.4 
to 1.5% moisture uptake between 50-90% RH and the hysteresis was not significant due 
to the hydrophobic polymer layer on the surface. From the DVS study, we can deduce 
that the chemical stability of coated RFDH formulations by the 3F-M would not be 
significantly different from the formulations manufactured by the 3F-S, although the 6 
month stability data have not yet been analyzed, since the moisture sorption-desorption 
profiles were quite similar each other. As shown above, the DVS study is a very useful 
tool to estimate the hygroscopicity of manufactured formulations. Additional DVS 
studies on further formulation compositions are given in Appendix D. 
The stabilities of the prepared formulations over 6 months were further confirmed 
by the DSC (Figure 6.10). No change in thermograms was found for the coated and 
uncoated RFDH formulations, whereas the onset of RF decomposition at 6 months is 
earlier than that of initial sample. This is good agreement with our previous data that the 









A novel surface coating method utilizing multi-channel spray nozzles has been 
introduced. A multi-channel nozzle spray drying method is often applied when spraying 
of two continuous liquid phases to manufacture composite materials of water insoluble 
and soluble drugs. In this study, we found the spraying of continuous liquid phase and the 
suspension can generate coated formulation. The coating performance of two different 
types of three-fluid (3F) nozzles, standard 3F nozzle (3F-S) and modified nozzle (3F-M), 
were compared. Coated rifampicin dihydrate (RFDH) powders with hydrophobic 
polymers, PLGA and PLA, were prepared using the two different types of 3F nozzles. 
The coated formulations contained at least 50% w/w of RF. The thin flaky morphology 
and crystalline structure of RFDH powders was maintained after coating, and this special 
flake-like morphology provides high spray drying yield with the RFDH formulation. 
Overall, the aerodynamic performance of coated RFDH particles were reduced compared 
to the RFDH due to an increased aerodynamic diameter by polymer coating; the MMAD 
values of coated formulations were in the range of 3.5 to 4.6 m, whereas the RFDH has 
a 2.2 m of MMAD. However, the coated formulations still provide more than 40% of 
FPFTD without a carrier. The maximum FPFTD was obtained from the powders coated by 
the 3F-S as 54%, which was higher than that of the powder coated by 3F-M, due to the 
thinner coating layer. 
The coated formulations showed lowered initial RF release followed by slow RF 
release after initial release compared to the uncoated RFDH crystals. The lowest initial 
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RF release was observed from the coated powders with PLA polymer using the 3F-M 
nozzle as 32% among other coated formulations. Overall, the formulations coated by the 
3F-M nozzle showed lower initial RF release with higher drug loading than 3F-S nozzle. 
The RF release from the coated RFDH formulation showed pH-dependency; the RF 
release slowed in slightly acidic dissolution medium (pH 5.2). The significance of pH-
dependent RF dissolution was larger for the coated formulation than for the uncoated 
RFDH powders due to the polymer barrier surrounding the core particle. It could be 
anticipated that the delivered coated RFDH powders via the pulmonary route would 
provide higher local (lung) drug concentrations with a longer drug residence time in the 
lung than that of uncoated formulation. From the series of studies, we can infer that 
coated RFDH powders deposited in the alveolar region would first deliver an initial 
therapeutic dose of RF, followed by sustained release (maintenance dose) from the coated 
particles. Additionally, coated particles may phagocytosed by alveoli macrophages 
(AMs), which is the main site of the Mycobacterium tuberculosis (MTB) proliferation, 
thus the targeting AMs and building up high intracellular drug concentrations could be 
possible. The coated RFDH powders are predicted to provide much better stability than 







Table 6.1  Physical characterizations of prepared formulations.  



















91  95.8 ± 0.02 100 8.8 ± 0.1 0.068 2.3  
M50LG 37.5  52.0 ± 0.6  104 24.5± 2.3 - - 
M50L 43.8 49.0 ± 0.9 98 22.7 ± 1.6  - - 
C50LG-M 72.5 49.9 ± 0.4 99.8 10.9 ± 0.2 0.128 3.9 
C50L-M 78 49.7 ± 0.1 99.4 12.0 ± 0.8  0.119 4.1 
C60L-M 70 58.3 ± 0.6 93.3 10.2 ± 0.4 0.108 3.3 
C50LG-S 75 51.5 ± 0.6 103 10.4 ± 0.4 0.110 3.4 
C50L-S 75 50.5 ± 0.6 101 10.1 ± 0.2  0.125 3.6 
 
*The sample name is coded as follows:  
i) M and S represent a matrix form and coated form, respectively 
ii) The digits, 50 and 60, represent the amount of encapsulated RF  
iii) LG and L represent a PLGA and PLA, respectively 
iv) S and M represent standard 3F nozzle and modified 3F nozzle, respectively  
 



















Table 6.2  Aerodynamic characteristics of the formulations at a flow rate of 60 L/min 
with Aerolizer®  (values are means ± SD, n = 3). 
Formulation ED (%) PFPTD (%) MMAD (m) 
RFDH  98.3 ± 0.2 68.5 ± 2.4 2.2 ± 0.1 
M50LG 71.0 ± 6.9‡ 32.6 ± 2.9* 4.3 ± 0.5 
M50L 72.9 ± 4.5‡ 35.5 ± 2.0* 2.8 ± 0.1 
C50LG-M 98.0 ± 0.3 40.4 ± 2.1* 4.2 ± 0.4 
C50L-M 97.6 ± 0.6 37.6 ± 1.7* 4.6 ± 0.3 
C60L-M 98.0 ± 0.2 40.8 ± 1.0* 3.6 ± 0.3 
C50LG-S 98.2 ± 0.2 53.7 ± 1.6*† 3.6 ± 0.1 
C50L-S 98.1 ± 0.26 54.4 ± 1.8*† 3.5 ± 0.1 
 
‡ Statistical difference among the groups  
*Statistical difference from RFDH    
† Statistical difference between two groups coated by two different types of 3F nozzles  


























Table 6.3  RF contents analysis for the prepared formulations stored under ambient 
condition (25 ºC/50 RH) over 6 months (values are means ± SD, n = 3), and the moisture 






Change in mass 
at 90% RH (%)  
Hysteresis at 
50% RH (%) 
RFDH Crystalline 95.8 ± 0.6 2.1 2.4 0.1 
M50LG Amorphous 52.0 ± 0.6 7.1 3.5 1.0 
M50L Amorphous 49.0 ± 0.9 4.5 3.1 0.6 
C50LG-S Crystalline 51.5 ± 0.6 1 1.5 0.05 
C50L-S Crystalline 50.5 ± 0.6 0.2 1.5 0.02 
C50LG-M Crystalline 49.9 ± 0.4 N.A. 1.5 0.08 
C50L-M Crystalline 49.7 ± 0.1 N.A 1.4 0.05 
 
*The drug contents of RFDH indicates RF contents  















Figure 6.1  Schematic diagram of two types of three-fluid (3F) spray nozzle for in-situ 











Figure 6.2  Scanning electron microscopy images of (A) RFDH, (B) MRF microsphere 
(M50LG), (C) coated RFDH with standard 3F nozzle (C50L-S), and (D) coated RFDH 









Figure 6.3  The intensity profiles obtained from the cross-section confocal laser 
scanning images of (A) the surface of uncoated RFDH and (B) the surface of coated 















Figure 6.4  Powder X-ray diffractograms of (A) RFDH, (B) coated RFDH (C50L-M) 


























Figure 6.5  Average particle size distribution measured by Spraytec®  at a flow rate of 





Figure 6.6  In vitro powder deposition profiles for RFDH, coated RFDH and MRF 
microspheres at a flow rate of 60 L/min with Aerolizer® , expressed as the percentage of 





















Figure 6.7  RF release profiles for the RFDH, coated RFDH, and MRF microsphere 
formulations in PBS containing 0.02% ascorbic acid (pH 7.4); (A) PLGA containing 
formulations and (B) PLA containing formulations (powders accumulated on the dose-
collection plate 3 were selected for dissolution, the error bars indicate the standard 






Figure 6.8  RF release profiles for the RFDH and coated RFDH (C50L-M) formulations 
in 0.2 M citrate buffer (pH 5.2) containing 0.02% ascorbic acid. Powders accumulated on 













Figure 6.9  Dynamic vapor sorption (DVS) isotherm of (A) MRF microsphere (M50LG), 
and (B) coated RFDH (C50L-M). The absorption is shown as solid lines and desorption 





Figure 6.10  DSC thermograms of (a) RFDH and (b) coated RFDH (C50LG-S) and (c) 
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7.1.1. Development of a standardized dissolution test method for inhaled 
pharmaceutical formulations 
A new dissolution testing prototype apparatus for evaluating the in vitro 
dissolution behavior of inhalation formulations has been introduced. The Next 
Generation Pharmaceutical Impactor (NGI) was modified with polycarbonate (PC) 
membranes to collect air-classified primary particles prior to dissolution assessment. The 
dissolution rates of hydrocortisone (HC), a model active pharmaceutical ingredient (API), 
powders with different particle sizes (0.5-5 µm), were tested using the newly designed 
dissolution apparatus. From the dissolution study, it was discovered that aerodynamic 
particle separation had a significant influence on dissolution profiles; the air-classified 
particles demonstrated at least a three-fold increase in HC dissolution rate than that of 
non-separated particles over the test period. This result indicates that an inappropriate 
introduction of test compounds into the dissolution media may produce misleading 
dissolution results. The performance of inhalers, particularly dry powder inhalers (DPIs), 
and the aerodynamic properties of test compounds greatly affected the dissolution 
profiles; homogeneously dispersed HC particles in the lactose carrier showed more 
consistent dissolution behavior than that of carrier-free bulk HC. This is because that the 
variations in the amount of powder loaded in the membrane holder, which is generally 
due to poor aerodynamic properties of formulations, lead to differences in 
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dissolution/diffusion activity that required to release all of the drug out to the reservoir 
from the to the membrane holder. Thus, we can conclude that this dissolution method 
may be used as a quality control study for various dry powder inhalers (DPIs). 
Specifically, the in vitro dissolution profiles of drug may provide an estimate of its 
dispersion characteristics which directly related to the device or aerosol performances. 
 
7.1.2. Study factors affecting the dissolution behaviors of aerosol products using 
experimental and mathematical analysis 
A novel, easy to use dissolution membrane holder (NGI membrane holder), which 
was designed specifically to be incorporated into the NGI for better dose collection 
performance than a previously developed prototype membrane holder, has been 
introduced. The new NGI membrane holder was easier and more efficient in dose 
collection than the previous prototype holder since the NGI membrane holder has a larger 
impaction area for particle collection than the prototype one. Additionally, 
aerodynamically separated particles can be directly collected on the NGI membrane 
holder without the modification of NGI with PC membranes. Dissolution procedures, the 
apparatus, the dose collection, the medium, and test conditions were developed with 
reference to the USP General Chapter <1092>. Dissolution profiles of two commercially 
available products, Ventolin®  HFA and Pulmicort Flexhaler™, were successfully tested 
using the optimized in vitro dissolution test method. It was found that the most critical 
factor in dissolution assessment using the NGI membrane holder was the amount of 
powder loading (thickness of powder bed), and the significance of this factor was shown 
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to be dependent on the hydrophobicity of the API tested. The dissolution kinetics of drug 
particles loaded in the NGI membrane holder was analyzed by mathematical simulation. 
From the mathematical analysis, it was further confirmed that the thick, dense, 
hydrophobic powder bed created by multiple device actuations, may retard the diffusion 
of dissolved drug molecule within a powder bed, resulting in retarded drug release from 
the membrane holder. Three different dissolution media with the same ionic strength and 
pH, phosphate buffered saline (PBS), phosphate buffer and simulated lung fluid (SLF), 
were screened to determine a suitable dissolution medium for evaluating a broad range of 
APIs. The SLF media is found to not be preferable for the routine quality control (QC) 
study for inhalation products due to its low buffering effect, whereas the PBS and 
phosphate buffer showed good pH stability whilst providing equivalent dissolution 
profiles to that of SLF. This dissolution method using the NGI membrane holder has 
several advantages over other existing methods. The advantages are as follows: i) 
commercially available USP dissolution apparatus can be incorporated with the 
membrane holder, thus further validation on the dissolution apparatus is not required, ii) 
the dissolution behaviors of primary particles that may be delivered to the various target 
sites of the lung can be evaluated by pre particle separation, iii) a particle separation prior 
to the dissolution study is easily achieved by aerodynamic separation of formulations 
using the NGI incorporated with the impaction insert of the NGI membrane holder, iv) 
several problems associated with poor powder wetting and particle aggregation in the 
dissolution study can be solved by enclosing the test compound in the NGI membrane 
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holder, and v) the thin liquid layer in the membrane holder allows the technique to more 
closely simulate conditions in the lung.  
 
7.1.3. A new respirable form of rifampicin 
Rifampicin dihydrate (RFDH) powders with MMAD of 2.2 m were successfully 
prepared using a simple recrystallization process. The RFDH powders have a thin flaky 
structure that provides improved aerosolization properties at maximal API loading. The 
spray drying process used to prepare the dry powder form of RFDH crystal also 
contributed to the formation of fluffy powder structure. No excipients or carrier particles 
were added to improve powder flow or aerodynamic properties, which is ideal for 
delivering a maximum potency of antibiotics directly to the site of infection, the lung. 
Moreover, possible drug-excipient interaction can be prevented by removing excipients 
from the formulation. The maximum FPFTD of the RFDH achieved with a low resistant 
dry powder inhaler, Aerolizer®  device, was 68%. There were no considerable differences 
in FPFTD and ED for the RFDH formulations between two devices with different device 
resistance, whereas the spray-dried RF (SP-RF) control formulation, showed significant 
differences in both FPFTD and ED, indicating that the aerodynamic performances of 
RFDH is less device dependent than the SP-RF. This is attributed to the relatively low 
interparticulate forces of flaky RFDH particles, compared to the small spherical SP-RF 
powders. The RFDH powders are predicted to deposit predominately in the central and 
peripheral regions of the lung following inhalation, with minimal oropharyngeal 
deposition. RFDH powders delivered via the pulmonary route are anticipated to provide 
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higher local (lung) drug concentrations than that of orally delivered powders, since the 
RF dissolves immediately in low pH media (pH 1.2) (and is rapidly decomposed by 
hydrolysis in acidic media) but dissolves slowly in neutral conditions. In the dissolution 
study using the NGI membrane holder method, the RFDH and SP-RF showed 74% and 
82% RF release in 1 hour. Additionally, RFDH powders show much better physical and 
chemical stability than the amorphous SP-RF formulation, which is attributed to the less 
hygroscopic nature of RFDH powders compared to the SP-RF. From the Dynamic Vapor 
Sorption (DVS) study, we found that water absorbed from the atmosphere is strongly 
bound to the SP-RF. The excipient free formulation of the RFDH offers the benefit of 
delivering a maximum potency formulation of the antibiotic directly to the site of 
infection, with minimum inspiratory efforts, through the use of a low resistant DPI 
device. 
 
7.1.4. Preparation of sustained release rifampicin microparticles for inhalation 
A novel surface coating method utilizing a multi-channel spray nozzle has been 
introduced. The three-fluid (3F) nozzle has two separate nozzles for spraying of aqueous 
solution, and the 3F nozzle was modified by adjusting a position of inner nozzle. The 
coating performance of two nozzles, a standard 3F nozzle (3F-S) and a modified nozzle 
(3F-M) were compared. The coated rifampicin dihydrate (RFDH) powders with 
hydrophobic polymers, PLGA and PLA, were prepared using two different types of 3F 
nozzles. The coated formulations contained at least 50% w/w of RF. The thin flaky 
morphology of RFDH powders was not changed by coating with PLA/PLGA polymers. 
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Overall, the aerodynamic properties of coated RFDH particles were somewhat worsened 
compared to the RFDH, due to an increased aerodynamic diameter by polymer coating; 
the MMAD values of coated formulations were in the range of 3.5 to 4.6 m, whereas the 
RFDH has a MMAD of 2.2 m . However, the coated formulations still provide more 
than 40% of FPFTD without a carrier. The maximum FPFTD was obtained from the 
powders coated by the 3F-S as 54%, which was higher than that of the powder coated by 
3F-M, due to the thinner coating layer. 
The coated formulations showed lowered initial RF release followed by a slower 
RF release after the initial release, compared to the uncoated RFDH crystals. The lowest 
initial RF release was observed from the coated powders with PLA polymer using the 3F-
M nozzle as 32% among other coated formulations. Overall, the formulations coated by 
the 3F-M nozzle showed lower initial RF release with higher drug loading than the3F-S 
nozzle. The RF release from the coated RFDH formulation showed pH-dependency; the 
RF release slowed in an acidic dissolution medium (pH 5.2). The significance of pH-
dependent RF dissolution was larger for the coated formulation than for the uncoated 
RFDH powders, due to the polymer barrier surrounding the core particle. The delivered 
coated RFDH powders via the pulmonary route is anticipated to provide higher local 
(lung) drug concentrations with a longer drug residence time in the lung, than that of an 
uncoated formulation. From the series of studies, we can conclude that the coated RFDH 
powders deposited in the alveolar region, deliver a first therapeutic dose of RF that is 
immediately followed by a sustained release from the coated particles. Additionally, parts 
of coated particles may be phagocytosed by alveoli macrophages (AMs), which is the 
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main site of Mycobacterium tuberculosis (MTB) proliferation, thus targeting AMs and 
building up high intracellular drug concentrations may be achieved. The coated RFDH 
powders are predicted to provide much better stability than the amorphous RF or 
uncoated RFDH crystals, due to their decreased hygroscopicity. 
 
7.2. FUTURE STUDIES 
 
7.2.1. In vitro-in vivo correlation (IVIVC) study 
There have been several methods to replicate the dissolution behaviors of APIs in 
the fluids that line the respiratory tracts where drugs are deposited. However, there have 
been no standardized in vitro systems to simulate lung dissolution since the lung has very 
unique features which are difficult to replicate in vitro. The dissolution system we 
developed has several features that replicate the dissolution of particles in the lung, such 
as aerodynamic separation prior to dissolution, and the thin liquid layer in the membrane 
holder. However, our dissolution study has been more focusing on the process 
optimization and comparison of in vitro dissolution profiles between inhaled drug 
products than the in vitro-in vivo correlation (IVIVC). Actually, to date, no IVIVC 
studies have been completed for inhalation products. Therefore, it may be valuable to do 
an IVIVC study to explore the potential of the developed dissolution method as an 
alternative test method of in vivo drug absorption study. Specifically, the 
pharmacokinetic study for budesonide (BD) (PulmicortFlexhaler™) would provide 
information about the dissolution system that offers the most bio-relevant dissolution 
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profiles among the methods developed by this group [1], Davies et al. [2], and Arora et 
al. [3]. All three methods examined the in vitro dissolution profiles of air-classified BD 
powders (either Pulmicort Flexhaler™ or Pulmicort Turbuhaler™), and huge differences 
in the dissolution profiles were found between the methods; 80% BD dissolution was 
achieved in about 15 minutes, 1 hour and 6 hours from the study conducted by this group, 
Davies et al. and Arora et al., respectively. Tmax of inhaled dry powder BD obtained from 
several clinical pharmacokinetic studies is in the range of 0.28 to 0.4 hours [4, 5]. From 
the results, our dissolution system can be predicted to be the most bio-relevant system. 
However, to verify the estimation, an IVIVC study needs to be conducted. 
 
7.2.2. Development of a novel apparatus for pulmonary dry powder administration 
to animal lung  
In this study, the in vitro dissolution behaviors of developed rifampicin (RF) 
formulations have been intensively studied using a novel dissolution method developed 
by this group. We believed that the in vitro dissolution method has a capability to 
differentiate formulation types, and perhaps give an estimate of a dissolution behavior in 
vivo since the RF is a class II drug of the Biopharmaceutic Classification System (BCS) 
where rate and extent of dissolution is critical for optimum bioavailability [6]. However, 
in vivo drug absorption study for the developed RF formulations with animal models 
hasn‘t been conducted since there were several technical difficulties in the intra-tracheal 
administration of dry powder formulations. There have been several devices utilized for 
delivery of powders into the lung, such as an insufflators and ventilators. These methods, 
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however, often necessitate surgery to introduce a tube into the trachea. Moreover, 
currently available powder dispersing devices cannot effectively classify the aerosol 
particles into the respirable particle size (1-5 µm) range, resulting in the administration of 
either carrier or API particles that may not be delivered to the lung by actual inspiration. 
Since the aerodynamic particle separation and particle size has a great influence on the 
dissolution properties of drugs, inappropriate drug dosing to an animal model would 
provide a wrong estimation of drug dissolution and absorption in vivo. Therefore, the 
development of new inhalation systems or powder dispersing devices which is able to 
deliver the respirable size of dry powder aerosols to the animal models, is necessary to 
achieve successful preclinical study with animal models.  
 
7.2.3. Pharmacokinetic study with animal model of TB 
In this study, two different types of RF formulations, immediate release RF 
(RFDH) and sustained release RFDH (coated RFDH), were developed. The microbial 
killing effect of the prepared formulations will be evaluated with animal model infected 
with Mycobaterium tuberculosis (MTB). As the microbial killing effect by RF is known 
to be dose-dependent [7], the appropriate dose range for the RFDH and coated RFDH to 
effectively kill the MTB or prevent the regrowth of MTB will be explored. Additionally, 
the combinations of RFDH and coated RFDH formulations will be dosed to the animal 
model to evaluate whether the administration of immediate release formulation (RFDH) 
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Appendix A: Modeling of Dissolution-Diffusion Controlled Drug 
Release Kinetics from the NGI Membrane Holder 
 
A.1. DISSOLUTION MODEL  
 
A.1.1. Primary model  
Mathematical model for the drug release from planner polymeric matrix systems 
was applied to estimate the dissolution kinetics of pharmaceutical compounds loaded in 
the NGI membrane holder [1, 2]. The dissolution kinetics of drug particles loaded in the 
NGI membrane holder was explained by Noyes-Whitney equation. The diffusion of 
dissolved drug molecules in the membrane holder was described according to Fick‘s 
second law. A primary model for the system containing drug particles assembled on the 
cross-sectional area of the membrane holder at x=x1 (Figure A.1) was derived. 
Concentration gradient of drug in two regions of membrane holder, C I and CII, can be 
described by the diffusion of dissolved drug in the 0 < x < x1 and x1< x < L regions, which 
are coupled by a concentrated drug dissolution source at x=x1. The mass balance 
equations for the drug release process from the NGI membrane holder are as follows: 
 
  
          
  
   
                                                                                              
in 0 < x < x1, t > 0 
 
  
           
  
   
                                                                                             
in x1 < x < L t > 0 
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which are subjected to the following boundary and initial conditions: 
 
  




    
 
  
                                                                                  
    is a surface mass source arising from drug dissolution process, which can be 




                                                                           
          
                                                                                        
            
                                                                                       
                                                                                                          
where D is diffusion coefficient of drug, P is the permeability coefficient, J is a flux, 
  
         
  are initial concentrations of dissolved drug in the 0 < x < x1 and x1< x < L 
regions, and CB is the concentration of dissolved drug in the reservoir (dissolution 
vessel). 
The partial differential equations (PDEs) above can be described by a single PDE 
as follows:  
 
  
        
  
   
                                                                              
in 0 < x < L, t > 0 








                                                                                   
According to diract delta function, the Eq. A.9 is a function of drug diffusion 
within the 0  x  L, except x=x1. At x=x1, the A.9 equation can be expressed as a function 
of both drug dissolution rate and diffusion as follows: 
 
  
         
  
   
                                                                               
     represents the dissolution rate of particles. It can be described as following equation 
according to Noyes-Whitney equation.) 
 
                                                                                                          
where KD is the dissolution rate constant of drug, Sn is the number of particle at x=xn, an is 
the surface area of single drug particles located at the position of x=xn, Cs is the saturation 
solubility of drug in the matrix and C (xn, t) is the concentration of drug at x=xn. It should 
be noted that           exists in time as long as an > 0, namely, while some drug 
particles remain undissolved at x=xn. The term of a1 is a function of time and can be 
expressed in terms of the mass of said particle, m1, since the particles are assumed to be 
spherical and also assumed that the particles maintain their spherical shape while 
dissolving.  
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(Density of particle was assumed to be 1) 
where   
       
   are the initial values. According to Eq. A.13, the time-dependent    
is governed by following dissolution rate equation: 
 
  
                                                                                           
 
From the Eq. A.14 and A.15, time-dependent     equation can be expressed as a 
following deferential equation:  
 
  
       
       
    
   
                                                                 
with following initial conditions: 
        
           
 
A.1.2. Expanded model for systems containing multiple layers of drug particles  
The primary model can be expanded for the systems containing several drug 
dissolution sources arbitrarily distributed at x1, x2,… xn of membrane holder, as shown in 
Figure A.1 (B). The Eq. A.9 can be simply expended by summation of the functions for 
the primary model at xn positions, as follows: 
 
  
        
  
   
                        
 
 
                            
in 0 < x < L,   t > 0,         is    at x=xn and 0 at x ≠ xn. 
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To solve the time-dependent surface area (    function at x1, x2,… xn, following 
equation can be used:  
 
  
       
       
   
   
                                                                       
for n = 1, 2,…, N , t > 0, with   
    
       
   as initial conditions. 
 
A.1.3. Numeric calculation 
To simulate the changes in concentration gradient and surface area of loaded drug 
particles in the progress of drug dissolution within the membrane holder, the Eq. A.17 





      







      
 
   
                          
 
       
   
   
                     
            
which are subjected to the following boundary conditions: 
 
  




                               
 
Since Dirac delta function,        , is non-zero only at x=xn, the Eq. A.17 can 
be expressed as following equation:  
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In Eq. (A.20),            is a “pulse train”. As   increases, the density of 
Dirac delta function within the range (0 < x < L) increases, as a result, it approaches a 
constant value 1 in the range with   being infinity.  
Accordingly, the Eq. A.17, when N is sufficiently large, can be approximately 
described as follows: 
 
  
        
  
   
                                                                         
 
Also,       in Eq. A.18 can be substituted with        . As   goes towards 
infinity, the Eq. A.18 can be re-written with a continuous variable x instead of a discrete 
variable   , yielding a following Eq. A.22. 
 
  
        
       
   
   
                                                                     
Combining Eq. A.21 and Eq. A.22 yields Eq. A.19. 
 
A.2. PARAMETERS AND VARIABLES  
Parameter and variables used for mathematical analysis are listed in Table A.1 
Diffusion coefficient, D, of drug can be calculated by Stokes-Einstein equation. 
The Stokes-Einstein equation is a classically theoretical model of the diffusion coefficient 




    
                                                                                                                              
 251 
where k is Boltzman constant, T is the temperature of solution, r is the molecular radius 
of budesonide and   is the viscosity of dissolution medium at 37C. Eq. A.20 is applied 
to the diffusion process of spherical molecules in non-viscose solution. The r value of 
drug can be calculated by following equation: 
            
 
 
                                                                                                    
where Mw is a molecular weight of drug, Na is Avogadro‘s number and  is density of 
drug (assumed as 1). 
Permeability coefficient, P, is calculated by following equation [4]: 
  
   
  
                                                                                                                               
D is a diffusion coefficient of drug calculated by Stokes-Einstein equation above, K is 
partition coefficient of drug to polycarbonate (PC) membrane, and hM is the thickness of 
membrane. K is assumed to be 1, since the PC membrane allows for dissolved drug 
molecule to free diffusion and no drug absorption on the membrane were observed by 
experimental analysis. 
Surface area of single BD particles,    
 , deposited at x=xn position of the NGI 
dose-collection plate for dissolution study was given by the formula for the surface area 
of a sphere,   since the particles are assumed to be spherical and the shapes are 
maintained while dissolution. Particle size of BD varies with the particles deposited on 
each NGI dose-collection plate. Dose-collection plate cut-off particle sizes calibrated 
from the NGI are reported to be 4.46, 2.82, 1.66, 0.94, 0.55, 0.34 μm at an inlet flow rate 
60 L/min for dose-collection plate stage 2-7, respectively [5, 6]. The geometric particle 
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size distribution (GSD) of BD particles is assumed to be same as the aerodynamic 
particle size distribution, since the micronized BD particles are dense spherical structure 
(density of micronized budesonide was assumed to be 1). 
The thickness of matrix containing dispersed particles, L, is estimated based on 
the number of device actuation and the particle size deposited on the NGI dose-collection 
plate. It was assumed that every device actuation creates a one particle layer at x=xn, thus 
L can be calculated by multiplying the number of device actuation by the particle size of 
budesonide particles deposited on each NGI dose-collection plate. 
Number of particles associated to the drug dissolution source at x=xn, Sn, can be 
calculated by dividing the total number of particle loaded on the membrane holder by the 
number of particle layer, n. The total number of particle loaded on the membrane holder, 
S, can be calculated by following mass balance equation: 
   
        
       
 
      
       
                                                                                                                           
mtotal is the total amount of drug loaded on the membrane holder and Vtotal is the total 
volume of the particle loaded,  is a density of drug particle (assumed as 1) and Vsingle is 
the volume of single drug particle. 
Saturation solubility, Cs, of drug in the matrix can be obtained from a solubility 
study. The saturated solubility of drug in dissolution medium at 37 C is considered as 
the Cs, since the sealed membrane holder with PC membrane has a liquid layer consisting 
of dissolution medium, thus the liquid layer is assumed as the matrix layer of the 
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membrane holder. Drug concentration in the reservoir ,CB, can be obtained from the 
dissolution experiment. 
Dissolution rate constant of drug, KD, can be obtained by means of an iterative 
process based on solving the Eq. A.18. The KD of drug particles loaded in the membrane 
holder is hard to be measured by dissolution assessment since only the amount of drug in 
the reservoir, which is released amount of drug from the membrane holder by diffusion, 
can be detected in the dissolution study using the membrane holder. To estimated the KD 
value, randomly selected values are plugged into Eq. A.18 until the surface area values 
obtained by the dissolution assessment (   
 
) and the mathematical calculation using the 
Eq. A.18 (    
 
) for the surface area of undissolved drug particles in the holder at the last 
time point of experiment become similar. The parameters for the sample containing 
single layer of particles assembled at x=xn are used to estimate KD value. Obtained KD 
value is constant for the drug substance having same particle size distribution.      
The surface area value obtained by experiment,     
 
 , can be calculated by 
following equation: 











                                                                                                               





A.3. TABLES  
Table A.1  Parameters and variables used for modeling 
Factors Abbreviation Unit Value 
Diffusion coefficient  
(when particles are aligned in 
monolayer, Figure 4.1(A)) 
D cm2/s 6.3e-6  
Thickness of membrane hM cm 6e
-4 
 
Partition coefficient  
(matrix/membrane) 
K - 1  
Permeability coefficient P cm/s 1.01e
-2 
 




 16.2  




 Experiment data  
Surface area of single drug 
particle at x = xn 
(as an initial condition) 
  
  cm2/s 
Varies with the particle size 
deposited on each NGI 
dose-collection plate  
Number of particles associated 
to the drug dissolution source 
at x = xn 
Sn - 
Varies with the amount of 
drug loaded on the NGI 
membrane holder 
Dissolution rate constant KD cm/s 6e
-4
 
Thickness of matrix L cm 
Varies with both the 
number of device actuation 







A.4. FIGURES  
Figure A.1  Schematic illustration of different structures of the NGI membrane holder 
containing aerodynamically classified drug particles to be mathematically described 
within a framework. Wide line represents impermeable boundary and dashed line 
represents permeable membrane barrier. (A) Primary system containing drug particle at 
x1 position and (B) Matrix system containing drug particles assembled on N cross-
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Appendix B: Impacts of Drying Conditions on the Physicochemical 




Generally, the drying of recrystallized particles involves heat or vacuum 
conditions to remove solvents used in the recrystallization process. However, those 
conditions may not be suitable if the prepared crystal is in the hydrate or solvate form, 
since desolvation may occur during the drying process [1, 2]. It has been known that 
desolvation of hydrate form of crystal usually results in the rearrangement of the crystal 
lattice, generally leading to loss of crystallinity or significant structural change [1, 2]. 
Beside, the particles for inhaled therapy have very fine particle size (1-5 µm), thus the 
aggregation of particles in the process of drying often leads to a decrease in aerodynamic 
performances. In this study, the impacts of various drying conditions on the 
physicochemical properties and aerodynamic properties of rifampicin dihydrate (RFDH) 




B.2.1. Preparation of rifampicin hydrate using two different drying methods 
A dry powder form of rifampicin dihydrate was prepared by two different drying 
method, spray drying (RFDH-S) and filter drying (RFDH-F). To prepare the rifampicin 
dihydrate crystal, RF powder (900 mg) was added to the hot anhydrous ethanol solution 
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(60C, 30 mL) and stirred until a saturated solution was obtained at room temperature. 
The suspension was placed into a Branson 5500 sonic bath (Branson ultrasonics, 
Danbury, CT) and sonicated at 25°C for 2 minutes to homogeneously disperse the 
particles. The resultant suspension was then spray dried with constant stirring using a 
Büchi Minispray dryer B-290 (Büchi Laboratory-Techniques, Flawil, Switzerland). The 
following conditions were used during spray drying: drying airflow, 40m
3
/h; spraying 
airflow, 500 L/h; suspension feed rate, 5 mL/min; nozzle size, 0.5 mm; the inlet 
temperature was established at 70 ºC and the outlet temperature was between 40 and 50 
ºC. Another RFDH suspension was prepared as above. The prepared suspension was 
filtered to remove the ethanol and dried in the fume hood for 6 hours.    
 
B.2.2. Desolvation study 
The desolvation behavior of RFDH-S was studied. The prepared powder stored in 
the uncapped amber vial was vacuum dried (25C/5% RH) in the desiccators for 1 week.  
Dynamic vapor sorption (DVS) was also used to investigate the desolvation 
behavior of RFDH-S. Samples (20 mg) were pre-weighed and added to quartz sample 
pans which were placed in the sample chamber of a DVS-1 apparatus (Surface 
Measurement Systems Ltd., London, UK). During this measurement, the RFDH-S 
powders were exposed to a continuous flow of N2. The sample was then dried at 0% RH 
until desolvated form of RFDH (dRFDH) is obtained. The dried samples were analyzed 
using thermal analysis to confirm the desolvation and the crystalline structure were 
examined using the XRD. 
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B.3. RESULTS AND DISCUSSION 
 
B.3.1. Impact of drying conditions on the resulting crystal forms 
Significant differences in powder properties were observed between RFDH 
crystals dried by two different methods, spray drying and filtering. As shown in Figure 
B.1, the RFDH-S powders were very bulky, whereas the RFDH-F was dried in the form 
of a highly packed sheet. Although the properties of bulk powders were greatly affected 
by drying conditions, the shape of single RFDH-S and RFDH-F crystals were identical as 
flaky structures, the result of a polymorphic transformation of RF, (Figure B.2). The 
spray drying process allows the RFDH crystal to dry without caking or aggregation since 
the powders can be further deaggregated by atomization involving the break-up of liquid 
feed into very fine droplets. Conversely, general solvent removing processes, such as 
filtering, centrifuge and evaporation, involve high pressure or vacuum to remove 
solvents, leading to strong interparticular adhesion.  
A process-induced transformation of RFDH crystal was studied using thermal 
analysis. The drying conditions have a great influence on the polymorphic forms of the 
resulting crystals. Particularly, upon heating, the desolvation of the hydrate form of 
crystal is often reported, resulting in an inevitable change in original crystalline structure 
[1, 2]. As shown in Figure B.3, the TGA weight losses corresponding to the dehydration 
of the water of crystallization were similar for the RFDH-S and RFDH-F as 4.24% and 
4.25% (w/w), respectively. These TGA results imply that although the the spray drying 
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process accompanies heat, the RFDH crystals can be dried without desolvation by spray 
drying due to its‘ very rapid drying process [3].  
Significant changes in the DSC thermogram were observed from the RFDH-F 
sample; the peak corresponding to the decomposition of RF at 257-260C was broad and 
split into two peaks, whereas the RFDH-S samples showed a single peak at 257 C 
(Figure B.3). Additionally, the RFDH-F crystal reflected endothermic processes 
associated with weight loss after desolvation (90-150ºC), which contradicts the results for 
RFDH-S showing an exothermic peak without weight loss after desolvation (Figure B.3 
and B.4). The color change was also found for the RFDH-F sample after drying for 6 
hours; the bright orange color of RFDH was changed into a dark orange color (Figure B.1 
(B)). These results suggest that the RFDH-F may be the mixture of different polymorphic 
forms or degradation products, probably due to long exposure time of the filtered RFDH 
crystal to air with remaining solvents. Polymorphic transformation or chemical 
degradation may occur by uptake of atmospheric moisture, specifically, the RF is known 
to be prone to polymorphic transformation or chemical decomposition in the presence of 
moisture [4, 5].  
 
B.3.2. Desolvation 
The impact of desolvation on the physicochemical and aerodynamic properties of 
the RFDH crystal were studied, since the loss of crystallographically coordinated solvent 
molecules can induce the solubility, bioavailabiity, dissolution rate and stability of solid 
state materials [1, 2]. To prepare desolvated forms of RFDH crystal (dRFDH) without 
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chemical decomposition, the RFDH-S powders were dried under very low humidity 
conditions (0-5% RH) with either vacuum or continuous N2 gas purging. The changes in 
DSC thermogram were observed for both RFDH-S samples dried under different 
conditions (Figure B.4); the peak corresponding to the desolvation at 90-150C 
disappeared, and the peak corresponding to the evaporation of physically absorbed water 
(30-100C) increased after desolvation. This result indicates that the dihydrate form of 
RF can be desolvated at very low humidity conditions, and the dRFDH is more 
hygroscopic than the RFDH-S, which can be attributed to an increase of the amorphous 
form of RF in the powder. The structural change was further confirmed by XRD. As 
shown in B.5, after desolvation, the XRD pattern shifted, with a small halo at the 
baseline, indicating that the original crystal lattice collapses upon desolvation. 
Additionally, the desolvation was accerelated by N2 gas, which is in agreement with 
previous reports [1, 2]. From the desolvation study, we can deduce that pharmaceutical 
processing involving heat, vacuum or N2 gas can cause the desolvation of RFDH crystal, 
leading to a rearrangement of the crystal lattice. 
There was no significant difference in the solubility and dissolution profiles 
between two samples, the RFDH-S and dRFDH; the saturation solubility values for the 
RFDH-S and dRFDH sample were 1.24 and 1.28 mg/mL at 37 C, and the dissolution 
profiles showed 72 and 74% of RF release in 1 hour for the RFDH-S and dRFDH, 
respectively (B.6 and B.7). This is because, although the RFDH-S has a crystalline 
structure, the packing density is low and the surface area of those two powders, RFDH-S 
and dRFDH, are very similar each other. Additionally, well separated particle status in 
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the membrane holder may contribute to the subsequent increase in the surface area of 
drug presented to the media.  
As shown in Figure B.8, no significant differences were observed in ED and 
FPFTD for both samples, since the morphology and particle size of RFDH-S were not 
changed by desolvation (B.2). In general, the morphology of particles can affect the 
aerodynamic performance of powders at various levels (molecular, particulate and 
aerosol) since the different particle shapes lead to a variation in surface energy and 
interparticulate forces [6-9]. Specifically, at the molecular level, different particle shapes 
of crystalline materials may have different chemical functional groups on specific faces 
of the particles, leading to variation in the hygroscopicity and electrostatic interactions. In 
RFDH-S crystals, the changes in the crystalline lattice structure and hygroscopicity upon 
desolvation were observed, whereas the shapes of crystal habit (flake-like) were 
maintained for both RFDH-S and dRFDH. Consequently, the improved aerosolization 
properties of RFDH-S are primarily attributed to the flaky morphology (crystal habit) of 




Different drying conditions have great influences on the structure of resulting 
RFDH powders. Spray drying process offers the flaky rifampicin dihydrate (RFDH) 
crystal to dry without caking or aggregation, and this unique morphology coupled with 
drying process provides improved aerosolization properties. The desolvated form of 
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RFDH (dRFDH) was obtained by exposing the powders at very low humidity with either 
vacuum or N2 gas. There are no significant differences in physicochemical properties and 
aerodynamic properties between the hydrated and desolvated forms. However, the 
dRFDH are predicted to be more easily prone to chemical decomposition associated with 
humidity than the RFDH-S since the dRFDH is more hygroscopic. Moreover, the 
degradation products in the bulk powder may lead to poor aerolization properties since 
the physicochemical properties of degradation products will be significantly different 
from original crystals. Therefore, the transformation of hydrated form of crystals to 
desolvated form should be prevented, which always require gentle and careful drying 






























Figure B.2  Scanning electron microscopy images of (A) RFDH-S, (B) dRFDH, (C) 


















Figure B.3  (A) DSC thermograms of a) RFDH-S and b) RFDH-F, and (B) TGA results 
for a) RFDH-S, b) RFDH-F and c) dRFDH (DSC and TGA were operated at a heating 









Figure B.4  DSC thermograms of (A) RFDH-S, (B) RFDH-S dried under vacuum for 2 
days (RFDH-VC-2D), (C) RFDH-S dried under vacuum for 7 days (RFDH- VC-7D), and 







































Figure B.6  Saturation solubility of RFDH-S, and dRFDH in PBS containing 0.02% 















Figure B.7  Release profiles of RFDH-S and dRFDH in PBS containing 0.02% ascorbic 
acid (pH 7.4). Powders accumulated on the dose-collection plate 3 were selected for 

















Figure B.8  Powder deposition profiles for the RFDH-S and dRFDH actuated from 
Aerolizer®  inhaler at a flow rate of 60 L/min, expressed as the percentage of total loaded 
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Appendix C: Impacts of Amount of Drug Loading on the Dissolution 




C.1.1. Dissolution study 
An impact of amount of drug loading on the dissolution profiles of RFDH was 
studied by a membrane holder method. The prepared powders (7 mg and 15 mg) were 
filled into size 3 HPMC capsules, placed into the Aerolizer®  device, and actuated into 
the NGI equipped with a gravimetric sampling cup (MSP Co. Shoreview, MN) including  
a dissolution impaction insert (Copley Scientific, Nottingham,UK) at a flow rate 60 
L/min for 4 seconds. The dissolution impaction insert containing air classified particles 
was removed from the gravimetric sampling cup, and a pre-soaked polycarbonate 
membrane was placed onto the top and sealed in place with a push fitted sealing ring. The 
membrane covered dissolution impaction plate was placed into each dissolution vessel 
containing 300 mL of PBS containing 0.02% of ascorbic acid.  
 
C.1.2. Scanning electron microscopy (SEM) 
RFDH, polymer coated RFDH (C50L-M), and micronized budesonide (BD) 
(PulmicortFlexhaler® ) following particle separation by impingement were observed 
using a LEO 1530 SEM (Zeiss/LEO, Oberkochen, Germany). The RFDH (7mg) and 
coated RFDH powders (15 mg) were filled into size 3 HPLC capsule. Each formulation 
was fired into the NGI fitted with a wax paper at the base of dose-collection plate 3, 
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which was the stage used for dissolution study. The RFDH and coated RFDH 
formulations were actuated one time and the PulmicortFlexhaler®  device was actuated 10 
times to obtain a thick powder bed for each formulation. The wax paper containing 
separated particles was removed from the NGI and cut into a small segment (suitable for 
mounting on a pin plate SEM stub). The cut membrane segments from each dose-
collection plate were mounted separately onto the stubs using double-sided copper tape, 
before sputter coating with silver for 40 seconds under vacuum at 30 mTorr. 
 
C.2. RESULTS AND DISCUSSION 
 
Overall, there was a no significant difference in the dissolution profiles between 
test samples loaded 1 and 2.2 mg of RFDH powder, except the values at 15 minute, but 
variability was greatly affected. As shown in Figure C.1, the test sample loaded 2.2 mg of 
RFDH shows more variable dissolution profiles than that of the 1mg sample, particularly, 
the values within 30 minutes, attributed to thicker powder bed leading to an incomplete 
wetting of powders. However, the release profiles of two different test samples become 
similar as the dissolution progresses. These results indicate that the diffusion of dissolved 
RF molecule and the dissolution media in the powder bed is not hindered, although the 
thicker RFDH powder bed takes more time until all the powders within the bed are 
completely wet, which is not in agreement with the results found from BD study showing 
a significant dose-dependency in the dissolution profiles. The difference in the dose-
dependent dissolution rate between two APIs is due to the differences in solubility and 
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packing density of drug particles loaded in the membrane holder. As shown in Figure 
C.2, the powder bed consisting of air-classified RFDH and coated RFDH particles have 
much more spaces between particles than that of BD powders since the flake-like RFDH 
particles are not closely packed, implying that the powder bed consisting of flaky 
particles is less dense than that of spherical BD. Moreover, the RFDH is much more 
soluble than BD; the saturation solubility of RFDH and BD at 37C is 1.28 and 0.016 
mg/ml, respectively. Accordingly, more spaces between RFDH particles will be created 
by dissolving of particles, leading to a faster diffusion of dissolved drug molecule and 
dissolution media in the powder bed. In other word, the dissolution of flaky structure 
particles with higher solubility is expected to be less influenced by the amount of drug 













Figure C.1  Release profiles of RFDH crystals for the test samples loaded 1 mg and 2.2 
mg of RFDH powders in PBS containing 0.02% ascorbic acid (pH 7.4). Powders 
accumulated on the dose-collection plate 3 were selected for dissolution. The error bars 


















Figure C.2  Scanning electron microscope (SEM) images of aerodynamically separated 
(A) RFDH, (B) coated RFDH (C50L-M) and (C) BD particles on the NGI dose-collection 
plate stage 3.  
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D.1.1. Preparation of lipid coated RFDH using a spray dryer equipped with three-
fluid (3F) spray nozzle 
The RFDH suspension (4% w/v) was prepared by recrystallization of RF in 
anhydrous ethanol solution. The coating solutions of lipid mixture (0.3% w/v), consisting 
of cholesterol and distearyl phosphatidylcholine (DSPC) in a ratio of 75: 25, respectively, 
was prepared by dissolving them in anhydrous ethanol. Two prepared spraying solutions 
were sprayed separately through two different liquid channels of the three-fluid (3F-S) 
spray nozzle (Büchi Laboratory-Techniques, Flawil, Switzerland). The RFDH suspension 
was introduced through the inner nozzle with constant stirring at the feed speed of 
1mL/min (40 mg/min). The coating solution was supplied through the outer spray nozzle 
disposed concentrically about a core nozzle at the feed speed of 8 mL/min, provided 
62.5% RFDH loading. The 3F nozzles used in this study had two separate nozzles for 
aqueous solution and one for gas fluid. The spray drying was performed using a Büchi 
Minispray dryer B-290 (Büchi Laboratory-Techniques, Flawil, Switzerland) under 
following conditions for both nozzles: drying airflow, 40 m
3
/h; spraying airflow, 600 L/h; 
the inlet temperature was established at 70C and the outlet temperature was adjusted 




D.2. RESULTS AND DISCUSSION 
 
Unexpectedly, the dissolution of lipid coated RFDH powders was significantly 
increased compared to that of uncoated RFDH particles, although lipids, cholesterol and 
DSPC, used for coating are not aqueous soluble materials (Figure D.1). This is may be 
due to the water absorbing powder of DSPC surrounding the RFDH particles. This 
finding suggests that the surface modification with materials have hydrophilic moieties, 
although the portion of hydrophilic moiety is very small, will increase dissolution rate. 
The moisture sorption-desorption study further confirmed the hygroscopicity of coated 
RFDH. As shown in Figure D.2, the coated RFDH powders show higher moisture up-
take at 90% RH than the RFDH, although the formulation contains 40% of lipid (30 and 
10% of cholesterol and DSPC, respectively). However, overall, the lipid coated powders 
shows smaller hysteresis between sorption and desorption profiles than RFDH. From the 
DVS results, we can estimate that the dissolution rate of RFDH powders may be 
increased, but the chemical degradation of RFDH under ambient storage condition can be 
minimized by coating with the lipids since the chemical degradation of RF is accelerated 
by the moisture binding to the molecule. As we seen from the series of data, the DVS 







Figure D.1  RF release profiles from RFDH and lipid coated RFDH (C60LP-S) in PBS 
containing 0.02% ascorbic acid (pH 7.4). Powders accumulated on the dose-collection 













Figure D.2  Dynamic vapor sorption (DVS) isotherm of (A) RFDH, and (B) lipid coated 
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